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CONSEQUENCES OF ARYL HYDROCARBON RECEPTOR ACTIVATION
IN CROHN’S DISEASE

Chairperson: Dr. David M. Shepherd

Activation of the aryl hydrocarbon (AhR), a ligand-activated transcription factor
present in many immune cells, can trigger immunosuppressive responses through the
generation of regulatory cells. Several AhR ligands exist in the diet including
environmental contaminants, such as its prototypical ligand 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD), and natural sources, such as indole-3-carbinol (I3C) and indirubin.
Crohn’s disease, a chronic inflammatory state of the gastrointestinal tract, affects millions
worldwide; however, the exact cause is unknown and treatments do not cure the disease.
The role of the AhR in mucosal immune responses is not well understood to date so we
aimed to understand the consequences of AhR activation in gut inflammatory responses.
The overall hypothesis of this project is that AhR agonists found in the diet have the
potential to dampen inflammation associated with Crohn’s disease. The first goal of this
project was to examine the role of AhR activation in the development and progression of
colitis using TCDD and the natural ligand I3C. TCDD suppressed TNBS-induced colitis,
as demonstrated by the decreased disease severity and dampened inflammation in the gut.
TCDD-treated mice exhibited decreased inflammatory mediator production and increased
frequency of regulatory cells, both Foxp3+ Tregs and dendritic cells (DCs) in gut
immune tissues. In comparison, I3C suppressed disease severity in females but not
males. Sex-specific effects on colonic cytokine production and gene expression were
observed. The second goal of this project was to define the cellular mechanisms by which
AhR ligands elicit their effects on important immune cell populations present in the gut.
Therefore, we investigated the immunomodulatory effects of the dietary AhR ligands I3C
and indirubin in bone marrow derived DCs (BMDCs). I3C- and indirubin-treated
BMDCs upregulated the expression of immunoregulatory genes, such as ALDH1A, IDO,
and TGFβ, and also drove the generation of Foxp3+ Tregs. Following LPS stimulation,
I3C- and IO-treated BMDCs suppressed the LPS-induced production of TNF-α, IL-1β,
IL-6 and IL-12. Anti-inflammatory effects were also observed in intestinal epithelial cells
(IECs) treated with AhR ligands. Thus, I3C and indirubin possess immunosuppressive
and anti-inflammatory effects in BMDCs and IECs. Taken together, our data demonstrate
that the AhR is a therapeutic target that warrants further investigation, as natural AhR
ligands may effectively prevent the onset of chronic inflammatory diseases or more
effectively induce and maintain remission when combined with conventional medicine.
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CHAPTER 1: INTRODUCTION

This study describes the effects of aryl hydrocarbon receptor (AhR) activation on
the initiation and progression of inflammation associated with Crohn’s disease. The
introductory chapter will: 1) describe the basic functions of the immune system with a
focus on the gut mucosal immune system 2) provide information regarding the role of the
AhR and its numerous ligands in immune responses 3) explain the immune dysregulation
contributing to Crohn’s disease and 4) describe the potential role of dietary AhR ligands
to modulate intestinal inflammation.

Immune system
Overview: functions and components
The immune system is a complex network of tissues, cells, and soluble mediators
that work together to effectively protect the body against infection and disease. There are
four primary functions of immune responses:

proper recognition of infection,

containment of infection, self-regulation to inactivate the robust protective response, and
protection from recurring disease due to the same pathogen.

Successful immune

responses typically involve both the innate and adaptive branches of the immune system.
Innate responses occur within hours of pathogenic invasions via non-specific recognition
of non-self molecules while the adaptive responses take days due to the recognition
specificity of foreign antigens, which are substances capable of activating the immune
system. Several factors contribute to the effectiveness of these immune responses
including genetics, stress, diet, age, and medications among many others.
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All cells involved in these immune responses arise from hematopoietic stem cells
in the bone marrow and further differentiate into various populations of leukocytes.
Innate cells, including neutrophils, macrophages, and dendritic cells (DCs), are the first
responders to initiate immune and inflammatory responses. T cells and B cells are the
lymphocytes responsible for mounting antigen-specific adaptive immune responses.
These leukocytes produce and secrete soluble mediators (such as cytokines, chemokines,
antibodies, and cytotoxic granules) that influence surrounding cells and thus the ensuing
immune response. A more detailed discussion is provided below regarding two critical
immune cell populations, DCs and T cells, and their specific roles in immunity and
inflammation.

Antigen presenting cells (APCs)
APCs are essential to properly mounting innate and initiating adaptive immune
responses that effectively fight infectious agents. Although DCs, macrophages, and B
cells all function as APCs, DCs are the professional APCs. DCs are unique in that they
are involved in the induction of both protective and regulatory responses, especially in
the gut. As shown in Figure 1.1, the life cycle of DCs involves antigen capture in the
periphery, migration to lymph nodes, and presentation to T cells, which results in
lymphocyte activation necessary to trigger adaptive responses (Banchereau et al., 2000).
During this process, DCs change from immature DCs in the periphery to mature DCs in
the lymphoid tissue. Consequently, alterations in cell surface phenotype and functions of
DCs also occur (Figure 1.2).
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Figure 1.1

Figure 1.1. Life cycle of dendritic cells (DCs). Immature DCs survey the periphery for
foreign antigens that have penetrated mechanical barriers and entered tissues. Upon
recognition, DCs take up antigen, process it, migrate to lymphoid organs, and present
antigen to lymphocytes, which results in their activation. Activated lymphocytes then
return to the site of infection to clear it from the body (Banchereau et al., 2000).
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Figure 1.2

Figure 1.2. Stages of DC maturation.

Following antigen uptake, immature DCs

undergo a maturation process to activated DCs, which results in several
immunophenotypic and function changes.
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Immature DCs are particularly efficient at antigen uptake but have poor abilities to
migrate to lymph nodes and activate T cells. Conversely, activated DCs do not take up
antigen but are very effective T cell activators.
Successful antigen processing and presentation by DCs first begins with proper
uptake of antigens via receptor-mediated phagocytosis or macropinocytosis.

The

recognition of pathogen associated molecular patterns (PAMPs) occurs through pattern
recognition receptors (PRRs), such as Toll-like receptors (TLRs) and scavenger
receptors, which are expressed on the surface of DCs. The antigen is then internalized,
processed, and displayed on the cell surface via major histocompatibility complexes
(MHC). Finally, to successfully activate T cells, three signals are required between the
APC and T cell (Figure 1.3). Signal 1 is an activation signal involving the MHC:peptide
complex with the T cell receptor (TCR) complex. Signal 2 is a co-stimulatory signal
between the B7 molecules on DCs with CD28 or CTLA4 on T cells. Signal 3 involves
cytokines and other secreted molecules that act as a differentiation signal. However, if
one of these signals is missing, T cells are not effectively activated. When T cells only
receive signal 1 they become unresponsive (anergic), which allows for peripheral
tolerance induction. These unresponsive cells are particularly important in avoiding
autoimmune responses to tissue-specific antigens. Furthermore, when signal 2 is received
in the absence of an antigen, no effects occur on T cells.
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Figure 1.3

Figure
1.3.

Figure 1.3. Three signal hypothesis of T cell activation. To effectively activate T cells
APCs, such as DCs, deliver three signals including (1) binding of the MHC2:peptide
complex to the TCR, (2) costimulation, and (3) cytokines (adapted from Cools et al.,
2007).
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T cells
T cells are important adaptive immune cells that function to kill pathogens as well
as to activate and regulate other cells in the body. The two broad classes of T cells
include CD4+ helper T cells (Th cells), which can activate APCs and B cells that
ultimately produce antibodies, and CD8+ cytotoxic T cells (CTLs), which kill tumor cells
or virus-infected cells. Following multiple signals from APCs, naïve T cells can
differentiate into a variety of effector or regulatory cells (Figure 1.4). In particular, naïve
CD4+ T cells can become Th1, Th2, Th17, Th22, or regulatory T cells (Tregs), which
each have distinct roles in the ensuing immune response. Each effector cell type is
characterized by the cytokine profile that leads to differentiation of that subtype and the
primary cytokines produced. Th1, Th17, and Th22 cells are known for their roles in
inflammatory and autoimmune responses whereas Th2 cells are best recognized for their
involvement in allergic responses. Tregs are vital to regulating immune responses by
suppressing effector cell proliferation and secretion of anti-inflammatory cytokines.
Finally, since these are adaptive cells, memory cells are generated in the course of the
immune response. These memory T cells will rapidly differentiate into effector cells
upon subsequent exposure to the same antigen.
The balance of effector and Tregs is necessary to maintain homeostasis within the
immune system. Defects leading to robust effector cell responses and/or weak regulatory
cell responses contribute to the immune dysregulation found in numerous chronic
inflammatory diseases, such as inflammatory bowel disease.
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Figure 1.4

Figure 1.4. Characterization of CD4+ T cell populations. Upon activation, naïve
CD4+ T cells (Th0) can differentiate into several subtypes based on cytokine production
and function in immune responses. Transcription factors necessary for each population is
shown below the cell, and function is listed on the right (adapted from Jetten, 2009).
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Inflammation
One of the essential steps in combating infection is inflammation. Innate cells,
such as the first responding neutrophils and macrophages, trigger the recruitment of other
cells to the site of infection by releasing pro-inflammatory cytokines and chemokines
(secreted mediators that direct cellular trafficking) through signaling cascades that
activate transcription factors, such as nuclear factor kappa B (NF-kB). Furthermore,
several acute response proteins are produced including C-reactive protein (CRP), serum
amyloid A (SAA), cyclooxygenase (COX), and nitric oxide (NO). The local
accumulation of cells and soluble mediators causes redness, swelling, heat, and pain,
which are the hallmark clinical signs of an inflammation. Later in the response, effectors
of the adaptive branch, such as effector T cells and antibodies, contribute to the
containment and clearance of infection.
Inflammation is generally a beneficial immune response when it is localized and
tightly regulated. Acute inflammation leads to resolution, healing, and priming of the
adaptive responses. Signaling cascades are eventually inactivated to ensure that the attack
does not spread to nearby tissues. Chronic inflammation and systemic inflammation
(sepsis), however, are damaging conditions that can lead to many diseases including
cancer and potentially death.

Under chronic inflammatory conditions, transcription

factors, such as NF-kB, remain activated thereby promoting the transcription of many
pro-inflammatory cytokine genes, such as IL-6, IL-12, and TNF-α. Tissues are often
damaged as constant activation of inflammatory pathways leads to granulomas, fibrotic
scar tissue, fluid accumulation, and abscesses. Thus, moderation is essential to reaping
the benefits of the inflammatory immune response.
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Gut mucosal immunity
Exposure to a diverse and extensive range of antigens and unusual effector and
regulatory responses makes the mucosal immune system distinctly different than the rest
of the immune system. It must properly distinguish between pathogens and innocuous
antigens including food particles and commensal bacteria, which are essential for the
clearance of toxins, xenobiotic metabolism, nutrient absorption, and prevention of
pathogenic bacteria colonizing the gut. The gut associated lymphoid tissues (GALT),
which include the Peyer’s patches of the small intestine, isolated lymphoid follicles, and
the intraepithelial lymphocytes (IELs), are responsible for mounting the appropriate
immune response to this vast array of antigens.

Unique features
There are two primary compartments of the intestines: the epithelium and the
lamina propria (Figure 1.5). The epithelium is the first line of defense in the gut, as the
tight junctions and mucus produced by Goblet cells are critical to preventing transfer of
luminal contents into the underlying tissue. Microfold cells (M cells) are another type of
specialized epithelial cells unique to the gut. These cells are the route by which antigen
enters the Peyer’s patch from the lumen. Most of the immune cells are found in the
lamina propria, which acts as the interface between the epithelium and lymphoid tissue
below and is where most immune cells are found in the intestines. In fact, large numbers
of effector cells reside in the gut tissue even in the absence of infection. Furthermore,
plasma cells (highly differentiated B cells) in the lamina propria that receive a
transforming growth factor-beta (TGF-β) switch factor signal produce copious amounts
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Figure 1.5

Figure 1.5. Components of the intestinal immune system. The epithelium and lamina
propria are the two major compartments in the intestines that contribute to protective and
tolerant immune responses. Intraepithelial lymphocytes, intestinal epithelial cells (IECs),
DCs, M cells, Paneth cells (not shown), and goblet cells (not shown) are found in the
epithelial layer lymphocytes, whereas DCs, macrophages, and other innate cells reside in
the lamina propria. Following antigen uptake, APCs travel to the mesenteric lymph
nodes to generate an adaptive response that includes IgA production by plasma cells
(Macpherson and Harris, 2004).
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of immunoglobulin A (IgA), which is present as a dimer and the predominant antibody
isotype produced in the gut. In the periphery, the IgG isotype dominates, and IgA is
present as a monomer. There are several functions of IgA at the epithelial surface:
neutralizing pathogens in the mucus layer to prevent penetration, neutralizing antigens
internalized in endosomes in the epithelial layer, and exporting pathogens from the
lamina propria.

Important cellular players of intestinal immune responses
As with the peripheral immune system, APCs play a critical role in mounting
appropriate mucosal immune responses. In the gut, both the intestinal epithelial cells
(IECs) and DCs play important roles in antigen recognition, processing, and presentation.
These cell populations sample luminal contents via pattern recognition receptors (PRRs)
expressed on their surfaces. IECs sample antigens directly whereas DCs sample the
luminal contents by projecting extensions through the epithelial layer (“snorkeling”) or
indirectly via antigen processed by IECs.

Both of these cell populations secrete

mediators, such as IL-10 and TGF-β, that can influence surrounding cells and the ensuing
immune response. Upon antigen uptake, DCs travel to the mesenteric lymph nodes
(MLNs) to trigger subsequent adaptive responses. The activated T cells then home back
to the gut primarily via expression of the surface marker α4β7, an integrin that mediates
the migration of cells to the intestines and associated immune tissues.
Based on the antigen sampled, DCs and IECs produce mediators to generate
either protective immunity, which is similar to peripheral responses, or oral tolerance,
which is an unresponsiveness to harmless food, commensal bacteria, or non-pathogenic
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bacteria. In the presence of pathogenic organisms, DCs become activated and express
strong costimulatory ligands that drive the differentiation of naïve CD4 T cells into Th1,
Th2, Th17, or Th22 cells. Alternatively, in the presence of commensal bacteria, which
lack the virulence factors necessary for penetrating the epithelium, immature DCs give
weak costimulatory signals and induce Tregs. Furthermore, in the absence of infection,
IECs produce prostaglandin-E2 (PGE-2), TGF-β, and thymic stromal lipoprotein (TSLP)
that inhibit DC maturation. These regulatory DCs express CD103 on the cell surface and
produce protective mediators, such as TGF-β and IL-10. Therefore, the activation state
of local DCs determines either protective immunity or tolerance, which is the default
immune status of the gut.
As previously mentioned, effector T cells are prevalent in the gut immune tissues,
which is typically indicative of an inflammatory phenotype; however, regulatory cells
play a prominent role in preventing potentially harmful responses by effector cells.
Following exposure to oral antigens, several classes of Tregs are induced including
thymic-derived Foxp3+ Tregs, mucosally-induced Foxp3+ Tregs, Tr1 cells, and Th3 cells
(reviewed in Weiner et al., 2011). These different classes likely differ in antigen
specificity, development, and mechanism of immune regulation. Interestingly, the
frequency of these Treg populations changes along the gastrointestinal tract due to the
nature of the different microenvironments, as the colon carries a significantly greater
bacteria load than the small intestine where the primary function is nutrient absorption.
Most IL-10 producing Tregs in the colon lamina propria are Foxp3+ Tregs while Foxp3Tr1 cells are more prevalent in the small intestine (Maynard et al., 2007). Although there
are several classes of Tregs responding, in general the primary function of Tregs is to
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induce/maintain tolerance and decrease inflammation in the gut. Therefore, perturbations
in this regulatory state can lead to disease involving intestinal inflammation including
inflammatory bowel diseases.

Factors that alter mucosal immune responses
Several factors including age, stress, and medications can modulate immune
responsiveness. Perhaps one of the most influential factors in the mucosal immune
system is the diet since dietary compounds directly contact the tissues in the
gastrointestinal tract. Numerous studies have identified dietary constituents that can
either promote or suppress inflammation in the gut. These compounds or their metabolite
can act directly on cells and tissues to alter inflammatory mediator production or
indirectly by altering the intestinal microbial communities.
More specifically, intake of certain fats and carbohydrates drastically affects
immune responses by promoting inflammation while intake of other nutrients suppresses
inflammatory responses. For example, fatty diets promote inflammation in the intestine
as well as in other peripheral tissues because they change the intestinal microflora such
that Gram negative bacteria, which contain endotoxin, predominate instead of Gram
positive bacteria (Cani et al., 2007). This increased presence of lipopolysaccharide (LPS)
in the gut is recognized by immune cells, such as DCs and IECs, which triggers
inflammation not only in the gut but also in other tissues and contributes to the
development of metabolic disease. Moreover, increased intake of linoleic acid, an omega6 fatty acid, alters the balance between omega-3 fatty acids and omega-6 fatty acids such
that omega-6 fatty acids dominate and promote inflammation (Wall et al., 2009). Finally,
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refined carbohydrates, from which fiber and essential nutrients have been removed, have
been shown to increase circulating levels of pro-inflammatory cytokines including IL-6
and TNF-α (Esposito et al., 2002).
In contrast, many dietary supplements including probiotics, fiber, fish oil, and
vitamins have the potential to dampen inflammation in the gut.

Probiotics, or the

beneficial bacteria found in many commercial food products, alter intestinal immune
responses in several ways (extensively reviewed in Sanders, 2011).

They decrease

pathogen binding, produce antibacterial substances, and decrease pro-inflammatory
cytokine production.

Additionally, barrier integrity is improved with increased

production of mucins and defensins. When this “good” bacteria is recognized by DCs,
they produce regulatory signals, such as IL-10, that drive the proliferation of Tregs,
which ultimately promotes tolerance and suppresses gut inflammation. Soluble fiber,
also known as the prebiotic non-starch carbohydrate, is also anti-inflammatory in nature.
Its main fermentation byproduct, butyrate, inhibits NF-kB signaling and therefore the
production of pro-inflammatory cytokines (Segain et al., 2000; Luhrs et al., 2002).
Omega-3 fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), also inhibit the production of several inflammatory mediators including proinflammatory cytokines and eicosanoids (Issa and Saeian, 2011). Foods also contain
many vitamins that can generate an immunoregulatory environment.

Vitamin A is

metabolized into retinoic acid (RA) by CD103+ regulatory DCs in the gut. In turn, RA
can contribute to the differentiation of naïve T cells into Tregs while also inhibiting the
generation of Th17 cells. Vitamin D has also been shown to increase Foxp3+ regulatory
T cells (Hardenberg et al., 2011).
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Clearly there are several sensitive pathways critical to maintaining mucosal
immune homeostasis, and the commensal bacteria play an important role in this process.
It is essential to understand the factors that are necessary to maintain a properly
functioning intestinal immune system. A better understanding of these mechanisms will
help us better understand intestinal immune disorders and how to effectively treat them.
Aryl hydrocarbon receptor
Many factors contribute to the immune responsiveness of cells.

The aryl

hydrocarbon receptor (AhR) is a cytosolic, ligand-activated transcription factor that is a
member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) protein family and
binds a variety of natural and synthetic compounds. The AhR is present and inducible in
immune cells but is constitutively expressed in DCs. Furthermore, AhR expression is
dramatically increased in Th17 cells compared to other subsets of Th cells, such as Th1
and Th2 cells (Veldhoen et al., 2008).
As shown in Figure 1.6, the canonical pathway involves ligand binding to the
AhR in the cytosol to activate the receptor. Following binding, accessory proteins (hsp90
and XAP2) dissociate and reveal the nuclear localization signal (nls) allowing the
ligand:AhR complex to translocate into the nucleus. There it complexes with the AhR
nuclear translocator (ARNT), binds to dioxin response elements (DREs), and modulates
transcription of several genes, including Phase I drug metabolizing enzymes, such as
CYP1A1. AhR activation is believed to modulate immune and inflammatory responses
via transcriptional regulation as there exist multiple (putative) DREs in the promoter
regions of several cytokine genes, such as those implicated in Tregs (TGF- and IL-10),
Th1 cells (IL-12), as well as Th17 cells (IL-21 and IL-23) (Kerkvliet, 2009). A non-
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Figure 1.6

Figure 1.6. Canonical and non-canonical AhR signaling pathways. In the canonical
AhR signaling pathway, a ligand diffuses into the cell and binds cytosolic AhR complex,
which triggers dissociation of chaperone proteins. Upon entering the nucleus, the ligandbound AhR binds ARNT before binding DREs thereby triggering transcription of the
AhR gene battery. In the non-canonical signaling pathway, the ligand-bound AhR binds
RelB in the nucleus thereby allowing binding to NF-kB response elements (adapted from
Tian et al., 2002).
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canonical AhR signaling pathway also exists, and involves binding of the ligand-bound
AhR to the nuclear factor-B (NF-B) family member, RelB, which subsequently
activates transcription of genes controlled by both the AhR and NF-B (Tian et al., 1999;
Tian et al., 2002; Vogel and Matsumura, 2009). Therefore, both of these AhR signaling
pathways have the potential to elicit immunomodulatory effects following AhR
activation.
The prototypical ligand of the AhR is 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), a byproduct of various industrial processes. TCDD is the most popular chemical
to study the effects of AhR activation because it is the highest affinity ligand for this
receptor and is resistant to metabolism (Ward, 1985; Davila et al., 1995; Mann et al.,
1999). Several adverse effects, including those on the immune system, are observed
following exposure to TCDD. Studies show that AhR null animals do not experience the
immunotoxic effects associated with administration of TCDD thereby indicating that the
AhR is necessary to mediate the immunosuppressive effects of TCDD and many TCDDlike chemicals. Since many immune cells express the AhR and many immune genes
contain DREs (Kerkvliet, 2009), it is critical to understand how AhR activation can affect
the function of the immune system.

Effects of the AhR on inflammatory responsiveness
Prior to discussing the role of the AhR in mediating the effects of various ligands,
it must be acknowledged that, independent of exogenous ligands, the AhR plays an
important role in controlling several physiological processes including inflammatory
responses. Recently, several studies have revealed that mice lacking the AhR are more
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sensitive to inflammatory responses. AhR null mice display increased sensitivity to LPSinduced septic shock, which was primarily due to macrophage dysfunction (Sekine et al.,
2009). Furthermore, these investigators found that LPS-stimulated bone marrow-derived
macrophages secreted more pro-inflammatory cytokines than the wildtype AhR cells.
Kimura and colleagues extended these results by demonstrating that AhR forms a
complex with Stat1 and NF-kB in macrophages to ultimately inhibit IL-6 activity
(Kimura et al., 2009). Similar effects have been observed in disease models. In murine
models of inflammatory bowel diseases, several investigators have revealed that AhR
deficiency results in a more severe disease phenotype (Arsenescu et al., 2011; Furumatsu
et al., 2011; Monteleone et al., 2011).

These data suggest that the AhR plays an

important role in regulating inflammation so intentional and targeted activation of the
AhR may be a promising therapeutic approach for the treatment chronic inflammatory
diseases, such as inflammatory bowel disease.

Immunoregulatory effects of TCDD
Although early reports suggested that TCDD exacerbates some inflammatory
responses, more recent studies have defined cellular mechanisms for its potent
immunosuppressive effects on both humoral and cell-mediated responses. TCDD affects
humoral immunity by suppressing CD40L-activated B cell proliferation (Ito et al., 2002;
Allan and Sherr, 2005). T cells were initially believed to be the primary target of TCDD
in the immune system due to thymic involution, which results in thymocyte loss, arrest of
T cell proliferation, and premature emigration of T cell progenitors (Laiosa et al., 2003;
Temchura et al., 2005; McMillan et al., 2007). In addition to suppressing CD4+ Th cell
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differentiation, TCDD also enhances the development of Tregs, as it has been
demonstrated that CD4+CD25+ Tregs producing suppressive cytokines are induced
following TCDD exposure (Funatake et al., 2005; Marshall et al., 2008). There are
several mechanisms by which the AhR can influence the differentiation and expansion of
Tregs: (1) the AhR can directly regulate Foxp3 expression due to the DREs present in the
Foxp3 promoter (Hauben et al., 2008; Kimura et al., 2008; Quintana et al., 2008); (2)
the AhR signaling pathway can affect TGF-β production via cross-talk with the TGF-β
signaling pathway (Guo et al., 2004; Santiago-Josefat et al., 2004; Gomez-Duran et al.,
2006; Thomae et al., 2006); and (Miller) cell-cell interactions and cytokine milieu
produced by DCs drastically alter the fate of naïve Th cells (Thorstenson and Khoruts,
2001; Akbari et al., 2002; Yamazaki et al., 2006; Bankoti et al., 2010a; Bankoti et al.,
2010b; Benson and Shepherd, 2011; Simones and Shepherd, 2011). In particular, AhR
activation in DCs triggers the induction of IL-10, TGF-β, aldehyde dehydrogenase, and
indoleamine-2,3-dioxygenase (IDO), an enzyme that catalyzes the essential amino acid
tryptophan via the kynurenine pathway.

Immunomodulatory effects of other AhR ligands
Being a promiscuous orphan receptor, the AhR can bind a structurally diverse
range of compounds including various environmental contaminants, endogenous
compounds, dietary components, and therapeutic agents. Many of these compounds act
as AhR agonists and have been shown to alter immune responses (Table 1.1). These
ligands, however, do not typically bind the AhR as strongly as TCDD and are usually
quickly metabolized, which can alter their effects on the immune system.
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Table 1.1. AhR ligands and their role in immunitya

a

A diverse range of compounds that bind the AhR and exert a variety of effects on

immune cells to modulate immune responsiveness.
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It has been suggested that by binding to the AhR in CD4+ T cells, tryptophan
metabolites can elicit their immunosuppressive effects by inducing a Treg phenotype
(Fallarino et al., 2002; Frumento et al., 2002; Terness et al., 2002; Belladonna et al.,
2006; Fallarino et al., 2006). One of the most studied metabolites is 6-formylindolo[3,2b]carbazole (FICZ) due to its potent AhR agonistic activity. It has been suggested that
AhR activation occurs in a ligand-specific manner as activation via TCDD results in Treg
production while activation via FICZ results in the production of Th17 cells, which may
be due to differences in the timing and duration of AhR activation (Ho and Steinman,
2008). Quintana and colleagues recently reported that prolonged activation of AhR via
TCDD resulted in the production of suppressive Treg cells while brief AhR activation via
FICZ generated inflammatory Th17 cells in a murine model of autoimmune encephalitis
(Quintana et al., 2008; Veldhoen et al., 2008). It could be hypothesized that significant
upregulation of the AhR in Th17 cells makes these cells more susceptible to endogenous
AhR ligands that could subsequently mount immunosuppressive Treg responses to
dampen the Th17-mediated responses.
In contrast to exacerbating autoimmunity, FICZ was recently reported to suppress
the severity of several models of murine colitis, which was partly dependent on IL-22
(Monteleone et al., 2011). FICZ-treated mice experienced decreased production of IFNγ, IL-17A, and TNF-α and increased IL-22 production. As previously mentioned, IL-22 is
a cytokine produced by Th22 and Th17 cells in an AhR-dependent manner (Veldhoen et
al., 2008; Trifari et al., 2009; Veldhoen et al., 2009). This cytokine is often associated
with autoimmunity since it promotes inflammation by acting synergistically with IL-17,
INF-γ, and TNF-α. In the gut, however, IL-22 exhibits a protective role because it
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induces antimicrobial peptides that help maintain mucosal barrier integrity. Thus, the
effects of IL-22 production induced by AhR activation seem to be dependent on the
microenvironment of the inflammatory response.
It must be emphasized that, to date, it is not well understood why some AhR
ligands have the potential to promote the development of a Th17-mediated inflammatory
response while others promote the development of a Treg-mediated suppressive response.
Due to the critical role that these T cell populations play in the generation of immune and
inflammatory responses in the gut mucosa, it is necessary to examine the effects of AhR
activation in this compartment.

Crohn’s disease
Inflammatory bowel disease (IBD), comprised of Crohn's disease and ulcerative
colitis, is a chronic inflammatory state of the gastrointestinal tract. This disease typically
affects young Caucasians aging from 15 to 35 years old that live in urbanized, developed
countries (Head and Jurenka, 2004). It is estimated that the average number of cases
currently ranges from 100-200 cases per 100,000 individuals in North America, northern
Europe, and the United Kingdom (Loftus et al., 1998; Bernstein et al., 1999; Loftus et al.,
2000; Loftus, 2004; Cho, 2008). Unlike ulcerative colitis, Crohn’s disease affects all
layers of the intestinal wall anywhere along the gastrointestinal tract, but especially in the
ileum and colon.

Due to a severe inflammatory response, Crohn’s disease patients

experience many unpleasant symptoms, such as frequent diarrhea, abdominal pain, and
rectal bleeding.

Many painful and potentially life-threatening intestinal and

extraintestinal complications can also affect patients. Since the exact cause of Crohn’s
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disease remains unknown, conventional treatments typically consist of a combination of
corticosteroids and immunomodulatory agents, azathioprine and 6-mercaptopurine, to
diminish flare-ups and induce remission. In addition to these conventional therapies,
many patients use various complementary and alternative therapies to enhance the effects
of conventional therapies or reduce the side effects caused by conventional medicine.

Intestinal immune dysregulation
As previously described, epithelial and immune cells sample antigens in the lumen of the
gut to induce a state of tolerance such that an immune response is not elicited towards
commensal bacteria under homeostatic conditions. There is a balanced differentiation of
Th0 cells into effector cells (Th1, Th2, Th17, Th22) and regulatory cells (Tregs). In
Crohn’s disease, this state of oral tolerance appears to be disrupted, as demonstrated in
Figure 1.7 (Sanchez-Munoz et al., 2008). Several factors have been implicated in the
pathogenesis of the disease, including a defective mucosal epithelium, imbalance
between effector T cells and Tregs, oxidative stress, and the hygiene hypothesis, which
suggests that lack of antigen exposure at a young age triggers the onset of Crohn’s
disease (Head and Jurenka, 2004). In the mucosal immune system, the epithelium is the
first line of defense, and defects in this barrier have been implicated in the pathogenesis
of Crohn’s disease (Baumgart and Dignass, 2002). Moreover, altered innate immune
mechanisms, including genetic polymorphisms associated with intracellular bacterial
processing and autophagy, could also lead to an inappropriate immune response to
commensal bacteria (Hugot et al., 2001; Ogura et al., 2001; Baumgart and Carding, 2007;
Cho, 2008). These environmental and genetic factors shift the balance between effector
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Figure 1.7

Figure 1.7.

Immune dysregulation contributing to Crohn’s disease (CD) and

ulcerative colitis (UC). In IBD, the balance between effector T cells and Tregs is
disrupted. Th1 and Th17 cells drive the immune dysregulation in CD whereas UC is a
Th2-mediated response.
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and regulatory cells such that Th1 inflammatory cells predominate over Tregs. Th1mediated immune responses are implicated in the development of colitis as Crohn’s
disease patients show elevated levels of IL-12 (Monteleone et al., 1997; Parronchi et al.,
1997; Liu et al., 1999).

Furthermore, decreased levels of IL-10, a potent

immunoregulatory cytokine, also play a role in this disease. It should be noted that
recently, Th17 cells, in addition to Th1 cells, have been implicated in the development of
Crohn’s disease. The differentiation, expansion, and stabilization of Th17 cells involves
the cytokine IL-23, which numerous genome-wide association studies have linked to the
development of Crohn’s (Abraham and Cho, 2008). Clearly the pathogenesis of Crohn’s
disease is very complex as it involves a combination of genetic and environmental factors
that alter multiple populations of innate and adaptive immune cells.

Complementary therapies for Crohn’s disease management
Numerous Crohn’s disease patients seek complementary therapies to alleviate
symptoms of the disease not relieved by conventional medicine and/or to reduce the side
effects from conventional medicines.

Many of these therapies include dietary

supplements, such as omega-3-fatty acids and probiotics, which have the potential to alter
inflammation. Since AhR activation can result in suppression of Th1-mediated immune
responses, dietary components that are AhR ligands would be expected to alter the
inflammatory response associated with Crohn’s disease. Cruciferous vegetables, such as
broccoli, brussel sprouts, and cabbage, contain glucosinolates, which are sulfurcontaining compounds that possess chemoprotective effects (Hayes et al., 2008). The
hydrolysis of glucobrassican forms indole-3-carbinol (I3C), which is sold as a
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commercially available dietary supplement. In the acidic environment of the stomach,
I3C forms a condensation product, diindolomethane (DIM). The oral consumption of
I3C has been shown to induce Phase I and Phase II enzymes similar to TCDD (Higdon et
al., 2007; Hayes et al., 2008). Additionally, the beneficial effects of this supplement may
also involve NF-kB as DIM has been shown to inhibit the activation of NF-B (Hayes et
al., 2008).

Most recently, Kim and colleagues revealed that DIM decreased

inflammatory damage and inflammatory mediator production induced by the dextran
sodium sulfate model of colitis in Balb/c mice (Kim et al., 2009). However, the cellular
signaling events responsible for this effect were not examined. In addition to dietary
supplements, traditional Chinese medicines (TCMs) may also alter AhR signaling.
Indirubin, a TCM used to treat chronic myelocytic leukemia and other inflammatory
conditions, increased CD4+CD25+Foxp3+ T cells in indirubin-treated mice (Zhang et al.,
2007).

Collectively, these results suggest that common dietary constituents may

modulate inflammation and immunity via activation of the AhR.
Since CD affects millions of Americans, it is important to study the mechanisms
underlying this disease so that new and more effective therapeutics can be developed.
Moreover, because AhR activation can effectively modulate both immune and
inflammatory responsiveness, studying the effects of both synthetic and natural AhR
ligands on the generation of Crohn’s disease is warranted. Therefore, the goal of the
studies described in this dissertation is to elucidate the role of AhR activation by dietary
supplements and TCM in the development and progression of inflammation associated
with Crohn’s disease. The results of this project will provide novel information about gut
mucosal immunity.
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Hypothesis and specific aims

The goal of the proposed research is to elucidate the role of aryl
hydrocarbon receptor activation (AhR) in the development and
progression of inflammation associated with Crohn’s disease.
This proposal is novel in that the role of AhR activation in
mucosal immunity has not been investigated. Ultimately this
research will lead to a better understanding of Crohn’s disease,
how dietary factors can affect it, and potential therapeutic
modalities that may be useful for humans.

Crohn's disease, one of the conditions encompassing inflammatory bowel disease (IBD),
is a chronic inflammatory disorder of the gastrointestinal tract typically affecting younger
patients of European descent. There is no known cause; however, it is suspected that the
disease likely results from various genetic and environmental factors triggering an
inappropriate immune response to normal gut bacteria. Currently, the most common
therapies for Crohn’s disease include a combination of corticosteroids and
immunomodulatory drugs. Since these drugs are often accompanied by unpleasant and
severe side effects, it is important to investigate the potential prophylactic and therapeutic
effects of natural products since it has been suggested that dietary components can alter
the inflammatory state of the gut. The AhR is a ligand-activated transcription factor most
recognized for its involvement in the toxicity of the prototypical AhR ligand TCDD, an
environmental contaminant that typically affects people through the diet. Activation of
the AhR by TCDD results in the regulation of transcription, an effect that is primarily
mediated via Dioxin Response Elements (DREs) in the promotor/enhancer regions of
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specific target genes, such as CYP1A1 (a xenobiotic metabolizing enzyme) and IL-2 (an
important immune cytokine). Moroever, TCDD is an extremely potent chemical that has
recently been shown to suppress immune responses via the generation of regulatory T
cells. In addition to TCDD, other potent dietary AhR ligands have the potential to
modulate the immune system presumably via activation of the AhR and DRE-mediated
gene regulation. Crohn’s disease patients often seek natural, complementary therapies in
addition to the conventional therapeutics.

Importantly, some compounds present in

dietary supplements are also potent AhR ligands. Therefore, the potential exists for these
chemicals to alter the generation of immune responses and inflammation associated with
Crohn’s disease. Common dietary supplements, such as indole-3-carbinol (I3C), a
compound found in cruciferous vegetables, and tryptophan, an essential amino acid, can
be potent natural AhR ligands. Moreover, tryptophan and its metabolites, such as 6formylindolo[3,2-b]carbazole (FICZ), have been shown to have immunomodulatory
effects following AhR activation. Furthermore, plants used in traditional Chinese
medicine, such as indirubin, also have a critical role in influencing inflammatory
responses. We hypothesize that AhR agonists found in the diet have the potential to
dampen inflammation associated with Crohn’s disease. This central hypothesis will
be tested by the following specific aims:

Specific Aim 1: Examine the role of AhR activation in development and progression
of inflammation associated with Crohn’s disease.

Specific Aim 2: Investigate the cell-specific mechanism(s) by which dietary AhR
ligands exert their effects inflammatory responses.
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Specific Aim 1
The purpose of these studies is to specifically investigate the role of AhR
activation by various ligands during the inflammatory response associated with Crohn’s.
Since the murine model of TNBS-induced colitis (described below) resembles human
Crohn’s disease in the histological outcome as well as the cytokine profile, we will utilize
this model. The approach to this Specific Aim involves 3 key experiments. To fully
characterize the role of AhR activation in Crohn’s, we will first examine the readouts of
inflammation using the prototypical AhR ligand, TCDD, in AhR+/+ mice. Secondly, we
will definitively show that the AhR is involved in this response by using AhR-/- mice.
Finally, we will then examine the effects of other dietary AhR ligands throughout the
development of Crohn’s disease. Overall, the results of Specific Aim 1 will define the
immunomodulatory effects of TCDD and other dietary AhR ligands in mucosal
immunity. Chapters 2-4 describe the results of this Aim.

Experimental approach: murine colitis models
Completion of Specific Aim 1 requires use of a murine model of Crohn’s disease.
There exist many animal models to investigate the development, progression and
maintenance of colitis (Bouma and Strober, 2003). Although none of these animal
models perfectly represent human Crohn’s disease, each model has its own advantages
for studying various aspects of inflammation in the gut (Pizarro et al., 2003). For
example, the CD4+CD45RBhigh SCID transfer model elicits a chronic Th1 transmural
response and defines specific effector and regulatory cell populations while the IL-10
knock out model elicits an acute Th1 transmural response and defines the role of pro-
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inflammatory and regulatory cytokines as well as specific cell populations in intestinal
inflammation. Perhaps the most commonly used animal model to study Crohn’s disease
is the TNBS-induced model of colitis that was first described by Neurath and colleagues
in 1995 (Neurath et al., 1995). This model shares similar immunological pathways as
human Crohn’s disease and is useful for testing new potential therapeutic interventions
(Pizarro et al., 2003).

More specifically, in this model the use of an ethanolic vehicle

disrupts the mucosal barrier, allowing TNBS to haptenate colonic proteins and leading to
a Th1-mediated immune response driven by IL-12 and other pro-inflammatory cytokines
including TNF-, IL-6, IFN-, and IL-17 (Kawada et al., 2007).

Deficiencies in

regulatory cytokines, including IL-10, and TGF-, have also been reported. Therefore,
we have chosen the TNBS-induced model of colitis primarily because the innate immune
response induced by this chemical most closely resembles the effects observed in people,
which is useful for investigating potential prophylactic therapeutics. Furthermore, in the
TNBS model, a sensitization step can be added such that T cells are primed and
subsequently elicit a more potent T cell response upon a secondary exposure during the
TNBS enema. Therefore, based on the potential for TCDD and other AhR ligands to
modulate inflammatory and immune responses by altering the differentiation of T cells,
the effects of AhR activation may be more pronounced in this model of colitis that
involves greater contributions from T cells.
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Specific Aim 2
The toxicity of TCDD is primarily due to binding of ligand:AhR:ARNT complex
to the DRE in the regulatory region of various target genes, including those involved in
innate and adaptive immune responses. However, it has also been suggested that the
effects of AhR activation may be due to DRE-independent events. It has been reported
that the ligand-bound AhR can interact with the Rel component of NF-B, which would
allow for altered transcription of immune genes that are under the control of the DRE or
NF-B. It is therefore important to evaluate the potential DRE-dependent and
independent events leading to the immunosuppressive effects of various AhR ligands.
The results obtained from this Specific Aim will provide data that will mechanistically
define the role of AhR activation by various ligands in immunity and inflammation.
Chapter 5 describes the results of this Aim.

Experimental approach
For this Aim, murine BMDCs were generated from the bone marrow of AhR+/+
and AhR-/- mice (both on a C57Bl/6 background) using the growth factor GM-CSF in the
presence of the DMSO vehicle or the AhR ligands, I3C and indirubin. Serveral endpoints
were evaluated in these studies including cell surface molecule expression via flow
cytometry, cytokine production via ELISAs, and gene transcription via qRT-PCR. The
role of NF-kB was determined with the TransAM NF-kB colorimetric assay, and cocultures with naïve antigen-specific T cells were generated to evaluate the
immuneregulatory potential of the ligand-treated DCs.
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ABSTRACT
Crohn's disease results from a combination of genetic and environmental factors
that trigger an inappropriate immune response to commensal gut bacteria. The aryl
hydrocarbon receptor (AhR) is well known for its involvement in the toxicity of 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant that affects people
primarily through the diet. Recently, TCDD was shown to suppress immune responses by
generating regulatory T cells (Tregs). We hypothesized that AhR activation dampens
inflammation associated with Crohn’s disease. To test this hypothesis, we utilized the
2,4,6-trinitrobenzenesulfonic acid (TNBS) murine model of colitis. Mice were gavaged
with TCDD prior to colitis induction with TNBS. Several parameters were examined
including colonic inflammation via histological and flow cytometric analyses. TCDDtreated mice recovered body weight faster and experienced significantly less colonic
damage. Reduced levels of IL-6, IL-12, IFN-γ, and TNF-α demonstrated suppression of
inflammation in the gut following TCDD exposure. Foxp3egfp mice revealed that TCDD
increased the Foxp3+ Treg population in gut immune tissue following TNBS exposure.
Collectively, these results suggest that activation of the AhR by TCDD decreases colonic
inflammation in a murine model of colitis in part by generating regulatory immune cells.
Ultimately, this work may lead to the development of more effective therapeutics for the
treatment of Crohn’s disease.

KEY WORDS
Aryl hydrocarbon receptor (AhR); 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); Crohn’s
disease; inflammation; regulatory T cells (Tregs)
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INTRODUCTION
Crohn’s disease, one of the conditions encompassed by inflammatory bowel
disease, is a chronic inflammatory disease of the gastrointestinal tract that primarily
affects younger European Americans (Head and Jurenka, 2004). The exact cause of
Crohn’s disease remains unknown; however, it is suspected that both genetics and
environmental factors contribute to an inappropriate immune response to commensal
bacteria. Normally there exists a state of tolerance in the gut such that effector and
regulatory cell differentiation is balanced and immune responses are not mounted against
commensal bacteria or food substances. In Crohn’s disease, however, imbalanced
differentiation of T effector cells (Teffs) and T regulatory cells (Tregs) results in Th1and Th17-dominated inflammatory responses (Sanchez-Munoz et al., 2008). Since
current medical treatment can be associated with severe side effects and life-threatening
complications, it is essential to better understand this immune dysfunction so that novel
and more effective therapeutics can be developed.
The aryl hydrocarbon receptor (AhR) is a member of the bHLH/PAS protein
family and acts as a cytosolic, ligand-activated transcription factor that binds a variety of
synthetic and natural compounds. The AhR is perhaps most recognized in the immune
system for its role in mediating the immunotoxic effects of the prototypical ligand
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Cannonical signaling involves ligand-

activated AhR interaction with dioxin response elements to modulate gene transcription.
Many immune cells express the AhR and several cytokine genes possess dioxin response
elements so AhR activation can significantly impact immune responses. Recently, it has
been shown that the generation of CD4+CD25+ Tregs is the likely mechanism
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responsible for the immunosuppressive effects following TCDD exposure (Funatake et
al., 2005; Marshall et al., 2008). Moreover, AhR-deficient mice do not experience
immunosuppression following exposure to TCDD and TCDD-like compounds, thus
demonstrating that the effects of these chemicals are AhR-mediated.
To examine the potential of new therapeutic agents to treat Crohn’s disease, the
2,4,6-trinitrobenzenesulfonic

acid

(TNBS)-induced

mouse

model

resembles

inflammatory responses in human Crohn’s disease so it is commonly used for this
purpose (Neurath et al., 1995; Pizarro et al., 2003). In this model, TNBS binds colonic
proteins to trigger a Th1-mediated response primarily driven by the pro-inflammatory
cytokine IL-12 as well as a Th17-mediated response driven by IL-17. Excessive amounts
of TNF- and IFN- along with deficiencies in the regulatory cytokines IL-10 and TGF-
have also been observed (Kawada et al., 2007). Based on the potential for TCDD and
other AhR ligands to modulate inflammatory and immune responses by altering the
differentiation of T cells, the effects of AhR activation may be quite pronounced in this
model of colitis involving Th1 and Th17 cells.
Since Crohn’s disease affects millions of people worldwide, it is essential to
investigate the underlying mechanisms of pathogenesis so that new and more effective
therapeutics can be developed. Additionally, activation of the AhR modulates immune
and inflammatory responses so studying the effects of AhR activation on the
pathogenesis of Crohn’s disease is warranted. Therefore, we explored the effects of
TCDD on the generation of TNBS-induced colitis in mice. We hypothesized that AhR
activation reduces the inflammation generated in a murine model of Crohn’s disease by
promoting an immunosuppressive environment in the gut. Collectively, our data
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demonstrate for the first time that AhR activation by TCDD in the gut suppresses
inflammation and generates regulatory cells in the TNBS model of colitis in mice. These
results also provide novel information regarding gut mucosal immunity and suggest the
AhR may be a potential therapeutic target for Crohn’s disease.

MATERIALS AND METHODS
Laboratory animals.

Six to eight week old male and female AhR+/+, AhR-/-, and

Foxp3egfp mice (all on the C57Bl/6 background) were bred and maintained in the animal
research facility at the University of Montana. C57Bl/6 AhR+/+ were originally obtained
from The Jackson Laboratories (Bar Harbor, ME) and bred in-house. C57Bl/6 AhR-/(B6.AhRtm1Bra) mice were obtained from Dr. Paige Lawrence (University of Rochester
Medical College, Rochester, NY) and bred as previously described (Schmidt and
Bradfield, 1996). Foxp3egfp mice were kindly provided by Dr. R. Noelle (Dartmouth
Medical School, Lebanon, NH) who originally obtained these mice from Dr. A.
Rudensky (University of Washington School of Medicine, Seattle, WA). All mice were
housed under specific pathogen-free conditions and maintained on 12 h dark/light cycles.
Throughout each experiment animals were individually caged, and standard laboratory
food and water were provided ad libitum. All protocols for the use of animals were
approved by the University of Montana Institutional Animal Care and Use Committee
and adhered to the current NIH guidelines for animal usage.

Chemicals for in vivo use. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was obtained
from Cambridge Isotope Laboratories Inc., (Woburn, MA), initially dissolved in anisole
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(Sigma-Aldrich, St. Louis, MO), and further diluted in peanut oil, which was used as a
vehicle control for gavages. 2,4,6-trinitrobenzenesulfonic acid (TNBS) was also obtained
from Sigma-Aldrich and dissolved in acetone/olive oil for pre-sensitization or 40%
ethanol for enema administration.

Colitis induction. As described in Figure 2.1, mice were gavaged on day -1 and day 6
with 15 μg TCDD per kg body weight (~200-250 μl total volume) or a comparable
volume of peanut oil vehicle control prior to pre-sensitization and colitis induction. Presensitization on day 0 involved an application of 150 μl 5% TNBS in a 4:1 acetone:olive
oil solution between the shoulder blades such that mice were not orally exposed to
TNBS. Colitis was then induced via an intrarectal injection with TNBS on day 7, as
previously described with modifications (Wirtz et al., 2007). Briefly, mice were
anesthetized with isoflurane and received an enema of 2.5 mg TNBS in 40% ethanol (50
l total volume) via a 3.5 F catheter inserted 3 cm into the colon. To ensure distribution
of TNBS in the colon, mice were held in a vertical position for 90 s before being returned
to their cages. Body weight loss and the severity of clinical symptoms (overall body
condition, stool consistency, and dehydration state via a skin pinch test) was monitored
daily, as fully described in Table 2.1A. Briefly, the severity of each clinical sign was
scored on a scale 0-3 and combined to determine the total severity score. On days 10-12,
mice were euthanized via CO2 asphyxiation followed by cervical dislocation.
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Figure 2.1

Figure 2.1. Experimental design. This schematic represents the experimental design
utilized for the studies in which animals were gavaged with 15 μg/kg TCDD, peripherally
sensitized with 5% TNBS, intrarectally injected with 2.5 mg TNBS, and subsequently
harvested for evaluation.
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Table 2.1. Scoring criteria for severity of clinical symptoms and microscopic damage

A. Clinical severity
Score

I. Stool Consistency

II. Dehydration

III. Body Condition

0

Well-formed

None

Normal

1

Semi-formed

Mild

Slower movements

2

Loose

Moderate

3

Liquid

Severe

Significant weight loss or
abdominal distension
Emaciated and very slow
movements

B. Microscopic damage
Score

I. Inflammatory Cell Infiltration

II. Tissue Lesions

0

Normal

Normal

Increased numbers of inflammatory
cells in the lamina propria
Inflammatory cells extending into
the submucosa

Surface epithelial degeneration and/or
mucosal hyperplasia

1
2
3

Transmural extension of infiltrate

Focal/multifocal ulcer and/or crypt loss
Extensive mucosal damage and
ulceration

(A) Clinical severity in terms of stool consistency, dehydration, and overall body
condition was documented during disease progression. Total severity score represents a
combination of all three categories (I-III) such that clinical severity scores range from 0
to 9. (B) Hematoxylin and eosin (H&E)-stained tissue sections were scored
microscopically based on inflammatory cell infiltration and tissue lesions. The total
damage score represents a combination of scores from both categories (I and II) such that
damage scores range from 0 to 6.
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Colon processing and histology. Colons were excised from each mouse and washed with
PBS to remove debris. For histological analysis, a 1 cm section from the distal colon was
fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue
Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using
the Shandon Histocentre 2 Embedding unit, sectioned at 7 μm using the Thermo Shandon
Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon
Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded
individual to determine the severity of inflammation based on the modified scale shown
in Table 2.1B (Hartmann et al., 2000). Briefly, the extent of inflammatory cell infiltration
and tissue lesions was scored on a scale 0-3 and combined to determine a total damage
score. Slides were imaged using the Nikon E800 Microscope with Cambridge Research
Instrumentation, Inc. and Nuance camera software version 1.62 at 4X magnification. The
remaining colon was divided into two sections for cell isolation, as described below, and
homogenization in lysis buffer from which the supernatants were analyzed for cytokine
production using commercially available ELISA kits.

Cytokine assays. Supernatants from homogenized colon tissue were examined for the
levels of IL-6, IL-10, IL-12, IL-17, IFN-γ, and TNF-α via enzyme-linked immunosorbent
assay (ELISA). Samples were analyzed according to the manufacturer’s instructions
using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San Diego, CA)
or R&D ELISA kits (Minneapolis, MN).
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Antibody production. IgA production was assessed in the colon, feces, and serum. Five
days after colitis induction, colons were harvested and homogenized in lysis buffer, and
supernatants from tissue were collected. Fecal pellets were collected from the distal colon
and homogenized in 0.01% NaN3 (1 μl 0.01% NaN3 per 1 mg feces), as previously
described (Kato et al., 2001). Supernatants were collected for antibody production
analysis. Finally, immediately after euthanization, a cardiac puncture was performed to
collect serum. All samples were stored at -20°C until subsequent evaluation of antibody
levels using a commercially available ELISA kit per the manufacturer’s instructions
(SouthernBiotech, Birmingham, AL).

qRT-PCR. RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad,
CA) followed by RNA clean-up using the Total RNA Kit with optional DNase treatment
(Omega Bio-Tek, Norcross, GA) according to the manufacturers’ instructions. First
strand cDNA synthesis was performed using qScript cDNA Supermix (Quanta
Biosciences, Gaithersburg, MD). Resulting cDNA was subjected to qRT-PCR using
commercially obtained primers (SABiosciences, Frederick, MD) including aryl
hydrocarbon receptor repressor (AhRR), aldehyde dehydrogenase family 1, subfamily A2
(Aldh1a2), a proliferation-inducing ligand (APRIL), B cell activating factor (BAFF),
cytochrome P450, family 1, subfamily a, polypeptide 1 (Cyp1a1), forkhead box P3
(Foxp3), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2
(IDO2), interleukin 17A (IL17A), interleukin 17F (IL17F), RAR-related orphan receptor
gamma (Rorc), transforming growth factor, beta 1 (Tgfb1), transforming growth factor,
beta 2 (Tgfb2), and transforming growth factor, beta 3 (Tgfb3). Reactions were performed

48

with PerfeCTa SYBR Green Supermix for iQ (Quanta Biosciences) on a Bio-Rad iQ™5
Multicolor RT-PCR Detection System. Resulting data were normalized to -actin, and
fold changes were calculated using the ∆∆Ct method, which compares threshold values
of the samples of interest for a particular gene relative to a housekeeping gene.

Preparation of cells from mesenteric lymph nodes (MLNs) and colon. Mesenteric
lymph nodes (MLNs) were removed, washed in media, homogenized using the end of a
syringe plunger, and subsequently filtered through a 40 m nylon cell strainer, as
previously described (Bankoti et al., 2010a). Lamina propria mononuclear cells were also
isolated from the colon tissue, as previously described (Weigmann et al., 2007). Briefly,
colons were excised and washed with PBS, digested with collagenase/DNase (SigmaAldrich/Invitrogen), filtered, and subjected to Percoll (GE Healthcare, Pittsburg, PA)
density centrifugation. Cells from both tissues were counted via Trypan blue exclusion on
a hemacytometer, and 2x106 cells were subsequently washed with buffer prior to cell
staining.

Flow cytometry. Expression of accessory molecules on isolated cells was determined by
flow cytometry, as previously described (Shepherd et al., 2001). Briefly, cells were
washed with PAB (1% bovine serum albumin and 0.1% sodum azide in PBS). To
eliminate non-specific staining, cells were blocked with 30 μg purified rat and/or hamster
IgG (Jackson ImmunoResearch, West Grove, PA).

Optimal concentrations of

fluorochrome-conjugated monoclonal antibodies were used to stain cells for an additional
10 min. Antibodies used in these experiments included CD4-AlexaFluor 700 (GK1.5),
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CD25-PerCP/Cy5.5 (PC61), CTLA4-APC (UC10-4B9), GITR-PECy7 (YGITR), α4β7PE (DATK32), CD103-Pacific Blue (2E7), CD11c-PE (HL3), MHC2-PECy7
(M5/114.15.2), CD86-APC (GL-1), and their corresponding isotype controls, all of which
were purchased from BioLegend (San Diego, CA) or BD Biosciences (San Jose, CA).
One to five hundred thousand events were collected using a BD FACSAria flow
cytometer and analyzed using FACSDiva (Version 6.1.2, BD Biosciences, San Jose, CA)
and FlowJo (Version 8.7.1, TreeStar, Inc., Ashland, OR) software programs.

Immunohistochemistry. Using the embedded colon tissue prepared as described above, 5
μm sections were mounted on slides and allowed to air dry prior to being deparaffinized
and coverslipped using the ProLong Gold anti-fade reagent with DAPI mounting media
(Invitrogen Molecular Probes). Slides were imaged at 40X magnification using the
Olympus FluoView 1000 LSC on an inverted 1x81 microscope with spectral detection
and TIRF module (Version 2.1b software with 405, 458, 488, 515, 559, and 635 laser
lines available).

Chemicals for cell culture. TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in DMSO was
obtained from Cambridge Isotope Laboratories Inc. (Woburn, MA). For in vitro cultures,
TCDD was used at a final concentration of 1 nM, and the vehicle control DMSO (SigmaAldrich) was used at a final concentration of 0.01%. These concentrations of TCDD and
DMSO were not cytotoxic.
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Cell culture. CMT-93 cells (ATCC, Manassas, VA) were cultured in complete RPMI
media (cRPMI) consisting of RPMI (GibcoBRL, Grand Island, NY) supplemented with
10% FBS (Hyclone, Logan, UT), 50 μM mercaptoethanol, 20 mM HEPES, 10 mM
sodium pyruvate, and 50 μg/ml gentamicin (GibcoBRL). Cells were maintained at 37°C
and 5% CO2 with weekly passage and utilized for experimentation at 80-90% confluency.

Cell activation and treatment. CMT-93 cells were incubated overnight in T25 flasks to
facilitate attachment prior to experimentation. Prior to activation, cells were 80%
confluent. Cells were then concomitantly stimulated with 1 μg/ml LPS (Escherichia coli
(055:B5), Sigma-Aldrich) and treated with 1 nM TCDD or the DMSO (0.01%) vehicle
control. After 24 h, cells were harvested for qRT-PCR analysis and supernatants were
collected for analysis of IL-6, IL-10, IL-12, IFN-γ, and TNF-α levels.

Statistics. All statistical analyses were performed using GraphPad Prism 4.0a for
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare
vehicle-treated groups and TCDD-treated groups while 2-way analysis of variance
(ANOVA) with Bonferroni’s post-hoc test was used to compare multiple groups. Values
p≤0.05 were determined to be significant.

RESULTS
AhR activation by TCDD decreases the severity of clinical symptoms in TNBS-treated
mice. In order to characterize the effects of TCDD on the progression of TNBS-induced
colitis in C57Bl/6 AhR+/+ mice, clinical symptoms were monitored throughout the course
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of the experiment. Crohn’s disease is a progressive wasting disease so body weight loss is
a hallmark indicator of clinical severity. As shown in Figure 2.2A, vehicle-treated mice
rapidly lost approximately 17% of their initial body weights following TNBS exposure
and did not recover by the end of the study. Conversely, TCDD-treated mice lost only 8%
of their initial weights and recovered weight rapidly. The protective effect of TCDD was
also observed in the clinical severity of colitis, as measured by stool consistency,
dehydration, and body condition (Table 2.1A). Vehicle-treated mice typically had loose
stools, mild dehydration, and slower body movements while the TCDD-treated mice had
semi-formed stools initially but recovered quite rapidly (Figure 2.2B). Thus, TCDD
decreases the severity of clinical symptoms of mice in the TNBS-induced model of
Crohn’s disease.

Inflammation and tissue damage in the colon decreases following treatment with
TCDD. Crohn’s disease results in transmural inflammation and ulceration of the colon
tissue. To examine the degree of inflammatory cell infiltration and tissue lesions, cross
sections of the distal colon were stained with H&E and assessed microscopically to
determine damage (Table 2.1B and Figure 2.3A). Transmural infiltration of inflammatory
cells and extensive mucosal damage was frequently observed in vehicle-treated mice
following TNBS exposure, which resulted in an average damage score of 5.5. However,
the extent of inflammatory cell infiltration and lesions was significantly less in TCDDtreated mice, as represented by an average damage score of 3.2. Representative images of
each treatment group are shown in Figure 2.3B. These results demonstrate that TCDD
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Figure 2.2

Figure 2.2. TCDD reduces wasting disease and clinical symptoms associated with
TNBS-induced colitis. Animals were monitored daily after disease induction for body
weight loss (A) and other clinical symptoms including body condition, dehydration state,
and stool consistency (B). Clinical severity was determined by combining the symptom
scores for a total possible severity score of 9, as described in Table 2.1A. Results are
shown as mean ± SEM (n=6) and representative of three separate experiments. *indicates
significances of p≤0.05, **indicates significance of p≤0.01, and ***indicates significance
of p≤0.0001.
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exposure prior to colitis induction significantly suppress colonic inflammation following
TNBS insult.

AhR activation decreases the production of inflammatory mediators in colitis.
TNBS-induced colitis is driven by pro-inflammatory cytokines including IL-6, IL12, and IL-17 (Kawada et al., 2007). Accordingly, cytokine production in supernatants
from homogenized colon tissue was evaluated. As shown in Figure 2.4, TCDD decreased
the production of IL-6, IFN-γ, and TNF-α by approximately 45% each as well as the
production of IL-12 by 18%. In a separate preliminary experiment, neither IL-6
(TCDD=36318 pg/ml; vehicle=38222 pg/ml) nor IL-12 (TCDD=2763141 pg/ml;
vehicle=2633190 pg/ml) colonic levels were significantly reduced in TCDD-treated
AhR null mice when compared to the vehicle-treated wild-type controls. Furthermore,
production of IL-10 and IL-17 in the colon was unaffected by TCDD in TNBS-treated
animals. Together, these results suggest that TCDD can alter the gut immune
environment by suppressing pro-inflammatory cytokines in an AhR-dependent manner
and decrease inflammation associated with TNBS-induced colitis.
The effects of TCDD on antibody production were also assessed because IgA
plays an important role in regulating immune responses in the gut. Following TCDD
treatment, IgA levels in the supernatants from homogenized colon tissue and feces
increased from 38.89 μg/ml to 54.99 μg/ml and from 5.85 μg/ml to 15.46 μg/ml,
respectively (Table 2.2), an effect that was not observed in AhR null mice treated with
TCDD (data not shown). While a trend was observed for a TCDD-induced increase in
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Figure 2.3

Figure 2.3. Colonic inflammation is reduced following exposure to TCDD. Animals
were harvested five days after disease induction, and a section of the distal colon assessed
microscopically. Damage score (A) was determined by combining the scores for
inflammatory cell infiltration (0-3) and tissue damage (0-3), as described in Supplemental
Table 1B. Representative images of H&E-stained tissues sections of vehicle-treated and
TCDD-treated animals are shown in B. Results are shown as mean ± SEM (n=6) and are
representative of three separate experiments. **indicates significance of p≤0.01.
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Figure 2.4

Figure 2.4. Modulation of cytokine production by TCDD in colon tissue. On day five
following disease induction, colons were excised, washed, and homogenized. The
supernatants were assessed for cytokine production, as described in the Materials and
Methods. Results are shown as mean ± SEM (n=6) and representative of three separate
experiments. *indicates significance of p≤0.05 and **indicates significance of p≤0.01.
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IgA in the serum of TNBS-exposed mice, this effect was not statistically significant.
TCDD also increased total Ig production in the colon from 48.67 μg/ml to 113.1 μg/ml
but did not alter total Ig levels in the feces or serum. Interestingly, without the TNBStriggered inflammatory response, TCDD did not induce significant increases in IgA
production in the gut (data not shown). Thus, TCDD modulates humoral immune
responses in the gut of TNBS-treated mice.
We also examined the potential for intestinal epithelial cells (IECs) to contribute to the
suppression of inflammation following TCDD treatment since these cells are important in
maintaining the mucosal barrier against gut flora and mounting immune responses by
acting as antigen presenting cells. CMT-93 cells, a murine intestinal epithelial cell line,
were stimulated with 1 μg/ml LPS and concurrently treated with TCDD. The LPSinduced production of IL-6, as determined by ELISA, was suppressed by TCDD
treatment (Table 2.3A). Similar effects were observed when cells were stimulated with
CpG and concomitantly treated with TCDD (data not shown). IL-10, IL-12, and IFN-γ
were not detected in either of these experiments (data not shown).

TCDD alters transcription of immunoregulatory genes in colonic tissue of TNBStreated mice.

To gain further insight into factors that may be responsible for the

immunomodulatory effects of TCDD in colitis, intestinal tissue was evaluated by qRTPCR to assess changes in gene transcription. Three days after colitis induction, which
was the peak of clinical disease severity, TCDD enhanced the expression of AhRR,
Cyp1a1, and IDO1 by 6.74, 216.40, and 2.91 fold, respectively (Table 2.4). Conversely,
mRNA levels of APRIL, IDO2, and IL17A were decreased. Five days after enema
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Table 2.2. Effects of TCDD on antibody production in TNBS-exposed micea

Colon
Feces
Serum

a

IgA (μg/ml)
Vehicle
TCDD
39.89 ± 3.75
54.99 ± 8.39*
5.85 ± 1.40
15.46 ± 3.31***
147.20 ± 7.11
173.70 ± 14.53

Total Ig (μg/ml)
Vehicle
TCDD
48.67 ± 4.52
113.1 ± 16.43***
8.38 ± 1.52
9.51 ± 1.80
3.056 ± 0.28§
2.43 ± 0.35§

Supernatants from colon tissue, feces, and blood were obtained five days after colitis

induction from vehicle- and TCDD-treated mice, as described in Supplemental Materials
and Methods, and subsequently analyzed for IgA and total Ig production. Data is shown
as mean ± SEM, which is representative of three separate experiments (n=6). *indicates
significance of p≤0.05 when compared to vehicle-treated controls and ***indicates
significance of p≤0.0001. §indicates mg/ml.
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Table 2.3. Effects of TCDD on cytokine production and gene transcription in cultured
IECs
A. TCDD decreases the LPS-induced production of IL-6
IL-6 (pg/ml)
Treatment
DMSO
BD
1 nM TCDD
BD
LPS
485.6 ± 15.8
1 nM TCDD + LPS
133.2 ± 6.9***
B. TCDD alters gene transcription in IECs
Gene
APRIL
BAFF
Cyp1a1
IL6
IDO1
IDO2
Tgfb1
Tgfb2
Tgfb3

LPS
Fold Change
4.53
3.12
-1.10
11.90
-1.76
1.92
1.27
2.00
-1.09

p-value
0.045
0.092
0.237
0.0003
0.274
0.035
0.058
0.013
0.322

1nM TCDD
Fold Change
p-value
0.006
2.83
1.04
0.397
124.80
<0.0001
0.0009
-3.15
-1.00
0.495
1.27
0.102
1.01
0.466
0.006
-1.91
-1.26
0.105

1nM TCDD + LPS
Fold Change
p-value
0.001
6.85
0.002
2.45
<0.0001
195.80
0.015
2.68
-1.06
0.454
2.00
0.053
0.017
1.98
1.48
0.070
1.27
0.175

(A) Supernatants were harvested 24 h after concurrent treatment of LPS and TCDD and
subsequently assessed for cytokine production, as fully described in the Supplemental
Materials and Methods. ***indicates significance of p≤0.0001 when compared to the
LPS-stimulated samples. BD represents below detection. (B) Cells were treated as
described in A and lysed in Trizol for qRT-PCR analysis. Fold change is relevant to
vehicle-treated mice and normalized to β-actin. Genes analyzed include: a proliferationinducing ligand (APRIL), B cell activating factor (BAFF), cytochrome P450, family 1,
subfamily a, polypeptide 1 (Cyp1a1), indoleamine-2,3-dioxygenase 1 (IDO1),
indoleamine-2,3-dioxygenase 2 (IDO2), interleukin 6 (IL6), transforming growth factor,
beta 1 (Tgfb1), transforming growth factor, beta 2 (Tgfb2), and transforming growth
factor, beta 3 (Tgfb3). Data shown are representative of one experiment (n=6). Bolded pvalues indicate significance of p≤0.05.
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administration, a significant upregulation of AhRR, Cyp1a1, and IDO was observed;
however, mRNA levels of IL17A and IL17F were unaffected by TCDD, which was
consistent with the results obtained from the ELISA. Although not significant, a modest
trend for increased TGFβ3 mRNA following AhR activation by TCDD was observed in
wild type animals. These effects, with the exception of Cyp1a1 and AhRR induction,
were specific to the inflamed colonic tissue and did not affect tissue from the small
intestine.
The ability of TCDD to also alter inflammatory responses by IECs was assessed
via qRT-PCR. TCDD induced Cyp1a1 mRNA and downregulated the LPS-induced
expression of IL6 (Table 2.3B). Moreover, TCDD treatment of LPS-stimulated IECs
resulted in a 6.85- and 2.45-fold upregulation in APRIL and BAFF, respectively. Thus,
IECs may be directly affected by TCDD to help mount immunosuppressive responses in
the inflamed gut by decreasing the production of pro- inflammatory cytokines and
enhancing the activity of B cells and their subsequent IgA responses.

Immunoregulatory cells in the MLNs and colon are induced following AhR activation.
AhR activation by TCDD promotes the generation of Tregs in several disease models so
we hypothesized that TCDD dampened inflammation in TNBS-treated mice by
increasing regulatory cell populations in the gut. Therefore, Foxp3egfp mice that contain a
knock-in allele encoding a green fluorescent protein (GFP)-Foxp3 fusion protein were
utilized to specifically assess the presence of Foxp3+ Tregs. Initial experiments with
these mice revealed no significant changes in regulatory cell populations when mice were
harvested five days after TNBS enema administration (data not shown). Since the
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Table 2.4. TCDD alters gene transcription in the intestinal tissue of TNBS-exposed micea

Gene
AhRR
Aldh1a2
APRIL
BAFF
Cyp1a1
Foxp3
IDO1
IDO2
IL17A
IL17F
Rorc
Tgfb1
Tgfb2
Tgfb3

a

Small Intestine
Day 3
Fold
p-value
Change
0.026
2.17
1.01
0.494
-1.01
0.475
-1.06
0.413
0.0009
50.56
1.26
0.331
1.65
0.109
-1.27
0.271
2.89
0.255
1.64
0.165
1.24
0.143
1.08
0.328
-1.25
0.270
-1.05
0.400

Colon
Day 3
Fold
Change
6.74
1.42
-2.05
-1.62
216.40
-1.07
2.91
-1.67
-9.40
1.46
1.23
1.36
1.00
1.16

Colon
Day 5

p-value
0.009
0.088
0.024
0.115
0.0002
0.450
0.006
0.067
0.009
0.220
0.198
0.116
0.495
0.274

Fold
Change
25.49
1.43
-1.29
-1.22
1807
-1.17
2.15
-1.05
-1.47
1.25
-1.38
-1.19
1.16
1.71

p-value
<0.0001
0.179
0.179
0.191
<0.0001
0.366
0.026
0.440
0.265
0.337
0.236
0.299
0.335
0.051

Three or five days following colitis induction, colon tissue from wild type mice treated

with TCDD was homogenized in Trizol and subjected to qRT-PCR to assess alterations
in gene transcription. Fold change is relevant to vehicle-treated mice and normalized to
β-actin. Genes analyzed include: aryl hydrocarbon receptor repressor (AhRR), aldehyde
dehydrogenase family 1, subfamily A2 (Aldh1a2), a proliferation-inducing ligand
(APRIL), B cell activating factor (BAFF), cytochrome P450, family 1, subfamily a,
polypeptide 1 (Cyp1a1), forkhead box P3 (Foxp3), indoleamine 2,3-dioxygenase (IDO1),
1 indoleamine 2,3-dioxygenase 2 (IDO2), interleukin 17A (IL17A), interleukin 17F
(IL17F), RAR-related orphan receptor gamma (Rorc), transforming growth factor, beta 1
(Tgfb1), transforming growth factor, beta 2 (Tgfb2), and transforming growth factor, beta
3 (Tgfb3). Bolded values indicate significance of p≤0.05. Data are representative of a
single experiment with n=6 mice per treatment group.
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peak of clinical disease severity occurred three days after disease induction, Foxp3egfp
mice were evaluated three days following the TNBS enema. Populations of regulatory
cells, both Tregs and dendritic cells (DCs), following TCDD treatment were analyzed in
the colon tissue and MLNs (Table 2.5). Several markers were used to define regulatory
cell populations: Tregs were characterized by the expression of CD4, CD25, Foxp3,
CTLA4, GITR, CD103, and α4β7 while DCs were characterized by the expression of
CD11c, MHC class II, CD86, and CD103.
In the MLNs, TCDD increased the percentage of CD4+CD25+Foxp3+ cells from
6.34% to 7.74%, and the percentage of these Tregs that expressed CD103 increased by
6.5% (Table 2.5A), an effect that did not occur in AhR null mice treated with TCDD
(data not shown). Additionally, the CD4+CD25-Foxp3+ Tregs were also evaluated since
it has recently been shown that TCDD-induced CD25- Tregs can effectively suppress
immune responses (Funatake et al., 2009). The percentage of CD103+ and α4β7+ cells
increased in the CD4+CD25-Foxp3+ Treg population by approximately 10% and 3%,
respectively. In the colon, TCDD increased the number of cells expressing CTLA4 from
4.05% to 13.80% as well as the relative expression (MFI) of GITR from 386 to 710 in the
CD4+CD25+Foxp3+ Tregs, even though this population was significantly decreased
following TCDD exposure. Additionally, this population of Tregs also exhibited a 12%
increase in cells expressing α4β7. AhR activation by TCDD also increased the percentage
of CD4+CD25-Foxp3+ cells expressing CTLA4 as well as the relative expression of
GITR from 325 to 458, CD103 from 1639 to 1915, and α4β7 from 155 to 185.
Immunohistochemistry performed on the colon tissue revealed an increased Treg
population in TNBS-treated mice, as more Foxp3+ expression was observed in mice
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treated with TCDD (Figure 2.8). It should be noted that TCDD treatment in the absence
of the TNBS enema did not induce an increased frequency of Foxp3+ cells in the gut
(data not shown).
Regulatory DCs were also examined in these experiments because these cells can
promote

the

generation

of

Tregs.

TCDD

increased

the

percentage

of

CD11c+MHC2+CD103+ DCs in the MLNs from 8.673% to 11.88% (Table 2.5B), an
effect that was also not observed in AhR null mice (data not shown). However, a greater
frequency of CD11c+ DCs isolated from the colon expressed decreased levels of MHC
class 2. Collectively, these results suggest that AhR activation by TCDD induces
regulatory immune cells in the gut that may reduce the inflammation in mice
experiencing TNBS-induced colitis.
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Table 2.5. Effects of TCDD on immune cells and their regulatory cell surface marker
expression during TNBS-induced colitis in Foxp3egfp micea
A. Tregs in the gut

CD4+CD25+Foxp3+
CTLA4
GITR
CD103
47
CD4+CD25-Foxp3+
CTLA4
GITR
CD103
47

Vehicle
6.34
11.78
83.86
45.36
18.12
3.90
2.20
78.66
32.90
5.60

MLNs
TCDD
7.74
12.30
85.52
51.90
20.04
3.98
2.94
78.88
42.74
8.36

p-value
0.036
0.411
0.274
0.008
0.263
0.444
0.151
0.472
<0.0001
0.009

Vehicle
26.8
4.05
386
1945
235
16.78
0.62
325
1639
155

Colon
TCDD
15.98
13.80
710
2072
263
17.02
1.42
458
1915
185

p-value
0.017
0.001
<0.0001
0.104
0.029
0.445
0.033
0.005
0.007
0.013

B. DCs in the gut

CD11c+
MHC2
CD86
CD103
MHC2+CD103+
a

Vehicle
3.43
81.73
652
24.43
8.673

MLNs
TCDD
2.74
82.4
592
33.14
11.88

p-value
0.036
0.369
0.228
0.005
0.024

Vehicle
9.56
20.56
338
88.54
6.595

Colon
TCDD
11.65
11.07
364
92.43
4.910

p-value
0.030
0.001
0.288
0.160
0.089

Leukocytes from colon tissue and mesenteric lymph nodes (MLNs) were isolated three

days after disease induction and immunophenotypically evaluated by flow cytometry to
determine the presence of regulatory T cells (Tregs) and dendritic cells (DCs). Values are
listed as the percent of the bolded parent population indicated in the table, except for
GITR, CD103, and α4β7 expression on colon T cells and CD86 expression on DCs,
which indicate the Median Fluorescence Intensity (MFI) values. Bolded p-values indicate
significance of p≤0.05. Data are representative of a single experiment (n=6).
Representative histograms are shown in Figures 2.5-2.7.

64

Figure 2.5

Figure 2.5. Representative histograms for T cells isolated from the MLNs.
Leukocytes were harvested from MLNs three days after disease induction, as described in
Materials and Methods. Gating strategy is displayed in a linear manner to define
regulatory characteristics of CD4+ T cells.
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Figure 2.6

Figure 2.6. Representative histograms for T cells isolated from colonic tissue.
Leukocytes were harvested from the colon three days after disease induction, as
described in Materials and Methods. Gating strategy is displayed in a linear manner to
define regulatory characteristics of CD4+ T cells.
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Figure 2.7

Figure 2.7. Representative histograms for DC isolated from the MLNs and colonic
tissue. Leukocytes were harvested from MLNs and the colon three days after disease
induction, as described in Materials and Methods. Gating strategy is displayed in a linear
manner to define surface phenotype of CD11c+ DCs.
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Figure 2.8

Figure 2.8. TCDD increases Foxp3 expression in colon tissue. Colons were harvested
from Foxp3egfp mice three days after disease induction. Tissues were sectioned, mounted
on slides, and stained with DAPI to visualize the nucleus. Slides were imaged at 40X
magnification using the Olympus FluoView 1000 LSC on an inverted 1x81 microscope
with spectral detection and TIRF module.

Images are representative of a single

experiment (n=6).
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DISCUSSION
Crohn’s disease arises from a combination of genetic and environmental factors
that trigger an inappropriate immune response against commensal bacteria. This disease
is characterized by progressive weight loss, transmural inflammation in the intestines,
and infiltration of inflammatory cells that produce inflammatory mediators. More
specifically, many pro-inflammatory cytokines, such as IL-12, are upregulated in the
inflamed intestinal mucosa of Crohn’s disease patients (Monteleone et al., 1997;
Parronchi et al., 1997; Liu et al., 1999; Abraham and Cho, 2008; Eastaff-Leung et al.,
2010). Thus, the first goal of this study was to characterize the effects of TCDD treatment
in gut mucosal inflammation associated with TNBS-induced colitis. When compared to
vehicle-treated mice, TCDD treatment significantly reduced disease severity, as indicated
by decreased body weight loss, recovery periods, and colonic inflammation. TCDD also
altered the cytokine environment by decreasing production of the inflammatory mediators
IL-6, IL-12, IFN-γ, and TNF-α. Notably, five days after colitis induction, TCDD did not
appear to affect IL-10 or IL-17 protein levels, which have both been implicated in human
IBD. Although the TNBS-induced colitic response in mice is mediated primarily by Th1
cells and may not correlate exactly with the human condition that involves both Th17 and
Th1 cells, no animal model perfectly represents human IBD. However, TNBS-induced
colitis in mice does induce many of the inflammatory sequelae that contribute to human
IBD, and thus this model is very useful for assessment of these early events.
Recently, Takamura and colleagues utilized the dextran sodium sulfate (DSS)
model of ulcerative colitis, another type of inflammatory bowel disease, to study the
effects of TCDD on gut inflammation (Takamura et al., 2010). In their model, pre-
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treatment with TCDD ameliorated disease severity, inflammation, and TNF-α production
in colonic tissue of DSS-treated mice. Although these results were obtained in a model
that elicits a slightly different immune response, our results are consistent with those
obtained in this independent study. Thus, TCDD treatment suppresses pro-inflammatory
cytokine production that may be responsible for propagating inappropriate effector T cell
responses in the gut. Interestingly, the TCDD dose (15 ug/kg) that was used in our studies
was slightly higher than the TCDD dose (5 μg/kg) used by Takamura and colleagues.
Selection of the dose of TCDD in our experiments was based on the reproducible, but not
overtly toxic, effects of 15 ug/kg in many models of immunity performed in C57Bl/6
mice. To date, we have not performed dose-response studies; however, it would be of
interest to evaluate the potential for both higher and lower doses to affect inflammation
associated with the colitic response in TNBS-treated mice.
The intestinal immune system is comprised of organized lymph tissue, various
innate and adaptive immune cells, and intestinal epithelial cells (IECs). In addition to the
cells located in the lamina propria, the mesenteric lymph nodes (MLNs) are essential sites
for mounting successful adaptive immune responses against pathogens in the gut. In the
healthy gut, there is a balance between effector and regulatory cells such that no response
is elicited against commensal organisms. In Crohn’s disease, this balance is disrupted and
many cellular components contribute to the exaggerated immune and inflammatory
responses. In the inflamed mucosa of Crohn’s disease patients, there is a significant
decrease in Foxp3 expression in CD4+CD25+ cells along with decreased numbers of
CD4+CD25+Foxp3+ cells, which may contribute to enhanced Th1- and Th17-mediated
immune responses (Eastaff-Leung et al., 2010). Moreover, TCDD has been reported to
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induce CD4+CD25+ T cells that express elevated levels of GITR and CTLA4 and
suppress proliferation of effector T cells (Funatake et al., 2005). Thus, we investigated
potential alterations in several key immune cell populations in the context of gut mucosal
immunity. Pre-treatment of Foxp3egfp mice with TCDD increased Foxp3+ cells in the gut
of TNBS-treated mice. These cells displayed increased levels of GITR, CTLA4, and
CD103, which indicate a regulatory potential for these cells. It must be acknowledged
that our flow cytometry data revealed a decreased frequency of Foxp3+ cells while the
immunohistochemistry images revealed increased Foxp3+ expression in the colonic
tissue. This discrepancy is potentially due to the fact that the colon section removed for
histology was at the site of TNBS administration, and therefore possessed the most severe
inflammation, while surrounding tissue was used to isolate leukocytes for flow
cytometric analyses. Even though the GFP fluorescence was not quantified in these
images, the increase of Foxp3+ Tregs at the site of inflammation in TCDD-treated mice
most likely contributes to decreased inflammation. Furthermore, Treg induction by
TCDD may primarily occur in the context of an inflammatory environment since we did
not observe increased Foxp3 expression with TCDD treatment alone. Regulatory DCs
were also present in the MLNs, as indicated by increased frequencies of CD103+ DCs.
Although not directly assessed by flow cytometry, downregulation of IL17A mRNA in
the colon suggests that TCDD may decrease Th17 cells; however, no corresponding
changes in IL-17 protein levels were observed. We expect that performing these studies
in Rorγt reporter mice will fully define the contribution of Th17 cells in this model and
how TCDD might affect this population of inflammatory T cells. Taken together, our
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results demonstrate that TCDD generates regulatory cells that may contribute to
decreased inflammation in the gut of TNBS-treated mice.
Successful antibody responses in the gut are essential to limiting inappropriate
responses against commensal bacteria. IgA is the primary antibody responsible for
limiting bacterial penetration in the gut (Macpherson and Uhr, 2004), and its production
is promoted by TGF-β. In the normal intestinal immune environment DCs maintain a
tolerogenic environment, as they are conditioned by TGF-β and PGE-2 to secrete IL-10
and/or TGF-β (Iwasaki and Kelsall, 1999; Chirdo et al., 2005). In addition, IECs play an
important role in the innate and adaptive immune responses in the gut. The epithelium is
not only the first line of defense against bacteria, but IECs can also act as antigen
presenting cells capable of influencing intestinal immune function. Defects in the
epithelial barrier have been associated with CD pathogenesis (Baumgart and Dignass,
2002). In our experiments, IgA production was increased in the colon tissue and feces
suggesting that TCDD may be acting on DCs and/or IECs to produce switch factors
necessary to induce IgA production by B cells in the gut. Additionally, BAFF and APRIL
are expressed in many immune cells and play important roles in lymphocyte homeostasis
(Ng et al., 2005). Although BAFF transcript levels were reduced in the colon, TGFβ
upregulation was observed, which may be responsible in part for the increased IgA
production in the gut following TCDD treatment in TNBS-exposed mice. Moreover,
stimulated IECs upregulated BAFF and APRIL mRNA levels following TCDD exposure.
Thus, IECs may contribute to the amelioration of disease severity in the TNBS-induced
colitis model by contributing to increased production of IgA. Additional studies focused
on further defining the effects of TCDD on IgA production in the gut and the
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mechanisms responsible for these effects are warranted. It must be emphasized that
TCDD may be acting on T cells, B cells and other immune and non-immune cells to
reduce inflammation in the gut, and we believe that these events need not be mutually
exclusive. Indeed, it is very likely that the effects of TCDD on all of these cells
collectively may be necessary to generate a regulatory environment during TNBSinduced colonic inflammation. Thus, to definitively determine if TCDD is acting directly
on T cells or indirectly on B cells, DCs or IECs to mount protective immune responses
during the generation of colitis, it would be necessary to perform adoptive transfer
experiments or generate TNBS-induced colitis in AhR conditional knockout mice. Our
laboratory is currently pursuing these experimental possibilities.
The effects of TCDD notably occur via activation of the AhR, which is a ligandactivated transcription factor present in many immune cells including T cells, B cells,
DCs, and macrophages (Marshall and Kerkvliet, 2010). As such, activation of the AhR
by TCDD results in the suppression of immune and inflammatory responses. Since it has
been demonstrated in AhR-deficient mice that the immunosuppressive effects of TCDD
are AhR-dependent, we anticipate that TCDD is also acting through the AhR to suppress
colitis. Although our preliminary study using AhR null mice suggested that many of our
observed TCDD-induced effects are dependent on the AhR, additional studies are
currently underway in our laboratory to fully examine the role of the AhR in mediating
the effects of TCDD as well as endogenous AhR ligands in TNBS-induced colitis.
Indoleamine-2,3-dioxygenase (IDO) has been implicated in promoting the
generation of Tregs. Tryptophan, an essential amino acid, is primarily catabolized via
induction of IDO, an enzyme that has been linked to immune tolerance. Furthermore,

73

tryptophan metabolites can activate the AhR (Fallarino et al., 2002; Frumento et al.,
2002; Terness et al., 2002; Denison and Nagy, 2003; Belladonna et al., 2006; Fallarino et
al., 2006). It has been suggested that by binding to the AhR in activated CD4+ T cells,
tryptophan metabolites can elicit their immunosuppressive effects by inducing a Treg
phenotype. Moreover, Bankoti and colleagues recently demonstrated that TCDD
upregulated IDO1, IDO2, TGFβ1, and TGFβ2 in LPS-stimulated inflammatory bone
marrow-derived DCs (Bankoti et al., 2010b). In our study, TCDD treatment increased
IDO1 transcript levels in the colon of TNBS-treated mice. It is therefore possible that
TCDD induces IDO in the intestinal DCs and/or CD4+ T cells subsequently leading to a
significant induction of Tregs in mice exposed to TNBS. Furthermore, tolerogenic DCs
capable of promoting Treg differentiation can be generated following the interaction of
ligand-activated AhR with RelB via the non-canonical NF-kB signaling pathway, an
effect that is mediated via IDO induction in DCs and subsequent Foxp3 expression in T
cells (Mellor et al., 2004; Belladonna et al., 2007; Curti et al., 2007; Tas et al., 2007;
Vogel et al., 2008; Bankoti et al., 2010b).
Current therapeutic strategies for Crohn’s disease involve a combination of
corticosteroids and immunomodulatory drugs to rapidly reduce inflammation and induce
remission. These therapeutics, however, often possess severe adverse effects. Although
TCDD suppressed colonic inflammation in this model, it is recognized that TCDD would
not serve as a useful therapeutic agent for Crohn’s disease patients due to its potential
toxic side effects. There are numerous other AhR ligands present in the diet, such as
indole-3-carbinol in cruciferous vegetables and resveratrol in grapes that have
documented anti-inflammatory properties and have little or no associated toxicity (Leibelt
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et al., 2003; Aggarwal and Shishodia, 2006; Cottart et al., 2010). Thus, it is possible that
AhR agonists found naturally in the diet can activate the AhR to reduce disease severity
similar to TCDD. Recent studies have suggested a potential protective effect in the colitic
response for 3,3’-diindolylmethane, the acid condensation product of indole-3-carbinol
(Kim et al., 2009) and resveratrol (Martin et al., 2006; Larrosa et al., 2009; Cui et al.,
2010). Although these studies were not performed in TNBS-treated mice, they
demonstrated decreased disease severity and gut inflammation during a colitic response;
however, the role of the AhR in mediating the effects in each of these studies was not
evaluated. Conversely, AhR activation by 6-formylindolo[3,2-b]carbazole (FICZ), a
typtophan metabolite, exacerbated inflammatory responses by promoting Th17
differentiation in some murine disease models, such as experimental autoimmune
encephalitis (Martin et al., 2006; Ho and Steinman, 2008; Quintana et al., 2008;
Veldhoen et al., 2008). Although ligand-specific effects may be due to the timing and
duration of AhR activation, it must be emphasized that, to date, it is not well understood
why some AhR ligands, such as FICZ, have the potential to promote the development of
Th17-mediated inflammatory responses while others, such as TCDD, promote the
development of Treg-mediated suppressive responses. Therefore, it is critical to continue
to evaluate the effects of AhR activation by multiple ligands in the context of gut
inflammation.
Collectively, our results demonstrate for the first time that the potent AhR ligand
TCDD suppresses gut inflammation and disease severity in the murine model of TNBSinduced colitis, an effect that correlates with an induction of Tregs. Further investigations
are needed to elucidate the signaling events responsible for Treg generation in the gut, as
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TCDD may induce Tregs directly or alternatively via the generation of regulatory DCs. It
would also be interesting to evaluate other AhR ligands, as these compounds may prove
to represent a new class of therapeutics to treat Crohn’s disease in humans.
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ABSTRACT
Due to the severe adverse effects that can accompany conventional therapies for
Crohn’s disease, the search for natural complementary therapies has increased
dramatically in recent years. Indole-3-carbinol (I3C), a constituent of cruciferous
vegetables, possesses anti-inflammatory properties; however, its effects on intestinal
inflammation have yet to be evaluated.

To test the hypothesis that I3C dampens

intestinal inflammation, C57Bl/6 mice were treated with I3C and exposed to 2,4,6trinitrobenzenesulfonic acid (TNBS) to induce colitis. Several parameters of disease
severity and inflammation were subsequently evaluated.

I3C dampened the disease

severity, as indicated by decreased body weight loss and decreased severity of clinical
signs.

Interestingly, this effect was observed in female but not male mice, which

displayed a trend towards exacerbated colitis. Differential effects were observed in the
profiles of cytokine production, as the production of pro-inflammatory cytokines was
increased in males.

The sex-specific effect of I3C in TNBS-induced colitis is a novel

finding and warrants further investigation since this is a common dietary compound and
is also available commercially.

KEY WORDS
Indole-3-carbinol (I3C); inflammation; Crohn’s disease
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INTRODUCTION
The desire to identify natural products to treat and prevent various diseases has
increased dramatically in recent years due to the decreased satisfaction with conventional
therapeutics. One compound of interest is indole-3-carbinol (I3C), a prevalent constituent
of cruciferous vegetables including broccoli, brussel sprouts, and cabbage.

I3C is

primarily recognized for its potent anti-cancer properties since it has the unique ability to
eliminate tumor cells while being protective in normal cells. Importantly, no immediate
or long-term severe adverse effects have been documented following human consumption
in several cancer clinical trials (Bradlow et al., 1994; Reed et al., 2005; Rosen and
Bryson, 2004; Wong et al., 1997) thereby emphasizing its usefulness as a therapeutic
agent.
Several molecular targets have been identified for I3C and its metabolites, such as
the primary acid condensation product diindolylmethane (DIM). Activities contributing
the observed effects of I3C include decreased proliferation, increased apoptosis, and
decreased metastasis (reviewed in Aggarwal and Ichikawa, 2005). Furthermore, I3C can
bind several cytosolic receptors and alter several important signaling pathways including
aryl hydrocarbon receptor (AhR), estrogen receptor (ER), androgen receptor (AR), and
nuclear factor-kappa B (NF-κB). A complex signaling cascade is likely induced
following I3C exposure due to crosstalk between these pathways including physical
interaction of the ligand-bound AhR with NF-κB (Vogel et al., 2007a; Vogel et al.,
2007b) and the ER (Matthews et al., 2005; Ohtake et al., 2003; Wormke et al., 2003).
While I3C has been primarily investigated for its anti-cancer properties, there has
been increased interest in evaluating its immunomodulatory properties.

It has been

83

documented that I3C can suppresses inflammation in vitro and in vivo in part by
inhibiting NF-κB activation and decreasing production of inflammatory mediators
(Benson and Shepherd, 2011b; Chang et al., 2011; Takada et al., 2005; Tsai et al., 2010).
Therefore, the potential exists for this compound to be effective in reducing the severity
of chronic inflammatory diseases including Crohn’s disease and ulcerative colitis, which
are inflammatory bowel diseases.

In fact, the I3C acid condensation product DIM

suppressed disease severity of dextran sodium sulfate (DSS)-induced colitis, which is an
animal model of ulcerative colitis (Kim et al., 2009). However, the potential beneficial
effects of its parent compound, I3C, on intestinal inflammation have yet to be
investigated.
In this study we assessed the potential of I3C to suppress inflammation in a
murine model of Crohn’s disease.

We hypothesized that I3C would exert anti-

inflammatory effects in the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis.
Our results demonstrate for the first time that I3C exerts sex-specific effects in TNBS
colitis, as it ameliorates disease severity and inflammation in female, but not male, mice.
I3C clearly has potential to be a useful therapeutic for intestinal inflammation; however,
future studies are necessary to further define the sex-specific effects of this compound in
the gut.

MATERIALS AND METHODS
Laboratory animals. Six to eight week old male and female C57Bl/6 mice, originally
obtained from The Jackson Laboratories (Bar Harbor, ME), were bred and maintained in
the animal research facility at the University of Montana. All mice were housed under
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specific pathogen-free conditions and maintained on 12 h dark/light cycles. Throughout
each experiment animals were individually caged, and standard laboratory food and water
were provided ad libitum. All protocols for the use of animals were approved by the
University of Montana Institutional Animal Care and Use Committee and adhered to the
current NIH guidelines for animal usage.

Chemicals. Indole-3-carbinol (I3C) was obtained from Sigma-Aldrich (St. Louis, MO),
and suspended in peanut oil, which was used as a vehicle control for gavages, at 10
mg/ml.

The purity and stability of I3C was verified in house via NMR.

2,4,6-

trinitrobenzenesulfonic acid (TNBS) was also obtained from Sigma-Aldrich and
dissolved in acetone/olive oil for pre-sensitization or 40% ethanol for enema
administration.

Colitis induction. As described in Figure 3.1, mice were gavaged daily starting on day -1
and ending on day 6 with 100 mg I3C per kg body weight (~200-250 μl total volume) or
a comparable volume of peanut oil vehicle control prior TNBS exposures. Presensitization on day 0 included an application of 150 μl 5% TNBS in a 4:1 acetone:olive
oil solution between the shoulder blades. Colitis was then induced via an enema
containing TNBS on day 7, as previously described (Benson and Shepherd, 2011). Body
weight loss and the severity of clinical symptoms (overall body condition, stool
consistency, and dehydration state) was monitored daily and scored as previously
described in detail (Benson and Shepherd, 2011a). On day 12, mice were euthanized via
CO2 asphyxiation followed by cervical dislocation.
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Figure 3.1

Figure 3.1. Experimental design. This schematic represents the experimental design
utilized for the studies in which animals were gavaged daily with 100 mg/kg I3C,
peripherally sensitized with 5% TNBS, intrarectally injected with 2.5 mg TNBS, and
subsequently harvested on day 12 for evaluation.
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Colon processing and histology. Colons were excised from each mouse and washed with
PBS to remove debris. For histological analysis, a 1 cm section from the distal colon was
fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue
Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using
the Shandon Histocentre 2 Embedding unit, sectioned at 7 μm using the Thermo Shandon
Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon
Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded
individual to determine the severity of inflammation based on an established scoring table
(Benson and Shepherd, 2011a). Slides were imaged using the Nikon E800 Microscope
with Cambridge Research Instrumentation, Inc. and Nuance camera software version
1.62 at 10X magnification. The remaining colon was divided into two sections for cell
isolation, as described in Supplemental Material and Methods, and homogenization in
lysis buffer from which the supernatants were analyzed for cytokine production, as
described below.

Cytokine assays. Supernatants from homogenized colon tissue were examined for the
levels of IL-1β, IL-6, IL-10, IL-12, IL-17, and IFN-γ via enzyme-linked immunosorbent
assay (ELISA). Samples were analyzed according to the manufacturer’s instructions
using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San Diego, CA)
or R&D ELISA kits (Minneapolis, MN).

qRT-PCR. RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad,
CA) and subjected to RNA clean-up using the Total RNA Kit with optional DNase
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treatment (Omega Bio-Tek, Norcross, GA) according to the manufacturers’ instructions.
First strand cDNA synthesis was performed using qScript cDNA Supermix (Quanta
Biosciences, Gaithersburg, MD). Resulting cDNA was subjected to qRT-PCR using
commercially obtained primers (SABiosciences, Frederick, MD or Integrated DNA
Technology, Coralville, IA) including aryl hydrocarbon receptor (AHR), aldehyde
dehydrogenase family 1, subfamily A1 (ALDH1A1), aldehyde dehydrogenase family 1,
subfamily A2 (ALDH1A2), estrogen receptor alpha (ESR1), estrogen receptor beta
(ESR2), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2 (IDO2),
interleukin 6 (IL6), interleukin 10 (IL10), interleukin 17A (IL17A), interleukin 17F
(IL17F), interleukin 22 (IL22), transforming growth factor, beta 1 (TGFB1), transforming
growth factor, beta 2 (TGFB2), and transforming growth factor, beta 3 (TGFB3).
Reactions were performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences)
on an Agilent Technologies Stratagene Mx3005P QPCR System (Santa Clara, CA).

Flow cytometry. Lamina propria mononuclear cells from colonic tissue and cells from
the mesenteric lymph nodes (MLNs) were isolated and evaluated for expression of
accessory molecules by flow cytometry, as previously described (Benson and Shepherd,
2011). Briefly, after cells were washed with PAB (1% bovine serum albumin and 0.1%
sodum azide in PBS), they were blocked with Fc block (BioLegend, San Diego, CA) to
eliminate non-specific staining.

Subsequently, cells were stained for 10 min using

optimal concentrations of fluorochrome-conjugated monoclonal antibodies. Antibodies
used in these experiments included CD4-PE (GK1.5), CD25-PerCP/Cy5.5 (PC61),
CD11c-APC (HL3), MHC2-FITC (M5/114.15.2), CD103-Pacific Blue (2E7), and their

88

corresponding isotype controls, all of which were purchased from BioLegend or BD
Biosciences (San Jose, CA). Two hundred thousand events were collected using a BD
FACSAria flow cytometer and analyzed using FACSDiva (Version 6.1.2, BD
Biosciences, San Jose, CA) and FlowJo (Version 8.7.1, TreeStar, Inc., Ashland, OR)
software programs.

Statistics. All statistical analyses were performed using GraphPad Prism 4.0a for
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare
vehicle-treated groups and I3C-treated groups while 2-way analysis of variance
(ANOVA) with Bonferroni’s post-hoc test was used to compare multiple groups. Values
p≤0.05 were determined to be significant.

RESULTS
Severity of TNBS-induced colitis is reduced with I3C treatment in females but not
males. I3C is a prevalent dietary compound with anti-inflammatory properties so its
potential to decrease inflammation in a murine model of colitis was evaluated. This
compound has been used extensively in clinical trials with no serious long-term adverse
effects reported. Therefore, the dose used in this study is comparable to a dose in humans
taking I3C supplements (Minich et al., 2007). In order to assess the potential for I3C to
ameliorate colitis, key indicators that mark the onset of Crohn’s disease, including
significant body weight loss, loose stools, and dehydration, were evaluated first. Female
mice treated with I3C did not lose as much weight and recovered more rapidly than
vehicle-treated mice (Figure 3.2A). The clinical severity, as determined by the overall

89

Figure 3.2

Figure 3.2. I3C ameliorates colitis in female, but not male, mice exposed to TNBS. Mice
were monitored daily after disease induction for body weight loss and other clinical signs
including body condition, dehydration state, and stool consistency. Clinical severity was
determined by combining the symptom scores for a total possible severity score of 9.
Closed circles represent vehicle-treated mice, and open circles represent I3C-treated
mice. Results are shown as mean ± SEM (n=5) and representative of three separate
experiments. *indicates significance of p≤0.05.
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body condition, stool consistency, and dehydration state, was also significantly less
severe in female I3C-treated mice. Conversely, when compared to vehicle-treated mice,
male mice treated with I3C lost weight, regained that weight more slowly, and
experienced a trend towards more severe clinical signs (Figure 3.2B).

Inflammation and tissue damage in the colon decreases following treatment with I3C
in females. Since intestinal inflammation associated with Crohn’s disease is transmural in
nature, inflammatory cell infiltration and tissue lesions were evaluated in the colon. In
line with the clinical signs, female I3C-treated mice colon inflammation decreased from
4.0 in vehicle-treated mice to 1.4 with I3C treatment (Figure 3.3A). Conversely, the
damage score increased from 4.0 to 5.3 in male vehicle- and I3C-treated mice,
respectively (Figure 3.3B). This increase, however, was not statistically significant.

I3C exerts differential effects on cytokine production in colonic tissue of TNBSexposed mice. Colitis is associated with significant production of pro-inflammatory
cytokines. To better understand how I3C may alter the onset of Crohn’s disease, cytokine
production in colonic tissue was measured. In I3C-treated female mice, IFN-γ levels
decreased from 337 pg/ml to 174 pg/ml (Figure 3.4). IL-10 increased from 591 pg/ml to
680 pg/ml, but this was not statistically significant.

It should be noted that IL-10 was

significantly increased in one of the three experiments while just a trend towards
increased IL-10 was observed in the other experiments. I3C did not alter the production
of IL-1β, IL-6, IL-12, or IL-17 in female mice. In I3C-treated male mice, IL-1β and IL-6
were both increased from 332 pg/ml to 817 pg/ml and from 66 pg/ml to 154 pg/ml,
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Figure 3.3

Figure 3.3. Sex-specific effects of I3C on colon damage. Colon tissue was removed on
day 5 post-enema and evaluated histologically to determine tissue damage. The final
damage score was based on the severity inflammatory cell infiltration and mucosal
lesions, both of which were scored on a scale of 0-3. Representative images are displayed
to the right of the graph. Results are shown as mean ± SEM (n=5) and representative of
three separate experiments. *indicates significance of p≤0.05.
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Figure 3.4

Figure 3.4. I3C induces production of anti-inflammatory and pro-inflammatory
mediators in colonic tissue of TNBS-treated mice. Colon tissue was harvested five
days after TNBS enema delivery, homogenized, and assessed for cytokine production.
Results are shown as mean ± SEM (n=5) and representative of three separate
experiments. *indicates significance of p≤0.05.
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respectively. IFN-γ levels decreased from 296 pg/ml to 167 pg/ml. As with female mice,
I3C did not alter the production of IL-12 or IL-17.

Differential regulation of gene expression by I3C in TNBS-induced colitis. Since
exposure to other dietary chemicals leads to the induction of regulatory genes that
correlates to decreased colitis, gene expression was evaluated in vehicle- and I3C-treated
mice five days after the TNBS enema (Table 3.1). Interestingly, I3C-treated female mice
downregulated IL17A expression by 3.5 fold while male mice treated with I3C
upregulated IL17A expression by 8.1 fold.

A similar trend was observed with IL6

expression with decreased levels in females and increased levels in males treated with
I3C. There was also a trend of increased expression of ALDHA1 and TGFB families of
genes in females and decreased levels in male mice. More specifically, in female I3Ctreated mice, there was a 2.3 fold decrease in ALDH1A2 levels and a 2.2 fold decrease in
TGFB1 transcript levels. Conversely, in male I3C-treated mice, TGFB3 expression was
increased by 6.6 fold while increases in other TGFB family members and the ALDH1A
genes were not statistically significant. Notably, IL10 expression was decreased by 2.4
fold in male mice but not significantly altered in female mice. Expression levels of AHR,
ESR1, and ESR2 were unchanged in both female and male mice five days post-enema.

Alterations in gut cell populations were not observed five days after TNBS enema. T
cells and dendritic cells (DCs) are particularly important for maintaining homeostasis in
the intestinal immune system. Therefore, cells were isolated from the colon tissue and
the mesenteric lymph nodes (MLNs) and evaluated for phenotypic changes that could
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Table 3.1. Differential regulation of gene expression by I3C in TNBS-induced colitisa

Gene
AHR
ALDH1A1
ALDH1A2
ESR1
ESR2
IDO1
IDO2
IL6
IL10
IL17A
IL17F
IL22
TGFB1
TGFB2
TGFB3

a

Female
Fold change
p-value
-1.1
0.4
-1.2
0.4
-1.5
0.2
1.1
0.4
1.1
0.4
1.2
0.4
1.4
0.3
-2.4
0.08
-2.2
0.2
-3.5*
0.05
-2.3
0.06
-1.7
0.3
-2.2*
0.03
-1.6
0.06
-1.1
0.4

Male
Fold change p-value
4.3
0.2
1.2
0.4
1.7
0.3
2.7
0.3
4.3
0.2
-1.3
0.3
1.3
0.4
4.1
0.2
-2.4*
0.02
8.1*
0.05
-1.2
0.5
1.3
0.4
2.7
0.2
1.8
0.2
6.6*
0.05

Colon tissue was harvested, homogenized in Trizol, and subjected to qRT-PCR to assess

alterations in gene transcription. Fold change is relevant to vehicle-treated mice and
normalized to β-actin. Data are representative of a single experiment with n=5 mice per
treatment group. *indicates significance of p≤0.05.
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Table 3.2. I3C does not significantly alter critical immune cells in colona
A. Colon (Percent Population)
Female
Immune cell
markers
Vehicle
I3C
2.4 ± 0.4
2.8 ± 0.6
CD4
77.9 ± 7.6
70.4 ± 5.5
CD25
2.7 ± 0.5
3.4 ± 0.8
CD11c
35.1
±
10.3
40.1
± 6.8
MHC2
73.1 ± 6.0
68.9 ± 4.6
CD103

Vehicle
3.1 ± 0.2
67.5 ± 5.1
3.9 ± 0.2
48.7 ± 6.2
64.2 ± 3.4

B. Colon (Mean Fluorescence Intensity)
Female
Immune cell
markers
Vehicle
I3C
536 ± 51
492 ± 18
CD4
426 ± 4
433 ±15
CD25
570 ± 73
620 ± 78
CD11c
3039 ± 159
3072 ± 153
MHC2
340 ± 38
290 ± 14
CD103

Male
Vehicle
I3C
512 ± 21
520 ± 21
443 ± 25
417 ± 26
651 ± 21
559 ± 102
2780 ± 167
3166 ± 405
368 ± 26
326 ± 28

C. MLNs (Percent Population)
Female
Immune cell
markers
Vehicle
I3C
18.3 ± 0.9
21.8 ± 1.4
CD4
8.1 ± 0.7
6.9 ± 0.4
CD25
1.4 ± 0.1
1.9 ± 0.2
CD11c
82.5 ± 1.6
81.1 ± 2.3
MHC2
18.3 ± 2.6
14.2 ± 1.0
CD103

Male
Vehicle
I3C
26.1 ± 3.1
20.2 ± 4.4
6.1 ± 0.6
8.2 ± 1.6
1.6 ± 0.3
1.3 ± 0.3
81.5 ± 1.5
83.5 ± 0.7
11.7 ± 1.0
17.4 ± 4.9

D. MLNs (Mean Fluorescence Intensity)
Female
Immune cell
markers
Vehicle
I3C
1115 ± 21
1183 ± 24
CD4
296 ± 23
472 ± 17
CD25
1208 ± 70
1114 ± 77
CD11c
5440 ± 132
5196 ± 273
MHC2
2094 ± 235
2230 ± 363
CD103

Male
Vehicle
I3C
1176 ± 37
1254 ± 59
465 ±14
488 ± 23
916 ± 62
1042 ±160
5050 ±153
5009 ± 257
1819 ± 308
1637 ± 713

a

Male
I3C
4.9 ± 1.5
67.1 ± 15.4
4.1 ± 0.6
36.8 ± 13.9
65.3 ± 11.2

Leukocytes were isolated from colonic tissue and mesenteric lymph nodes (MLNs) five

days after enema administration. For T cells, CD25+ cells were gated out of the CD4+
population, and for dendritic cells MHC2+ and CD103+ cells were gated out of the
CD11c+ population. Results are representative of three independent experiments (n=5).
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indicate the presence of regulatory cells following exposure to I3C. Five days after
administration of the TNBS enema, no significant changes in T cells or DCs were
observed (Table 3.2).

DISCUSSION
The cruciferous vegetable constituent I3C is a potent anti-cancer agent, but its
effects on inflammatory responses, especially in the gut, are not well documented. Since
I3C and its primary metabolite DIM recently have been shown to produce antiinflammatory and immunoregulatory effects in vitro (Benson and Shepherd, 2011b;
Chang et al., 2011; Cho et al., 2008; Tsai et al., 2010), these compounds have the
potential to elicit protective effects in diseases characterized by chronic inflammation.
The current conventional medicines for Crohn’s disease, a chronic inflammatory disease
of the gastrointestinal tract, can be accompanied by severe adverse effects so many
patients have turned towards natural and complementary therapies as part of their
treatment regimens. Consequently, we evaluated the potential of I3C to decrease the
severity of Crohn’s disease using a murine model of colitis.
To characterize the effects of I3C on colitis, we evaluated the hallmark signs of
disease onset: significant body weight loss, clinical severity, damage to colonic tissue,
and inflammatory mediator production. I3C suppressed the body weight loss and the
severity of clinical signs, but this effect was surprisingly only observed in female mice
while male mice displayed a trend to a more severe disease phenotype. Furthermore,
inflammatory cell infiltration and tissue lesions were decreased in the colons of female,
but not male, mice. The acid condensation product DIM has been reported to ameliorate
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the DSS model of colitis in terms of clinical signs and histological scoring of the tissue.
In this report, however, Balb/c mice of an unspecified sex were used in the experiments
(Kim et al., 2009). Using the prototypical AhR ligand TCDD, our laboratory previously
reported that TCDD dampened disease severity in TNBS-induced colitis (Benson and
Shepherd, 2011a). In those studies we used male and female mice, and both sexes
benefited from TCDD administration.
Colitis induction is characterized by increased production of inflammatory
mediators. Thus, an important aspect of potential therapeutic would be to decrease the
production of these damaging mediators. Interestingly the profile of cytokines produced
in the gut was quite surprising. As expected, the exacerbated disease state in males was
associated with increased production of pro-inflammatory cytokines following I3C
treatment. In female mice, only IFN-γ production was reduced. With DIM treatment in
DSS-induced colitis, decreased levels of IL-6, IFN-γ, TNF-α, PGE-2, and NO were
observed (Kim et al., 2009). Additionally, there was a trend towards decreased IL-10
production at highest dose evaluated (20 mg/kg). The authors concluded that decreased
inflammation was likely due to decreased NF-κB binding activity in colon tissue.
In contrast to I3C, following TCDD treatment of both female and male mice we
observed decreases in the pro-inflammatory cytokines and no change in IL-10 (Benson
and Shepherd, 2011a). Furthermore, TCDD treatment resulted in significant increases in
the expression of AHRR, CYP1A1, and IDO in the colons of mice five days after enema
delivery. I3C primarily affected ALDH1A2, IL17A, IL10 and the TGFB family members.
Importantly, I3C did not have lasting effects on AHRR or CYP1A1 gene expression (data
not shown), which suggests that the AhR is not the sole or primary factor responsible for
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the suppression of TNBS-induced colitis in females. These differences suggest that
different mechanisms of action are responsible for mediating the effects of the dietary
AhR ligands TCDD and I3C.

Since I3C possesses anti-estrogenic properties, the

estrogen receptor (ER) may also play a role, especially since the AhR and the ER have
been demonstrated to physically interact (Matthews et al., 2005; Ohtake et al., 2003;
Wormke et al., 2003). Although we did not observe changes in ER expression five days
after colitis induction, additional studies assessing the role of the ER in mediating the
effects of I3C in TNBS colitis would be worthwhile.
Even though there was not an overwhelming decrease in pro-inflammatory
cytokines in female mice, I3C may be acting on several important immune cells in the gut
to ameliorate colitis. Dendritic cells (DCs) play important role in maintaining intestinal
immune homeostasis. In a recent report from our laboratory, we demonstrated that bone
marrow-derived DCs grown in the presence of I3C and cultured with antigen-specific
naïve CD4+ T cells generated Foxp3+ regulatory T cells (Tregs) (Benson and Shepherd,
2011b). Therefore, it is possible that DCs increased Tregs in the gut consequently
leading to the decreased gut inflammation observed in I3C-exposed mice. This would be
consistent with what we observed in TNBS-treated mice exposed to TCDD (Benson and
Shepherd, 2011a).

Although we did not observe any significant alterations in cell

populations on day five post-enema, it is possible that the functions of DCs and T cells in
the mesenteric lymph nodes and colon tissue were altered earlier in the inflammatory
response. Thus, there may be direct and/or indirect effects of I3C on T cells in the gut,
and this possibility must be further evaluated.
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Taken together, our results demonstrate the novel finding that I3C imparts sexspecific effects in the TNBS colitis model. Since these findings could have significant
implications for Crohn’s disease patients consuming increased amounts of cruciferous
vegetables and/or I3C dietary supplements, additional studies are warranted to define the
specific mechanisms responsible for the divergent effects on colonic inflammation
induced by I3C.
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ABSTRACT
The aryl hydrocarbon receptor (AhR) has been identified as a potential
therapeutic target for chronic inflammatory diseases, as activation of the AhR by various
ligands can suppress disease severity. In the process of confirming the role of the
receptor in mediating the effects in murine colitis, several investigators demonstrated that
AhR knockout (KO) mice were more sensitive to inflammatory stimuli and consequently
developed a more severe disease phenotype. Similarly we set out to further evaluate the
role of the receptor in TNBS-induced colitis in our laboratory. In contrast to published
results, our AhR KO mice exposed to TNBS developed a less severe disease state, as
demonstrated by decreased weight loss, decreased colonic inflammation, and decreased
expression of pro-inflammatory cytokine genes. However, by using the AhR antagonist
CH223191 in AhR wild-type (WT) exposed to TNBS, we generated the anticipated
results in that CH223191-treated mice developed colitis and also displayed increased
colonic inflammatory mediator production as well as increased expression of
inflammatory genes, which are indicative of a more severe disease state. Taken together,
our results demonstrated that AhR KO mice in this animal facility are less sensitive to
intestinal inflammation induced by TNBS. Since there was no definitive explanation for
the decreased responsiveness to TNBS in AhR KO mice, additional studies are necessary
to better understand the gut mucosal immune responses in these mice.

KEY WORDS
Aryl hydrocarbon receptor (AhR), inflammation, colitis
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INTRODUCTION
The aryl hydrocarbon receptor (AhR) is critical in modulating immune responses
and other physiological processes, as evident by the potentially adverse effects exerted by
its prototypical ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Importantly, these
effects induced by TCDD are not usually observed in AhR knockout (KO) mice thereby
emphasizing the role of this receptor in the documented pathologies. The AhR also plays
important roles in normal cellular and developmental processes, as abnormalities in AhR
KO mice have been observed including hypertrophy and fibrosis of cardiac and hepatic
tissues, lymphocyte depletion in the spleen, skin lesion, and rectal prolapses in aging
AhR KO mice (Schmidt et al., 1996; Fernandez-Salguero et al., 1997). Notably, the AhR
is critical in regulating inflammatory responses. AhR KO mice are more susceptible to
inflammatory stimuli, such as lipopolysaccharide, as increased production of
inflammatory mediators and increased mortality due to sepsis have been documented
(Kimura et al., 2009; Sekine et al., 2009).
Since the AhR has critical roles in immune and inflammatory responsiveness,
numerous studies in recent years have targeted the AhR via TCDD and other ligands for
the treatment of chronic inflammatory disorders. While performing our studies using the
TNBS colitis model, reports emerged regarding the role of the AhR in the dextran sodium
sulfate (DSS) colitis model, a chemically induced colitis model that primarily triggers a
Th2-mediated immune response in the gut. AhR activation by TCDD was also protective
in these studies, as decreased disease severity and decreased production of inflammatory
mediators was decreased (Takamura et al., 2010). The role of the receptor in this model
was also investigated independent of ligand treatment. AhR KO mice exposed to DSS
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developed a more severe colitis phenotype that resulted in the death of several mice
(Arsenescu et al., 2011; Furumatsu et al., 2011).
Our laboratory has previously demonstrated the beneficial effects of the AhR
ligands TCDD and I3C against 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced
colitis (Benson and Shepherd, 2011). In line with other investigators, we wanted to use
AhR KO mice to definitively demonstrate that the receptor is indeed involved in
mediating the effects of various ligands that dampened disease severity. Therefore, in
this study we first aimed to reproduce the results generated in AhR KO mice independent
of ligand treatment and hypothesized that TNBS-exposed AhR KO mice should
experience a more severe disease phenotype compared to AhR wild-type (WT) mice. Our
results surprisingly revealed that AhR KO mice were less sensitive to the intestinal
inflammation induced by TNBS. When AhR WT mice were exposed to an AhR
antagonist prior to TNBS, however, colitis was successfully induced. Thus, distinctly
different outcomes were observed in our animal facility in mice lacking receptor versus
blocking receptor activity in wild-type mice.

MATERIALS AND METHODS
Laboratory animals. Six to eight week old AhR WT and AhR KO female mice (both on
the C57Bl/6 background) were bred and maintained in the animal research facility at the
University of Montana. C57Bl/6 AhR WT mice were originally obtained from The
Jackson Laboratories (Bar Harbor, ME) and bred in-house. C57Bl/6 AhR KO
(B6.AhRtm1Bra) mice were obtained from Dr. Paige Lawrence (University of Rochester
Medical College, Rochester, NY) and bred as previously described (Schmidt and
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Bradfield, 1996). All mice were housed under specific pathogen-free conditions and
maintained on 12 h dark/light cycles. Throughout each experiment animals were
individually caged, and standard laboratory food and water were provided ad libitum. All
protocols for the use of animals were approved by the University of Montana Institutional
Animal Care and Use Committee and adhered to the current NIH guidelines for animal
usage.

Chemicals. 2,4,6-trinitrobenzenesulfonic acid (TNBS) was obtained from Sigma-Aldrich
and dissolved in 4:1 acetone:olive oil for pre-sensitization or 40% ethanol (EtOH) for
enema administration. The acetone/olive oil solution was used for the vehicle in the
antagonist experiment. The AhR antagonist CH223191 (Sigma-Aldrich) was dissolved in
DMSO (final concentration 0.07%) and further diluted in PBS for i.p. delivery.

Colitis induction. Colitis was induced with TNBS, as previously described (Benson and
Shepherd, 2011). As shown in Figure 4.1, pre-sensitization was conducted on day 0, as
previously described (Benson and Shepherd, 2011). For experiments utilizing an AhR
antagonist, 10 µg CH223191 in PBS was delivered via i.p. injection on day 6. The dose
as well as the delivery and timing were based on the study conducted by Monteleone and
colleagues (2011). Body weight loss and clinical signs were monitored daily. Briefly, the
severity of each clinical sign was scored on a scale 0-3 and combined to determine the
total severity score. On day 12, mice were euthanized via CO2 asphyxiation followed by
cervical dislocation.
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Figure 4.1

Figure 4.1. Experimental design. AhR WT and KO mice were peripherally sensitized
with TNBS and subsequently received an enema containing TNBS to induce colitis on
day 7. In experiments utilizing the AhR antagonist in AhR WT mice, CH223191 was
delivered via i.p. injection on day 6.

Tissues were harvested 5 days after disease

induction for evaluation.
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Colon processing and histology. Colons were excised from each mouse and washed with
PBS to remove debris. For histological analysis, a 1 cm section from the distal colon was
fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue
Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using
the Shandon Histocentre 2 Embedding unit, sectioned at 7 µm using the Thermo Shandon
Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon
Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded
individual to determine the severity of inflammation based on the scale developed by our
laboratory (Benson and Shepherd, 2011).

Briefly, the extent of inflammatory cell

infiltration and tissue lesions was scored on a scale 0-3 and combined to determine a total
damage score. Slides were imaged using the Nikon E800 Microscope with Cambridge
Research Instrumentation, Inc. and Nuance camera software version 1.62 at 10X
magnification. Another section of the colon was homogenized in lysis buffer from which
the supernatants were analyzed for cytokine production using commercially available
ELISA kits. The last section of the colon was homogenized in Trizol for gene expression
analysis.

Cytokine assays. Supernatants from homogenized colon tissue were examined for the
levels of IL-6, IL-10, IL-12, IL-17, IL-22, IFN-γ, and TNF-α via enzyme-linked
immunosorbent assay (ELISA). Samples were analyzed according to the manufacturer’s
instructions using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San
Diego, CA) or R&D ELISA kits (Minneapolis, MN).
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qRT-PCR. RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad,
CA) followed by RNA clean-up using the Total RNA Kit with optional DNase treatment
(Omega Bio-Tek, Norcross, GA) according to the manufacturers’ instructions. First
strand cDNA synthesis was performed using 500 ng RNA and qScript cDNA Supermix
(Quanta Biosciences, Gaithersburg, MD). Resulting cDNA was subjected to qRT-PCR
using commercially obtained primers (SABiosciences, Frederick, MD) including aryl
hydrocarbon receptor (AHR), cytochrome P450 A1 (CYP1A1), interferon gamma (IFNG),
interleukin 6 (IL6), IL10, IL12, IL17A, IL22, and tumor necrosis factor alpha (TNFA).
Reactions were performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences)
on an Agilent Technologies Stratagene Mx3005P® QPCR System (Santa Clara, CA).
Resulting data were normalized to β-actin, and fold changes were calculated using the
∆∆Ct method, which compares threshold values of the samples of interest for a particular
gene relative to a housekeeping gene.

Statistics. All statistical analyses were performed using GraphPad Prism 4.0a for
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare
WT versus KO groups while 2-way analysis of variance (ANOVA) with Bonferroni’s
post-hoc test was used to compare multiple groups. Values p≤0.05 were determined to be
significant.
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RESULTS
TNBS colitis is less severe in AhR KO mice. In order to investigate the role of the AhR
in colitis, the clinical signs of colitis were first monitored in AhR WT and KO mice that
were not treated with an AhR ligand. As shown in Figure 4.2, both WT mice and KO
mice rapidly lost more than 10% of their initial body weights following TNBS exposure.
Surprisingly, the AhR KO mice were less sensitive than AhR WT mice, as they lost less
body weight (Figure 4.2A) and recovered more rapidly from clinical signs (Figure 4.2B).
Furthermore, the degree of inflammatory cell infiltration and tissue lesions was also
lower in KO mice compared to WT mice, as the average damage score was 4.7 in AhR
WT mice and 2.5 in AhR KO mice (Figure 4.2C).

Inflammatory and protective mediator production in mice experiencing colitis. To
further evaluate how AhR KO mice respond to TNBS-induced colitis, the production of
cytokines critical to potentiating colonic inflammation were assessed. In AhR KO mice,
IL-10 production increased from 1096 pg/ml in AhR WT mice to 1252 pg/ml, and IL-12
production decreased from 1628 pg/ml in WT mice to 1342 pg/ml in AhR KO mice
(Figure 4.3). No significant changes were observed in IL-6, IL-17, IL-22, IFN-γ, or
TNF-α levels in the colon.
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Figure 4.2

A.

B.

C.

Figure 4.2. TNBS colitis is less severe in AhR KO mice. AhR WT mice (•) and AhR
KO mice (°) were monitored daily after disease induction for body weight loss (A) and
other clinical symptoms including body condition, dehydration state, and stool
consistency (B). Damage in colonic tissue was also evaluated for inflammatory cell
infiltration and tissue lesions (C).

Results are shown as mean ± SEM (n=5) and

representative of three separate experiments. *indicates significances of p≤0.05.
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Figure 4.3

Figure 4.3. Inflammatory and protective mediator production during colitis.
Colonic tissues from AhR WT and KO mice were homogenized, and cytokine levels in
the supernatants were measured by ELISAs. Results are shown as mean ± SEM (n=5)
and representative of three separate experiments. *indicates significances of p≤0.05.
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Altered gene expression in AhR KO mice exposed to TNBS. Modifications in colonic
gene expression were evaluated next to better understand the unexpected results in
TNBS-exposed AhR KO mice.

In contrast to the relatively unchanged protein

expression, several genes were down-regulated in TNBS-exposed AhR KO mice
compared to AhR WT mice (Table 4.1). Notably, decreased mRNA expression was
observed in AHR by 154-fold, IFNG by 46.7-fold, IL6 by 10.9-fold, IL10 by 5.9-fold,
IL12 by 8.7-fold, IL17A by 13.9-fold, and TNFA by 12.0-fold. No significant changes
were observed in CYP1A1 or IL22 expression.

AhR WT mice exposed to the AhR antagonist CH223191 develop colitis. Recently it
was demonstrated that the AhR antagonist CH223191 generated results similar to studies
using AhR KO mice (i.e. more severe disease phenotype) in mice exposed to TNBS
(Monteleone et al., 2011). Since we did not observe a more severe outcome in
conventional AhR KO mice treated with TNBS, this AhR antagonist was used to block
AhR activity in wild-type mice during TNBS-induced colitis. As expected, mice exposed
to the EtOH control only (with no TNBS enema and with/without CH223191) did not
develop disease, as demonstrated by no decrease in body weight or increase in severity of
clinical signs (Figure 4.4A). While both groups of mice exposed to TNBS developed
colitis, the difference between CH223191 and its PBS vehicle was not statistically
significant. Histological evaluation revealed significant inflammatory cell infiltration and
tissue lesions following TNBS exposure (Figure 4.4B). However, CH223191-treated
mice experienced a trend towards increased colonic damage, as indicated with a score of
5.0 with CH223191 treatment compared to the score of 4.38 with vehicle treatment.
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Table 4.1. Gene expression is decreased in the gut of AhR KO mice during colitis

Gene
AHR
CYP1A1
IFNG
IL6
IL10
IL12
IL17A
IL22
TNFA

Fold change
-154*
-1.7
-46.7*
-10.9*
-5.9*
-8.7*
-13.9*
-1.6
-12.0*

p-value
0.02
0.4
0.007
0.006
0.008
0.03
0.02
0.3
0.03

Colon tissue was harvested on day 5 post-enema, homogenized in Trizol, and
subsequently subjected to qRT-PCR to assess changes in gene expression. Fold change is
relevant to AhR WT mice and normalized to β-actin. Data are representative of one
experiment (n=5). *indicates significances of p≤0.05.
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Figure 4.4
A.

B.

Figure 4.4. TNBS colitis is induced in CH223191-treated WT mice. Mice were
monitored daily after disease induction for body weight loss and other clinical symptoms
including body condition, dehydration state, and stool consistency (A).

Damage in

colonic tissue was also evaluated for inflammatory cell infiltration and tissue lesions (B).
Results are representative of one experiment (n=3-6). *indicates significances of p≤0.05.
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CH223191 treatment alters inflammatory mediator and gene expression profiles.
Treatment with the AhR antagonist CH223191 significantly altered cytokine production
in the colon of TNBS- and vehicle-exposed mice (Figure 4.5). In TNBS-exposed mice,
CH223191 increased IL-6 from 411 to 1462 pg/ml, IL-10 from 287 to 340 pg/ml, IL-17
from 158 to 196 pg/ml, and IFN-γ from 117 to 176 pg/ml. Conversely, IL-12 and TNF-α
production was significantly decreased. In absence of the TNBS inflammatory stimulus,
mice exposed to CH223191 exhibited increased IL-10 production from 319 to 410 pg/ml
and increased IL-22 production from 99 to 142 pg/ml.
CH223191 also induced several changes in colonic gene expression on day 5
post-enema (Table 4.2). In TNBS-exposed mice, CH223191 significantly increased the
expression of several inflammatory mediators including IFNG by 12.5-fold, IL6 by 3.2fold, IL10 by 9.9-fold, IL12 by 9.5-fold, and IL17A by 6.2-fold. Although CH223191
had no effect on AHR gene expression, CYP1A1 expression was not increased, which is a
hallmark indicator of AhR activation by an agonist. In line with other investigators, AHR
expression was significantly upregulated by 636-fold in TNBS-exposed mice compared
to the ethanol vehicle control (data not shown). Finally, in the absence of TNBS,
CH223191 did not induce changes in colonic gene expression at the time of harvest.
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Figure 4.5

Figure 4.5. CH223191 alters cytokine production in AhR WT mice during colitis.
Colonic tissues were collected on day 5 post-TNBS enema, homogenized, and cytokine
levels in the supernatants measured by ELISA. Results are shown as mean ± SEM (n=5)
and representative of one experiment (n=3-6). *indicates significances of p≤0.05.

118

Table 4.2. Gene expression is altered in the gut of CH223191-treated mice

Gene
AHR
CYP1A1
IFNG
IL6
IL10
IL12
IL17A
IL22
TNFA

TNBS
Fold change p-value
2.3
0.2
1.2
0.4
12.5*
0.02
3.2*
0.05
9.9*
0.04
9.5*
0.02
6.2*
0.04
1.0
0.5
1.2
0.4

EtOH
Fold change p-value
-1.3
0.4
-1.7
0.3
-1.5
0.3
1.5
0.3
-1.0
0.5
1.3
0.4
-1.1
0.5
-1.2
0.4
1.4
0.3

Colon tissue was harvested on day 5 post-enema, homogenized in Trizol, and
subsequently subjected to qRT-PCR to assess changes in gene expression. Fold change is
relevant to vehicle-treated mice and normalized to β-actin. Data are representative of one
experiment (n=3-6). *indicates significances of p≤0.05.
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DISCUSSION
Since immune suppression is a classic response following activation of the AhR,
this signaling pathway has been investigated as a new therapeutic target for chronic
inflammatory diseases, such as Crohn’s disease and multiple sclerosis. In fact, numerous
studies have been published recently regarding the beneficial effects of AhR activation by
TCDD to reduce disease severity (Quintana et al., 2008; Kerkvliet et al., 2009; Takamura
et al., 2010; Benson and Shepherd, 2011). Recently several laboratories have focused
their studies on the role of the AhR in intestinal inflammation. As such, AhR KO mice
have been used to confirm the role of the AhR in mediating the effects of various ligands.
In addition to demonstrating that the AhR was responsible for mediating the protective
effects against colitis, it has also been shown that AhR KO mice were more sensitive to
inflammation (Arsenescu et al., 2011). Similarly, in this study we also aimed to
definitively demonstrate the role of the AhR by using conventional AhR KO mice in the
TNBS-induced colitis model.
We first evaluated the role of the AhR in TNBS-induced colitis independent of
AhR ligand treatment in AhR WT and KO mice. Surprisingly, AhR KO mice appeared
to be less sensitive to disease severity and colonic inflammation. Furthermore, there was
a significant decrease in the expression of several pro-inflammatory genes in the colon
including IFNG, IL6, IL12, IL17A, and TNFA. Thus, decreased inflammatory mediator
production may be partially responsible for reduced inflammation in the gut of our AhR
KO mice. This finding is in complete contrast to a previously published report that was
conducted in WT and AhR KO mice using DSS-induced colitis, as it was revealed that
AhR KO mice exposed to DSS died within 7 days of the beginning of treatment whereas
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the AhR WT mice developed colitis as expected (Arsenescu et al., 2011). Furumatsu and
colleagues also confirmed increased mortality in AhR KO mice exposed to DSS and
consequently suggested that the endogenous ligands that regulate homeostasis in AhR
WT mice cannot do so in AhR KO mice thereby resulting in exacerbated DSS-induced
colitis (Furumatsu et al., 2011). Although this hypothesis is plausible for their results, it is
not consistent with the ameliorated disease state we observed in AhR KO mice treated
with TNBS to induce colitis.
Instead of using AhR KO mice, several laboratories use chemical antagonists to
block AhR receptor activity to specifically evaluate the role of the AhR in mediating
various physiologic responses. One such antagonist is CH223191, which was first
identified as an antagonist by Kim and colleagues because this compound blocked
TCDD-induced gene transcription responsible for mediating the toxic effects of TCDD
(Kim et al., 2006). However, CH223191 is a ligand-selective antagonist as it inhibits
some AhR agonists, such as TCDD and related halogenated aromatic hydrocarbons, but
not others, such as polycyclic aromatic hydrocarbons, flavonoids, and indirubin (Zhao et
al., 2010). Moreover, it is currently unknown if this antagonist blocks the binding of
endogenous ligands. Nevertheless, using an antagonist such as CH223191 can be
advantageous over AhR KO mice since it is used in WT mice that develop normally and
do not have other physiological defects that have been reported in conventional AhR KO
mice.
Accordingly, the AhR antagonist CH223191 was administered to AhR WT mice
prior to inducing colitis with TNBS (Monteleone et al., 2011). In this study, the authors
observed increased disease severity and inflammation in mice co-treated with TNBS and
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CH223191, which is consistent with the observations in AhR KO mice exposed to DSS.
Since our results in the TNBS-induced colitis model using AhR KO mice were not
consistent with previously published reports using either TNBS or DSS, we performed an
additional study using CH223191 in an experimental approach (i.e. dose and regimen)
similar to Monteleone and colleagues (2011).

We found that administration of

CH223191 to AhR WT mice resulted in the induction of colitis by TNBS. This outcome
was distinctly different than what we previously observed with AhR KO mice in which
colitis disease severity was attenuated in AhR WT mice. Interestingly, although the
differences were not statistically significant, there was also a trend towards increased
colonic damage and more severe clinical signs in mice exposed to CH223191.
In addition to the effects on disease severity observed in TNBS-treated mice,
CH223191 also significantly altered the production of several pro-inflammatory
cytokines.

There was increased production of IL-6, IL-17, and IFN-γ, which is

supportive of the anticipated exacerbated disease phenotype. Interestingly, CH223191
decreased IL-12 and TNF-α production, which was not observed by Monteleone and
colleagues (2011). The expression of several inflammatory genes was also increased in
CH223191-treated mice with the TNBS inflammatory stimulus, which is suggestive of a
more severe disease phenotype. However, we did not detect a decrease in AHR gene
expression induced by CH223191 at the time of harvest, an effect that was observed by
Monteleone and colleagues (2011). It is possible that AhR protein levels decreased in
colonic tissue even though gene expression was unchanged; however, this possibility has
yet to be evaluated. Nevertheless, the trend toward an anticipated increased disease
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severity and increased inflammation was observed in our AhR WT mice exposed to
CH223191.
While we could not replicate the published results of colitis in AhR KO mice, we
were able to generate results that were more consistent with published observations using
an AhR antagonist in AhR WT mice. Thus, several factors may be affecting the immune
responsiveness in the gut of our AhR KO mice. First of all, it must be noted that there
are multiple conventional AhR KO mice commercially available on the C57Bl/6
background. One strain was generated by the Gonzalez laboratory by targeting exon 1
for deletion (Fernandez-Salguero et al., 1997) whereas another strain was generated by
the Bradfield laboratory by targeting exon 2 for deletion (Schmidt et al., 1996).
Although several similar pathologies are observed in both AhR KO mice, there are
numerous discrepancies between the two null alleles (reviewed in (Lahvis and Bradfield,
1998). This may be due to different targeting strategies that can alter the function of
neighboring genes, different genetic backgrounds used to generate AhR KO mice, and/or
the variability of housing environments. In our studies we used the mice generated from
the Bradfield laboratory; however, other conventional AhR KO mice were used in other
studies. Furumatsu and colleagues used another null mouse generated by the FujiiKuriyama laboratory (Shimizu et al., 2000), while Arsenescu and colleagues (2011) did
not specify which AhR KO mice strain they obtained from Jackson Laboratories.
Therefore, it is very possible that the differences in the AhR null alleles contribute to the
inconsistencies observed in our studies compared to the current literature.
Additionally, we observed sex-specific effects on colitis severity when dietary
AhR ligand indole-3-carbinol was administered to mice. Although not previously
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documented, male and female AhR KO mice in our facility could respond differently to
absence of the AhR. In our studies, we used female mice, as at the time of the study we
had a greater availability of female AhR KO mice. Arsenescu and colleagues (2011)
used male AhR KO mice while Furumatsu and colleagues (2011) did not specify the sex
of mice utilized. Thus, a combination of sex differences and difference in null alleles
could be contributing to the decreased disease severity observed in our studies.
Finally, it is also possible that the microbiome and/or various environmental
conditions (i.e. bedding, food, etc…) in this facility have significantly impacted the
inflammatory responsiveness of AhR KO mice making them less susceptible to TNBSinduced colitis. Accordingly, AhR KO fecal samples were sent to Charles River for a
PCR Rodent Infectious Agent (PRIA) panel analysis to assess the presence of parasites,
viruses, bacteria, and fungi that may be affecting gut mucosal immune responses (data
not shown). Results revealed that our AhR KO mice tested positive for mouse norovirus
(MNV), Pasturella pneumotropica-Heyl and Helicobacter hepaticus.

MNV and P.

pneumotropica are very common in many animal facilities, and MNV has been present in
our animal facility for several years. AhR KO mice are known to have Helicobacter
present in the gut, which is a contributing factor to rectal prolapses in mice greater than 9
months (Schmidt et al., 1996; Fernandez-Salguero et al., 1997), an effect that we have
observed over the last several years in our AhR KO colony. MNV has been attributed to
worsened intestinal inflammation in a bacteria-induced model of colitis (Lencioni et al.,
2008).

Although some pathogens are present in the gut of AhR KO mice, these

pathogens are not necessarily supportive of making these mice less sensitive to colitis
induction by TNBS. However, there could be a shift in commensal bacteria in this

124

facility that alters immune responsiveness to TNBS, which has yet to be investigated.
Furthermore, preliminary microarray and proteomics analyses (Appendix 1) conducted
on naïve AhR KO mice did not provide a definitive answer to explain the discrepancies,
but the data suggested that decreased NF-kB signaling and decreased apoptosis in the
AhR KO gut may contribute to the decreased disease severity in AhR KO mice. Future
studies evaluating the importance of these signaling pathways in the gut of AhR KO mice
in this facility may help elucidate the mechanisms responsible for their decreased
sensitivity to TNBS.
Collectively, our results demonstrate that AhR KO mice in the University of
Montana Laboratory Animal Facility are less sensitive to intestinal inflammation induced
by TNBS whereas AhR WT mice treated with an antagonist develop colitis as expected.
By achieving the documented trend towards increased disease severity using the AhR
antagonist in AhR WT mice, this strongly suggests that a complex set of factors is
drastically impacting the ability of these mice to respond to the TNBS inflammatory
stimulus. Additional studies are warranted to better understand the gut mucosal immune
responses in our AhR KO mice.
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ABSTRACT
Activation of the aryl hydrocarbon receptor (AhR) in immune cells, such as
dendritic cells (DCs), can lead to suppressed immune responses.

Although AhR

activation is most recognized for mediating the effects of its prototypical ligand 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD), many compounds existing in dietary sources can
also bind the AhR. Since the immunomodulatory effects of indole-3-carbinol (I3C) and
indirubin-3’-oxime (IO) have yet to be investigated in DCs, we evaluated the potential
immunomodulatory effects of these compounds on murine DCs. We hypothesized that
I3C and IO suppress immune and inflammatory responses in DCs. We found that both
I3C and IO decreased the expression of CD11c, CD40, and CD54 while they increased
expression of MHC2 and CD80. Following LPS-activation, I3C and IO suppressed the
production of pro-inflammatory mediators including TNF-, IL-1, IL-6, IL-12, and
nitric oxide but increased IL-10 levels. These effects of I3C and IO were partially
mediated by the AhR. Additionally, immunoregulatory genes, such as ALDH1A, IDO and
TGFB, were upregulated following treatment with I3C or IO. Both I3C and IO decreased
basal levels of NF-B p65 but only I3C suppressed the LPS-induced activity of RelB.
Finally, when cultured with naïve T cells, BMDCs treated with the dietary AhR ligands
increased the frequency of Foxp3+ Tregs in an antigen-specific manner. Taken together,
these results indicate that I3C and IO exhibit immunosuppressive and anti-inflammatory
effects on DCs. Since I3C and IO are significantly less toxic than TCDD, these natural
products may ultimately become useful therapeutics for the treatment of autoimmune and
inflammatory diseases.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen presenting cells (APCs) that bridge
the innate and adaptive branches of the immune system. As such, these cells are critical
to mounting successful immune and inflammatory responses against antigens as well as
promoting tolerance. Following antigen uptake in the periphery, DCs mature and migrate
to lymph nodes where they present processed antigen to naïve T cells. Many factors
contribute to the ensuing adaptive immune response. One of these involves activation of
the aryl hydrocarbon receptor (AhR), the cytosolic ligand-activated transcription factor
responsible for the toxic and immunomodulatory effects of its prototypical ligand,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The AhR is expressed in immune cells and
is involved in many important physiological processes, as AhR deficient mice have
numerous defects including slowed early growth, anal prolapses, and hepatic
abnormalities (Schmidt et al., 1996). Importantly, AhR activation by TCDD in DCs
results in immune suppression via induction of indoleamine-2,3-dioxygenase (IDO) and
subsequent generation of regulatory T cells (Tregs) (Vogel et al., 2008; Mezrich et al.,
2010; Nguyen et al., 2010; Simones and Shepherd, 2011).
Besides environmental contaminants, additional compounds present in the diet
have the potential to bind and activate the AhR. One of these dietary constituents is
indole-3-carbinol (I3C), which is found in cruciferous vegetables, and another is
indirubin, which is a component in the traditional Chinese medicine Danggui Longhui
Wan. However, neither of these compounds binds the AhR as potently as TCDD. Both
I3C and indirubin have well-documented anti-cancer properties, as they both work in part
by inhibiting cyclin dependent kinases that leads to cell cycle arrest in various cell lines.
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More specifically, I3C has been evaluated for the treatment of both breast and prostate
cancer (Weng et al., 2008) while indirubin has been used traditionally for the treatment of
chronic myelocytic leukemia (Eisenbrand et al., 2004).
Despite these known effects on cancerous cells, the effects of I3C and indirubin
on immune cells have not yet been investigated in depth. I3C suppresses the production
of pro-inflammatory cytokines in macrophages (Chen et al., 2003; Tsai et al., 2010;
Chang et al., 2011) while indirubin has been demonstrated to suppress these mediators in
splenocytes and microglial cells (Kunikata et al., 2000; Jung et al., 2011). Therefore,
studies evaluating the effects of these dietary AhR ligands on additional immune cell
populations, such as DCs that constitutively express the AhR, are warranted since these
compounds are present in the diet or readily consumed supplements and have great
potential as complementary therapies in chronic inflammatory diseases.
In this study we aimed to define the specific immunomodulatory effects of I3C
and indirubin on murine bone marrow-derived DCs (BMDCs). We hypothesized that
these natural AhR ligands alter DC maturation such that they suppress immune and
inflammatory responses in DCs. To test this hypothesis, we conducted an array of in
vitro experiments to assess changes in BMDC fate and function following exposure to
I3C and indirubin. The results obtained in this study suggest that both I3C and indirubin
generate immunosuppressive effects on DCs that may promote a regulatory environment,
which may be useful to suppress chronic inflammatory diseases and/or autoimmunity in
vivo.
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MATERIALS AND METHODS
Chemicals and reagents. Indole-3-carbinol (I3C) and indirubin-3’-oxime (IO), a
commercially available indirubin derivative that is also an AhR agonist (Guengerich et
al., 2004), were obtained from Sigma-Aldrich (St. Louis, MO) and dissolved in DMSO
(Sigma-Aldrich). Both compounds were >99% pure when purchased, and the purities of
I3C and IO were also confirmed in house prior to use via NMR and HPLC, respectively
(data not shown).

For initial concentration-response studies, I3C was used at

concentrations of 25, 50, 100, and 200 μM and IO was used at 0.01, 0.1, 1.0, and 5.0 μM.
For all other experiments, I3C and IO were used at final concentrations of 50 μM and 1
μM, respectively. The final concentration of solvent used in cell culture was below 0.1%
and did not induce DC cytotoxicity.

Mice. Six- to 8-week old male AhR+/+, AhR-/-, and OTII Foxp3egfp mice (all on a C57Bl/6
background) were bred and maintained in the animal research facilities at the University
of Montana. C57Bl/6 AhR+/+ were originally obtained from The Jackson Laboratories
(Bar Harbor, ME) and bred in-house. C57Bl/6 AhR-/- (B6.AhRtm1Bra) mice were
generously provided by Dr. B.P. Lawrence (University of Rochester Medical College,
Rochester, NY) and bred as previously described (Schmidt and Bradfield, 1996). OTII
Foxp3egfp mice were kindly provided by Dr. Randolph J. Noelle (Dartmouth Medical
School, Lebanon, NH), who originally obtained these mice from Dr. A. Rudensky
(University of Washington School of Medicine, Seattle, WA), and bred as previously
described (Wang et al., 2008). To verify identity of mutant mice prior to use in
experiments, AhR-/- mice and OT II Foxp3egfp mice were genotyped via PCR and
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phenotyped via flow cytometry, respectively. The genotype of AhR+/+ and AhR-/- mice is
based on the presence of AhRb or AhRd alleles. The AhR+/+ mice possess the AhRb allele
(AhRb/b), which is 300bp, whereas AhR-/- mice possess the d allele (AhRd/d), which is
260bp. AhR+/- mice possess both the b and d alleles thus resulting in both the 300bp and
260bp products. Mice were housed under specific pathogen-free conditions and
maintained on 12 h dark/light cycles. Standard laboratory food and water were provided
ad libitum. All protocols for the use of animals were approved by the University of
Montana Institutional Animal Care and Use Committee and adhered to the current
National Institutes of Health (NIH) guidelines for animal usage.

Bone marrow-derived dendritic cells (BMDCs). BMDCs were prepared as previously
described (Bankoti et al., 2010). Briefly, bone marrow cells were collected by flushing
murine femurs and tibias with complete media (cRPMI) comprised of RPMI (GibcoBRL,
Grand Island, NY) supplemented with 10% FBS (Hyclone, Logan, UT), 50 µM
mercaptoethanol, 20 mM HEPES, 10 mM sodium pyruvate, and 50 µg/ml gentamicin
(GibcoBRL, Grand Island, NY). Subsequent gradient centrifugation using the
Lympholyte-M reagent (Cedarlane Laboratories Limited, Ontario, Canada) removed red
blood cells. The hematopoietic cells were cultured at a density of 1x106 cells/ml in tissue
culture flasks or 6-well plates in cRPMI supplemented with 30 ng/ml murine GM-CSF
(PeproTech, Rocky Hill, NJ) and treated with AhR ligands or vehicle control. Cells were
grown for 7 d at 37°C and 5% CO2. Media, growth factor, and AhR ligand treatment
were refreshed on days 3 and 5. On day 7, non-adherent cells representing immature
DCs were harvested and purified using anti-CD11c (N418) beads (Miltenyi Biotec,
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Auburn, CA) and the Miltenyi AutoMACS per the manufacturer’s instructions. BMDC
purity was verified via flow cytometry, and cells subsequently cultured were >90%
CD11c+. Cells were ≥95% viable as determined by Trypan blue exclusion.

Flow cytometry. Accessory molecule expression on isolated cells was determined by
flow cytometry, as previously described (Shepherd et al., 2001). Briefly, cells were
washed with PAB (1% bovine serum albumin and 0.1% sodum azide in PBS). Fc block
(BioLegend, San Diego, CA) was used to eliminate non-specific staining. Optimal
concentrations of fluorochrome-conjugated monoclonal antibodies were used to stain
cells for an additional 10 min on ice. Antibodies used in these experiments included
CD11c-APC (HL3), MHC2-PECy7 (M5/114.15.2), CD86-AlexaFluor700 (GL-1), CD80PE (16-10A1), CD54-Pacific Blue (YN1/1.7.4), CD40-FITC (3/23), CD4-APC (RM4-5),
CD25-PerCPCy5.5 (PC61), and their corresponding isotype controls, all of which were
purchased from BioLegend (San Diego, CA) or BD Biosciences (San Jose, CA). One to
five hundred thousand events were collected using a BD FACSAria flow cytometer and
analyzed using FACSDiva (Version 6.1.2, BD Biosciences, San Jose, CA) and FlowJo
(Version 8.7.1, TreeStar, Inc., Ashland, OR) software programs.

Cell activation and cytokine assays. Purified vehicle- or AhR ligand-treated BMDCs
were cultured in 6-well plates at a density of 1x106 cells/ml and stimulated with 1 μg/ml
lipopolysaccharide [LPS, Escherichia coli (055:B5), Sigma-Aldrich] for 24 h. Cells were
harvested for immunophenotypic and qRT-PCR analyses while supernatants were
collected and evaluated for cytokine production using enzyme linked immunosorbent
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assays (ELISAs). Levels of IL-1, IL-2, IL-6, IL-10, IL-12, IFN- and TNF- were
measured using BD ELISA kits (BD Biosciences, San Jose, CA) per the manufacturer’s
instructions.

Levels of nitric oxide (NO) were measured using the Griess Reagent

System (Promega, Madison, WI) per the manufacturer’s instructions.

Quantitative real-time polymerase chain reaction (qRT-PCR). RNA was isolated from
BMDCs with Trizol reagent (Invitrogen, Carlsbad, CA) followed by RNA clean-up using
the Total RNA Kit with optional DNase treatment (Omega Bio-Tek, Norcross, GA)
according to the manufacturers’ instructions. First strand cDNA synthesis was performed
using qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD). Resulting
cDNA was subjected to qRT-PCR using commercially obtained primers (SABiosciences,
Frederick, MD) including aldehyde dehydrogenase 1 family, member A1 (ALDH1A1),
aldehyde dehydrogenase 1 family, member A2 (ALDH1A2), cytochrome P450 A1
(CYP1A1), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2
(IDO2), interleukin 6 (IL6), interleukin 10 (IL10), interleukin 27 (IL27), latent binding
protein 3 (LTBP), transforming growth factor, beta 1 (TGFB1), transforming growth
factor, beta 2 (TGFB2), and transforming growth factor, beta 3 (TGFB3). Reactions were
performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences) on an Agilent
Technologies Stratagene Mx3005P QPCR System (Santa Clara, CA). Resulting data
were normalized to -actin, and fold changes were calculated using the ∆∆Ct method,
which compares threshold values of the samples of interest for a particular gene relative
to a housekeeping gene.
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NF-kB activity. DMSO-, I3C-, and IO-treated BMDCs were prepared and purified, as
described above.

Purified BMDCs (2x106 cells/well) were stimulated with LPS (1

μg/ml) for 45 min in 6-well plates. Cells were harvested, and nuclear protein extracts
were prepared using the Active Motif Nuclear Lysis kit (Active Motif, Carlsbad, CA).
Protein concentrations were measured using the Bradford reagent (Bio-Rad Laboratories,
Hercules, CA), and nuclear protein (3 μg/well) was subsequently used in the Active Motif
TransAM colorimetric assay to evaluate the DNA binding activity of NF-B p65 and
RelB per the manufacturer’s instructions.

DC:T cell co-cultures. BMDCs were grown in the presence of the DMSO vehicle, I3C,
or IO for 7 d and subsequently purified, as described above. BMDCs were cultured with
1 μg/ml OVA323-339 peptide (Mimotopes, Clayton, Victoria, Australia) for 2 h and washed
twice prior to culturing with T cells. Spleens as well as the popliteal and brachial lymph
nodes of OTII Foxp3egfp mice were harvested, and CD4+ T cells were purified to >75%
using a naïve CD4 T cell isolation kit (Miltenyi Biotec, Auburn, CA) and the Miltenyi
AutoMACS per the manufacturer’s instructions. Cells were ≥95% viable as determined
by Trypan blue exclusion. DCs and T cells were co-cultured for 3 d at a ratio of 1:5
(DC:T cells) in 96-well plates. On day 3, cells were harvested, evaluated via flow
cytometry for the frequency of CD4+Foxp3+ T cells, and supernatants were collected for
subsequent evaluation of cytokine production, as described above.
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Statistical analyses. Data sets with multiple comparisons were evaluated by one-way
analysis of variance (ANOVA) with Dunnett’s post-hoc test while data sets with 2 groups
were analyzed by student’s t-test. Values of p<0.05 were considered significant.

RESULTS
Concentration-dependent effects of I3C and indirubin-3’oxime (IO) on the viability
and proliferation of BMDCs. Since the effects of I3C and IO on DCs have not yet been
evaluated and both compounds can trigger cell cycle arrest, the concentration-dependent
effects on proliferation and viability of these dietary AhR ligands was initially examined
in GM-CSF-derived BMDCs. Concentrations of I3C were based on physiologically
relevant concentrations (reviewed in Howells et al., 2007) while IO concentrations were
based on other published in vitro studies (reviewed in Eisenbrand et al., 2004), as the
bioavailability of IO has not yet been determined to our knowledge. Neither compound
affected the viability of the non-adherent, immature DCs at any concentration tested;
however, all concentrations of I3C examined decreased DC cell numbers, the highest
concentrations of I3C (100 μM and 200 μM) decreased cell proliferation by as much as
60% and 97%, respectively, as indicated by decreased cell numbers (Figure 1). The
highest concentration of IO (5 μM) also significantly decreased DC cell numbers.
Therefore, based on the results obtained in this initial experiment demonstrating no
cytotoxicity and slight anti-proliferative effects, concentrations of 50 μM I3C and 1 μM
IO were selected for subsequent experiments.
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Figure 5.1

Figure 5.1. Concentration-dependent effects of I3C and IO on BMDC proliferation
and viability. BMDCs were grown in the presence of the 0.1% DMSO vehicle control
or various concentrations of I3C (A) and IO (B). After 7 d, non-adherent cells were
stained with Trypan blue to determine cell numbers and viability.

Results are

representative of 3 separate experiments with n=3. *indicates significance of p≤0.05.
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Immunophenotypic changes induced by I3C and IO. After determining non-cytotoxic
concentrations of I3C and IO, the effects of these compounds on BMDC
immunophenotype were evaluated via flow cytometry (Figure 2).

Both compounds

significantly decreased the relative expression of CD11c, CD40, and CD54 on BMDCs
while the expression of MHC class 2 (MHC2), MHC2hi and CD80 was increased.
Differential effects were observed on CD86 expression, as I3C increased the expression
of this co-stimulatory molecule while IO decreased its expression.

I3C and IO alter the LPS-induced changes in surface marker expression and cytokine
production. DCs play critical roles in mounting appropriate immune responses to various
pathogens and inflammatory insults; therefore, the effects of LPS stimulation on BMDCs
treated with I3C or IO were examined. Alterations in cell surface molecule expression
were assessed initially (Figure 3). Both compounds inhibited the LPS-induced
upregulation of CD11c and CD40 while enhancing the LPS-induced increase in the
expression of MHC2 and CD80. I3C upregulated CD86 and CD54; however, IO slightly
decreased the LPS-induced expression of both CD86 and CD54.
The effects of I3C and IO on pro-inflammatory cytokine production following
LPS activation in BMDCs were also assessed. As anticipated, 1 μg/ml LPS induced the
production of several pro-inflammatory cytokines including IL-1β, IL-6, IL-12, and TNFα. BMDCs exposed to I3C or IO and subsequently stimulated with LPS generally
produced lower levels of pro-inflammatory cytokines (Figure 4). I3C and IO decreased
the LPS-induced production of IL-1β from 1506 pg/ml to 1040 pg/ml and 941 pg/ml,
respectively. This effect was also observed with the LPS-induced IL-6 production in
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Figure 5.2

Figure 5.2.

Alterations in BMDC phenotype following AhR ligand treatment.

BMDCs were grown in the presence of the DMSO vehicle control, 50 μM I3C, or 1 μM
IO for 7 d and subsequently evaluated for their relative expression (MFI) of surface
markers via flow cytometry (numerical values are listed in the corresponding table below
the histograms). Thin gray lines indicate isotype control, dotted black line indicate
DMSO-treated cells, thick black lines indicate I3C-treated cells, and thick gray lines
indicate IO-treated cells. Arrows indicate MHC2/MHC2hi, CD86, CD80, CD54, and
CD40 expression on CD11c+ cells. Results are representative of 3 separate experiments
with n=3. *indicates significance of p≤0.05.
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Figure 5.3

Figure 5.3. Dietary AhR ligands alter LPS-induced changes in surface phenotype of
BMDCs. BMDCs were grown in the presence of the DMSO vehicle control, 50 μM I3C,
or 1 μM IO for 7 d and purified. The immature BMDCs were subsequently treated with 1
μg/ml LPS for 24 h, and the immunophenotype was evaluated by flow cytometry. Results
are representative of 3 separate experiments with n=3. #indicates significance of p≤0.05
compared to unstimulated DMSO control, *indicates significance of p≤0.05 compared to
LPS-stimulated DMSO control.
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Figure 5.4

Figure 5.4. Suppression of LPS-induced pro-inflammatory cytokine production by
I3C- and IO-treated BMDCs. BMDCs were grown in the presence of the DMSO
vehicle control, 50 μM I3C, or 1 μM IO for 7 d and purified. The immature BMDCs
were subsequently treated with 1 μg/ml LPS for 24 h, and protein levels of cytokines
present in the supernatants were measured by ELISA. Results are representative of 3
separate experiments with n=3.

#indicates significance of p≤0.05 compared to

unstimulated DMSO control, *indicates significance of p≤0.05 compared to LPSstimulated DMSO control.
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which I3C and IO decreased IL-6 levels from 60 ng/ml to 32 ng/ml and 40 ng/ml,
respectively. IL-12 production decreased from 628 pg/ml to 525 pg/ml with I3C and 204
pg/ml with IO. This effect was also observed with TNF-α, as this cytokine was decreased
from 5415 pg/ml to 4338 pg/ml with I3C and to 4427 pg/ml with IO. Lastly, the LPSinduced nitric oxide (NO) production was suppressed from 35 μM to 13 μM with I3C and
to 21 μM with IO.

Conversely, I3C and IO increased the production of the anti-

inflammatory cytokine IL-10 after LPS stimulation from 598 pg/ml to 1211 pg/ml and
1501 pg/ml, respectively.

Taken together, these results suggest that I3C and IO

significantly suppress the inflammatory responsiveness of LPS-stimulated BMDCs by
inhibiting inflammatory mediator production and promoting anti-inflammatory mediator
production.

I3C and IO induce immunoregulatory genes in BMDCs. AhR activation in DCs results
in the induction of regulatory genes, an effect that correlates with a DC-induced
expansion of CD4+Foxp3+ Tregs (Bankoti et al., 2010; Quintana et al., 2010; Simones
and Shepherd, 2011). Thus, the expression of several key immunoregulatory genes was
assessed in BMDCs treated with I3C or IO to further evaluate the immunosuppressive
potential of these dietary AhR ligands (Table 1). Without stimulation, BMDCs grown in
the presence of I3C upregulated ALDH1A1 by 3.6 fold, CYP1A1 by 5.2 fold, IDO1 by 6.7
fold, IDO2 by 5.7 fold, TGFB2 by 2.4 fold, and TGFB3 by 5.8 fold (Table 1A).
Conversely, ALDH1A2 and IL27 decreased by 2.3 fold and 4.1 fold, respectively.
Following LPS stimulation, IDO1, IDO2, IL6, TGFB2, and TGFB3 was upregulated
while IL10, IL27, and TGFB1 decreased in I3C-treated BMDCs. Similar trends were
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observed in IO-treated BMDCs with and without LPS stimulation (Table 1B).

In

unstimulated cells, IO upregulated ALDH1A1 by 2.6 fold, CYP1A1 by 4.7 fold, IDO1 by
3.1 fold, IDO2 by 3.0 fold, TGFB2 by 3.5 fold, and TGFB3 by 4.0 fold. In LPS-activated
cells, IDO1, IDO2, TGFB2, and TGFB3 were upregulated and ALDH1A2, IL6, and IL27
were downregulated. Overall, in an inflammatory environment, I3C- and IO-treated
BMDCs increase their expression of key immunoregulatory genes and thus may possess
the potential to suppress immune responses.

AhR-dependence of I3C and IO on BMDCs. To investigate whether the observed
effects of I3C were dependent on the AhR, BMDCs from AhR-/- mice were generated in
the presence of I3C or IO.

Surface marker expression of unstimulated and LPS-

stimulated cells (Tables 2A and 2B) as well as cytokine production (Table 2C) was
assessed. When AhR-deficient BMDCs were grown in the presence of I3C, changes in
the expression of CD11c and CD54 were not observed relative to the vehicle control
thereby indicating that the effects on these molecules were dependent on the AhR. The
immunomodulatory effects of IO appeared to be more dependent on the AhR, as changes
in CD11c, MHC2, CD80, and CD54 were not observed in unstimulated AhR-/- BMDCs.
LPS-activated cells revealed that the expected alterations in the expression of CD11c on
I3C-treated BMDCs, and CD11c, MHC2, CD80 and CD54 on IO-treated BMDCs were
not observed in cells lacking the AhR. Additionally, suppression of many of the LPSinduced pro-inflammatory cytokines examined was observed in AhR-deficient BMDCs
treated with I3C (IL-1, IL-6, TNF- and NO) and IO (IL-6, IL-12 and TNF-).
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Table 5.1. Dietary AhR ligands induce regulatory gene expression in unstimulated and
LPS-stimulated BMDCsa
A. Indole-3-carbinol (I3C)
Gene
ALDH1A1
ALDH1A2
CYP1A1
IDO1
IDO2
IL6
IL10
IL27
LTBP
TGFB1
TGFB2
TGFB3

Unstimulated
Fold
p-value
change
3.6*
0.008
-2.3*
<0.001
5.2*
0.008
6.7*
0.001
5.7*
<0.001
1.3
0.328
-1.6
0.144
-4.1*
<0.001
-1.2
0.324
1.1
0.373
2.4*
<0.001
5.8*
0.005

LPS
Fold
change
-1.1
-3.4*
1.0
13.5*
5.1*
1.5*
-1.6*
-2.6*
1.2
-1.3*
2.5*
1.8*

p-value
0.420
<0.001
0.475
<0.001
<0.001
0.008
0.040
<0.001
0.139
0.032
0.001
0.034

B. Indirubin-3’-oxime (IO)
Gene
ALDH1A1
ALDH1A2
CYP1A1
IDO1
IDO2
IL6
IL10
IL27
LTBP
TGFB1
TGFB2
TGFB3

a

Unstimulated
Fold
p-value
change
2.6*
0.040
-1.2*
0.019
4.7*
0.009
3.1*
0.004
3.0*
<0.001
1.2
0.367
-1.4
0.051
-3.4*
<0.001
1.4
0.407
1.1
0.244
3.5*
0.001
4.0*
0.027

LPS
Fold
change
1.4
-1.4*
-1.4
6.6*
4.2*
-1.3*
-1.2
-3.1*
1.6*
1.1
3.2*
1.7*

p-value
0.140
0.016
0.262
0.001
<0.001
0.016
0.262
0.004
0.011
0.362
0.001
0.037

Purified BMDCs grown in the presence of vehicle, 50 μM I3C or 1 μM IO for 7 d were

activated with 1 μg/ml LPS for 24 h to evaluate changes in gene transcription by qRTPCR. Fold change is relevant to vehicle-treated cells and normalized to β-actin. Results
are representative of 3 separate experiments. *indicates significance of p≤0.05 compared
to the vehicle control.

144

Table 5.2. Immune modulation by I3C and IO is not entirely AhR-mediated in BMDCsa
A. Immunophenotype of unstimulated cells
Surface
marker
CD11c
MHC2
CD86
CD80
CD54
CD40

DMSO
3391 ± 142
2833 ± 81
1299 ± 15
1176 ± 23
548 ± 7
334 ± 72

AhR+/+
I3C
2603 ± 326*
8056 ± 400*
1493 ± 3*
1901 ± 8*
507 ± 11*
290 ± 11*

IO
2219 ± 312*
6432 ± 255*
1270 ± 10
1412 ± 8*
435 ± 6*
291 ± 5*

AhR-/I3C
4822 ± 107
2912 ± 125*
950 ± 27*
1129 ± 14*
630 ± 12
308 ± 16*

DMSO
4611 ± 548
1970 ± 100
1279 ± 5
839 ± 14
649 ± 6
409 ± 18

IO
3992 ± 280
2067 ± 100
1180 ± 31*
822 ± 13
633 ± 10
358 ± 6*

B. Immunophenotype of LPS-stimulated cells
Surface
marker
CD11c
MHC2
CD86
CD80
CD54
CD40

DMSO
1950 ± 74
3182 ± 37
1433 ± 9
1219 ± 29
510 ± 6
452 ± 11

AhR+/+
I3C
1702 ± 55*
8189 ±61*
1787 ± 21*
3257 ± 92*
545 ± 3*
417 ± 12*

IO
1770 ± 96
6514 ±170*
1370 ± 8*
1874 ± 30*
439 ± 2*
373 ± 21*

DMSO
2665 ± 74
1817 ± 11
1665 ± 5
981 ±15
583 ± 5
589 ± 12

AhR-/I3C
2645 ± 98
3386 ±143*
1304 ± 8*
1544 ± 52*
650 ± 12*
497 ± 9*

IO
2198 ± 174
1901 ± 71
1523 ± 25*
998 ± 39
560 ±17
499 ± 18*

C. Cytokine production following LPS stimulation
Cytokine
IL-1β (pg/ml)
IL-6 (ng/ml)
IL-10 (pg/ml)
IL-12 (pg/ml)
TNF-α (pg/ml)
NO (μM)

a

DMSO
1056 ± 53
47 ± 2
598 ± 49
1463 ± 159
5347 ± 181
9.3 ± 0.3

AhR+/+
I3C
813 ± 31*
21 ± 1*
1211 ± 92*
984 ± 25*
5121 ± 135*
2.4 ± 0.5*

IO

DMSO

AhR-/I3C

992 ± 42*
24 ± 1*
1501 ± 83*
427 ± 30*
3962 ± 283*
7.5 ± 0.8*

1212 ± 56
47 ± 0.3
417 ± 67
1921 ± 140
7471 ± 603
28 ± 1

862 ± 69*
31 ± 1.6*
127 ± 10*
2018 ± 93
5972 ± 280*
16 ± 2*

IO
1053 ± 52
36 ± 2.6*
543 ± 67
1323 ± 88*
5040 ± 194*
30 ± 2

AhR+/+ and AhR-/- BMDCs were grown in the presence of vehicle, 50 μM I3C or 1 μM

IO and subsequently immunophenotyped (A) prior to or following activation (B) with
LPS (1 μg/ml) for 24 h. Cytokine production was also assessed (C). Mean fluorescence
intensity (MFI) and protein concentrations values are shown as mean ± standard error.
Data are representative of 2 independent experiments with n=3. *indicates significance
of p≤0.05 compared to DMSO control of respective cell type.
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Conversely, the effects of I3C on IL-12 and the effects of IO on IL-1, IL-10 and NO
were demonstrated to be dependent on the AhR. Interestingly, IL-10 production was
decreased in LPS-stimulated, AhR-/- BMDCs treated with I3C in contrast to the effects
observed in AhR+/+ BMDCs. Finally, the induction of several immunoregulatory genes
also appeared to be independent of the AhR, as significant upregulation of ALDH1A1,
ALDH1A2, IDO1, and TGFB2 was observed in I3C and IO-treated AhR-deficient
BMDCs (data not shown).

Thus, both I3C and IO exert effects on BMDCs by a

mechanism that is partially, but not entirely, dependent on the AhR.

I3C and IO differentially alter NF-kB signaling in BMDCs.

Because the

immunomodulatory effects of I3C and IO on BMDCs were not entirely dependent on the
AhR, NF-kB binding activity was evaluated since both I3C and IO can disrupt NF-kB
signaling (Figure 5). In unstimulated cells, both I3C and IO reduced the activity of
nuclear NF-kB p65; however, similar effects were not observed in LPS-activated DCs.
Conversely, there was a trend for increased basal levels of RelB following IO but not I3C
treatment, whereas I3C, but not IO, significantly decreased the levels of RelB following
LPS activation.

I3C- and IO-treated BMDCs promote the generation of antigen-specific Tregs. AhRactivated immunoregulatory DCs can induce the generation of CD4+Foxp3+ Tregs
(Quintana et al., 2010; Simones and Shepherd, 2011); therefore, the potential for dietary
AhR ligand-treated BMDCs to induce OVA323-339-specific Tregs was investigated.
Culturing naïve CD4+ OTII T cells for 3 days in the presence of I3C- or IO-treated,
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OVA323-339-loaded BMDCs significantly increased the frequency of CD4+Foxp3+ T cells
(Figure 6A). When compared to vehicle-treated BMDCs, I3C treatment increased the
frequency of OTII Tregs by approximately 2.4-fold while IO treatment increased the
frequency by almost 2-fold. Cytokine production was also measured in the supernatants
from these cultures (Figure 6B). OTII T cells cultured with IO-treated BMDCs
significantly increased IL-2 production from 112 pg/ml to 6505 pg/ml. I3C- and IOtreated BMDCs decreased the production of IFN-γ in the co-cultures by approximately
33% and 45%, respectively. IL-10 production was also decreased by both the I3C- and
IO-treated BMDCs when cultured with naïve OTII T cells.
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Figure 5.5

Figure 5.5. I3C and IO differentially alter NF-kB signaling. Purified I3C- and IOtreated BMDCs were stimulated with 1 μg/ml LPS for 45 min, and nuclear protein
extracts were subsequently prepared for evaluation of the binding activity of NF-kB p65
(A) and RelB (B). Results are representative of 1 experiment with n=3. #indicates
significance of p≤0.05 compared to unstimulated vehicle control and *indicates
significance of p≤0.05 compared to vehicle control of similarly activated samples.
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Figure 5.6

Figure 5.6.

DCs treated with dietary AhR ligands increase the frequency of

CD4+Foxp3+ Tregs and alter cytokine production. AhR ligand-treated BMDCs and
naïve CD4+ OTII T cells were prepared as described in the Materials and Methods. (A)
The percent of CD4+Foxp3+ T cells is shown in the histogram. (B) Cytokine production
of IL-2, IL-10 and IFN- was also measured from the culture supernatants as described in
the Materials and Methods. Results are representative of 2 separate experiments with
n=3. *indicates significance of p≤0.05.
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DISCUSSION
Modulating the fate and function of DCs has important therapeutic implications in
the treatment of a large variety of immune-mediated diseases.

The AhR signaling

pathway can play an important role in shaping the fate and function of DCs in immune
and inflammatory responses.

Given that activation of the AhR generates

immunoregulatory cells, including DCs and Tregs, it is essential to evaluate the effects of
non-toxic AhR ligands, including agonists and antagonists, on critical cell populations in
the immune system. I3C and indirubin are particularly interesting dietary AhR ligands
since they both possess potent anti-cancer properties, but currently our knowledge of
their effects on immune cells is limited. Therefore, in this study we investigated the
potential of I3C and indirubin to promote immunosuppressive and anti-inflammatory
effects via the AhR.
Following AhR activation in DCs, several changes in cell surface molecule
expression, cytokine production, and regulatory gene induction contribute to suppressive
and tolerogenic immune responses. The exogenous, prototypical ligand TCDD and the
endogenous ligand 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
(ITE) both decrease the expression of CD11c and upregulation of MHC2 and CD86 in
murine BMDCs (Bankoti et al., 2010).

Alternatively, the small molecule VAF347

decreases CD86 and HLA-DR in human DCs (Ettmayer et al., 2006) while the
environmental contaminant benzo(a)pyrene (BaP) induces few changes in the expression
of CD11c, MHC2, and CD86 on murine DCs (Hwang et al., 2007). Consistent with the
results from TCDD- and ITE-treated DCs, we demonstrated that I3C and IO decreased
the expression of CD11c, CD40, and CD54 while increasing the expression of MHC2
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and CD80. Decreased CD11c expression on DCs following exposure to I3C and IO
suggests altered differentiation of these professional antigen-presenting cells.
Furthermore, since CD40 and CD54 are critical immune molecules involved in the
interactions of T cells with DCs, decreased expression of these markers on DCs suggests
that their ability to successfully activate effector T cells may be defective. Although both
I3C and IO are AhR agonists (Miller, 1997; Guengerich et al., 2004), changes in the
immunophenotype of BMDCs were not entirely dependent on the AhR as observed when
using BMDCs from mice lacking the AhR. Similarly, it has been noted that the effects of
BaP are not entirely AhR-dependent (Hwang et al., 2007). This is distinctly different
than the effects of TCDD, which are entirely dependent on the AhR (Bankoti et al.,
2010). Overall, the changes in surface marker expression on DCs treated with I3C and
IO could be contributing to the generation of immune suppression, in part via AhR
activation.
Cytokines are soluble mediators that play a critical role in influencing immune
responses. Following activation by bacterial stimuli, such as LPS, DCs secrete many proinflammatory cytokines that can promote inflammatory responses. Consequently, we
determined the effects I3C and IO on the LPS-induced production of inflammatory
mediators. In general, we found that I3C and IO suppressed the secretion of many proinflammatory cytokines thereby indicating anti-inflammatory activity.

Interestingly,

TCDD was recently shown to increase the LPS-induced production of IL-6 and TNF-α
(Bankoti et al., 2010) whereas other AhR ligands including BaP, ITE, and VAF347
decrease the production of pro-inflammatory cytokines (Ettmayer et al., 2006; Lawrence
et al., 2008; Quintana et al., 2010). Thus, I3C and IO elicit cytokine patterns much more
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similar to readily metabolized AhR ligands than TCDD, an extremely stable and
persistent AhR agonist.
To further explore the immunosuppressive and anti-inflammatory properties of
dietary AhR ligands, gene transcription was evaluated in unstimulated and LPS-activated
BMDCs. Both I3C and IO upregulated IDO and TGFB genes, which have important
implications in the generation of regulatory immune cells. Several investigators have
demonstrated that AhR activation by TCDD in DCs induces regulatory genes that
promote the expansion of Tregs (Mellor et al., 2004; Tas et al., 2007; Bankoti et al.,
2010; Simones and Shepherd, 2011). Our laboratory previously reported that TCDD
induced IDO1, IDO2, and TGFB3 in both unstimulated and LPS-stimulated BMDCs.
Prior to activation, TCDD upregulated TGFB3 while TGFB1 and TGFB2 were
upregulated following LPS activation (Bankoti et al., 2010). Importantly, the induction of
IDO expression by DCs has been associated with the non-canonical NF-κB pathway (Tas
et al., 2007; Vogel et al., 2008). Aldehyde dehydrogenase is associated with retinoic acid
metabolism, which has been linked to regulatory DCs that drive Treg expansion. In our
studies, ALDH1A1 was upregulated by both compounds while ALDH1A2 did not seem to
have an important role in producing DCs of a regulatory phenotype. This effect was also
observed with the endogenous ligand ITE, as ALDH1A1 was induced in DCs possessing
regulatory functions (Quintana et al., 2010).

Overall, upregulation of these

immunoregulatory genes by I3C and IO suggest that these compounds have the potential
to generate a regulatory environment that promotes the induction of regulatory T cells.
Because DCs acquired an immunoregulatory phenotype following treatment with
I3C or IO, we evaluated their ability to generate Tregs from naïve CD4+ T cells in an
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antigen-specific manner.

In this study, I3C- and IO-treated BMDCs significantly

increased the frequency of CD4+Foxp3+ T cells in vitro. These findings are consistent
with a study that demonstrated that indirubin increased CD4+CD25+Foxp3+ T cells in
vivo (Zhang et al., 2007). However, in this study it was not determined if indirubin acted
directly on the T cells or indirectly via other immune cells such as the DCs. To date, no
studies have reported direct and/or indirect effects of I3C on Foxp3+ Treg induction.
TCDD, VAF347, and ITE have all been shown to increase CD4+CD25+Foxp3+ Tregs
(Hauben et al., 2008; Quintana et al., 2010; Simones and Shepherd, 2011). ITE was
recently demonstrated to induce Tregs both directly via effects on T cells and indirectly
by altering DC function. Moreover, these effects in the DCs were found to be dependent
on the generation of retinoic acid, as Foxp3+ Treg generation was blocked following the
addition of a retinoic acid inhibitor (LE135) to the DCs (Hauben et al., 2008; Quintana et
al., 2010; Simones and Shepherd, 2011). On the other hand, a recent study from our
laboratory demonstrated that DCs treated with TCDD increased the frequency of OVAspecific, CD4+Foxp3+ Tregs in an IDO-dependent manner (Simones and Shepherd,
2011). Thus, based on the imunoregulatory profiles of DCs exposed to different AhR
ligands, it is possible that Treg induction can occur through several mechanisms
including retinoic acid, kynurenines, and/or TGF-β.
Both I3C and indirubin have traditionally been used in anti-cancer and antiinflammatory applications. To date, neither I3C nor IO has been specifically evaluated
for their potential anti-inflammatory effects on DCs, and information regarding the
effects of these compounds on other immune cells is also limited. I3C has been assessed
in vitro using the murine macrophage cell line RAW264.7 and primary murine
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macrophages. These studies revealed that I3C decreased the LPS-induced production of
several inflammatory mediators, such as nitric oxide (NO) and TNF-α, which has been
associated with decreased translocation of NF-κB into the nucleus (Chen et al., 2003;
Tsai et al., 2010; Chang et al., 2011). Our laboratory has recently demonstrated that I3C
ameliorates disease severity and inflammation associated with a murine model of colitis
(manuscript in preparation), which is consistent with our previously published work
regarding the anti-inflammatory and immunosuppressive effects of TCDD on colitis
(Benson and Shepherd, 2011). The anti-inflammatory effects of indirubin have been
considerably less studied. Kunikata and colleagues reported that indirubin inhibited IFNγ production from human myelomonocytic HBL-38 cells, IL-6 production by murine
splenocytes, and ear swelling in a murine model of delayed-type hypersensitivity
(Kunikata et al., 2000). Most recently, IO inhibited the LPS-induced production of NO,
TNF-α, IL-1β, and PGE-2 by rat brain microglia cells via inhibition of NF-κB activation
(Jung et al., 2011).
Since suppression of NF-κB signaling has been associated with decreased
inflammatory mediator production by both I3C and IO, it is likely that these compounds
also interfere with NF-κB signaling to contribute to the anti-inflammatory responses we
observed in BMDCs. The AhR can interact with NF-kB signaling components (Ruby et
al., 2005; Vogel et al., 2007a; Vogel et al., 2007b). Therefore, it is conceivable that I3C
and IO may interact with the AhR and/or NF-κB in DCs to reduce their inflammatory
responsiveness. In this study, we demonstrated that I3C and IO decrease the binding
activity of NF-κB p65 found in the nucleus of the BMDCs, but only I3C significantly
decreased RelB activity following LPS activation. Therefore, it is possible that altered
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NF-κB signaling contributes, at least in part, to the suppression of LPS-induced
inflammatory cytokine production in DCs. Overall, our data suggest that both the AhR
and NF-κB signaling pathways may contribute towards the immunoregulatory and antiinflammatory effects of I3C and IO in DCs. Additional studies utilizing DRE and NF-κB
luciferase reporter assays conducted in DCs may help delineate the contribution of these
pathways, as most studies on these compounds to date have been conducted in cancer
cells. For example, it was shown that 60 μM I3C decreased relative luciferase activity in
breast cancer cells with regards to NF-κB activity (Rahman KM et al., 2004) while the
DRE-driven luciferase of indigoids has been documented in a derivative of human
hepatoma HepG2 cells (Guengerich et al., 2004).
Given that the effects observed in this study were not entirely dependent on either
the AhR or NF-κB, it is possible that other factors contributed to the observed effects, as
IO has been reported to inhibit Src kinase activity and subsequently the phosphorylation
of STAT3, which has been implicated as an important factor in Th17 cell differentiation
(Nam et al., 2005; Kimura et al., 2007). AhR activation leads to the generation of Tregs
and IO may decrease Th17 differentiation so these factors together may contribute to the
observed immunosuppressive environment.
It should be noted that in the acidic environment of the stomach, I3C forms the
acid condensation product diindolylmethane (DIM). Since I3C is rapidly metabolized
into DIM following oral consumption, the use of I3C in cell culture experiments has been
criticized, as it has been shown that DIM is primarily responsible for the anti-cancer and
anti-proliferative effects in vivo. However, a recent study demonstrated that following the
addition of I3C to cultured cells, DIM spontaneously forms and accounts for much of the
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documented effects in vitro (Bradlow and Zeligs, 2010). Accordingly, we expect that
DIM also formed in our cell cultures and thereby is at least partially responsible for the
observed effects on murine BMDCs.
Collectively, we have demonstrated that the dietary AhR ligands I3C and IO exert
anti-inflammatory and immunoregulatory effects on DCs in vitro. Although both of these
compounds bind the AhR, the effects we observed on cell surface marker expression,
cytokine production, and gene transcription were not entirely dependent on the AhR.
Moreover, altered NF-kB signaling pathway may be contributing to the antiinflammatory effects of both I3C and IO. Since no severe adverse reactions have been
reported in humans consuming I3C or indirubin (clinical trials reviewed in Eisenbrand et
al., 2004; Minich and Bland, 2007), these compounds may ultimately be useful
complementary therapeutics for treating inflammatory disorders by altering DC fate and
function, consequently creating an immunosuppressive environment. Importantly, our
results also suggest that the generation of regulatory DCs and T cells following exposure
to I3C and indirubin may significantly reduce the utility of these natural products as anticancer reagents. It is plausible that different metabolism occurs in vivo versus in vitro
leading to a differential effect in animals compared to cell culture. It is also possible that
the anti-proliferative effects of I3C/DIM on tumor cells combined with additional antiinflammatory and regulatory effects on the immune system may limit damage generated
by the tumor cells permitting a more robust immune response. Therefore, focused in vivo
studies to investigate these possibilities are warranted based on previously published
studies and our results presented herein.
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CHAPTER 6: CONCLUSIONS

Crohn’s disease is a multifactorial gastrointestinal disorder of unknown etiology
that affects millions of people worldwide. The goal of current conventional therapeutics
is to induce and maintain remission by controlling the inflammation that causes
symptoms.

This

is

accomplished

with

five

basic

categories

of

treatments

(aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologics) that are
used in combination to treat patients, as corticosteroids rapidly reduce inflammation
while immune modulators help maintain remission, for example. These medications,
however, must be tailored to each patient and are also accompanied by severe adverse
effects, especially with extended use. Thus, there is a need to develop new therapeutics
that more effectively and more safely control and possibly prevent intestinal
inflammation.
The aryl hydrocarbon receptor (AhR) has emerged recently as an attractive
therapeutic target for several disease states including those that involve chronic
inflammation. The AhR is perhaps most recognized for mediating the toxic effects of its
prototypical ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) via events that are both
dependent and independent of dioxin response elements (DREs). A notable effect of
AhR activation by TCDD is the generation of Foxp3+ regulatory T cells (Tregs), which
potently suppress inflammation. Due to its severe adverse effects, TCDD would not be a
realistic therapeutic option for human diseases. Therefore, there is a need to identify AhR
ligands that selectively block DRE-driven transcription associated with TCDD toxicity
but still repress acute phase genes. These selective AhR modulators ultimately have the
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potential to be used in combination with current therapies for inflammatory diseases and
hormone-dependent cancers since they do not exert the toxic effects associated with
TCDD (McDougal et al., 2001; Okino et al., 2009; Murray et al., 2010; Murray et al.,
2011; Smith et al., 2011).
Since AhR activation by various ligands can generate immunoregulatory and antiinflammatory effects and little is currently known about the role of the AhR in gut
immune responses, we explored the role of AhR activation in the mucosal immune
system and the potential for natural ligands to ameliorate intestinal inflammation without
eliciting toxic effects. Our central hypothesis was that that AhR agonists found in the diet
have the potential to dampen inflammation associated with Crohn’s disease. We utilized
a murine model of colitis to evaluate the role of the receptor in the gut and also conducted
in vitro experiments to further investigate the mechanisms of dietary AhR ligands on
important immune cells present the gut. The following sections highlight the primary
conclusions from this project and future directions worth pursuing to extend the research.

Dietary AhR ligands modulate intestinal inflammatory responsiveness
The first goal of this project was to test the hypothesis that AhR activation by the
prototypical AhR ligand TCDD would reduce the inflammation generated in a murine
model of Crohn’s disease by promoting an immunosuppressive environment in the gut.
We demonstrated for the first time that TCDD suppressed 2,4,6-trinitrobenzenesulfonic
acid (TNBS)-induced intestinal inflammation, as indicated by decreased disease severity,
decreased inflammatory mediator production, and increased Foxp3+ Tregs in colon tissue
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(Benson and Shepherd, 2011a). Thus, the amelioration of colitis likely occurred via the
Treg generation following AhR activation.
Since TCDD is not a viable treatment option for Crohn’s disease patients, it is
necessary to identify other AhR agonists lacking the toxic effects associated with TCDD.
Indole-3-carbinol (I3C) is a natural AhR agonist present in cruciferous vegetables that
possesses the potential to dampen inflammation (Takada et al., 2005; Kim et al., 2009;
Tsai et al., 2010; Chang et al., 2011). We found that I3C exerted sex-specific effects on
disease severity by dampening inflammation in female, but not male, mice (Benson and
Shepherd, 2011c). Due to the potential crosstalk with several signaling pathways,
complex interactions of the AhR with the estrogen receptor and/or nuclear factor-kappa B
(NF-kB) signaling pathways are likely responsible for this effect (Ohtake et al., 2003;
Wormke et al., 2003; Matthews et al., 2005).
Collectively, these in vivo studies demonstrated the importance of AhR activation
in the gut by exerting anti-inflammatory and immunoregulatory effects.

Several

investigators have also reported an increased frequency of Tregs following AhR
activation, which consequently suppressed autoimmune diseases induced in mice
including multiple sclerosis (Quintana et al., 2010), diabetes (Kerkvliet et al., 2009), and
uveoretinitis (Zhang et al., 2010). With respect to colitis, several ligands have been
shown to suppress intestinal inflammation following AhR activation. These compounds
that activate AhR signaling include the I3C metabolite diindolylmethane (DIM) (Kim et
al., 2009), 6-formylindolo[3,2-b]carbazole (FICZ) (Monteleone et al., 2011), and
Lactobacillus bulgaricus OLL1181 (Takamura et al., 2011).

To our knowledge,

however, I3C is the first documentation of an AhR ligand exerting sex-specific effects on
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intestinal inflammation. This suggests that effects of ligands may vary based on the
context of inflammation in certain tissues. Moreover, I3C is a commercially available
supplement so it could have significant implications for self-medicating patients who
want to relieve symptoms not suppressed by conventional medicine or to relieve the
symptoms of the medicine.

Regulatory cells present in the gut are induced by natural AhR ligands
The second primary goal of this project was to investigate the mechanism(s) by
which dietary AhR ligands exert their effects on important immune cells found in the gut.
Dendritic cells (DCs) constitutively express the AhR and are a critical cell population in
the gut that maintains tolerance by promoting the expansion of Tregs. We found that I3C,
as well as the traditional Chinese medicine component indirubin, exerted antiinflammatory

effects

via

the

reduction

of

lipopolysaccharide

(LPS)-induced

inflammatory cytokines in bone marrow-derived DCs (BMDCs). I3C and indirubin
increased the expression of several regulatory genes including indoleamine-2,3dioxygenase (IDO), transforming growth factor beta (TGFB), and aldehyde
dehydrongenase (ALDH1A). The ligand-treated BMDCs also induced Foxp3+ Tregs
when co-cultured with antigen-specific naïve CD4+ T cells (Benson and Shepherd,
2011b). Collectively, the results obtained demonstrate the anti-inflammatory and
immunoregulatory effects of I3C and indirubin.
Several mediators, especially IDO, TGF-β, and retinoic acid, are critical for
maintaining a regulatory environment to prevent inappropriate responses to food particles
and commensal bacteria in the gut. In line with our in vitro findings, it was recently
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demonstrated that immunoregulatory DCs suppressed TNBS-induced colitis, which was
partially dependent on IDO (Hoshino et al., 2011). In fact, IDO inhibition exacerbates
TNBS-induced colitis (Gurtner et al., 2003). Previous investigations in our laboratory
revealed that TCDD generates regulatory DCs capable of inducing Foxp3+ Tregs in an
IDO-dependent manner (Simones and Shepherd, 2011). Thus, it is possible that I3C or
indirubin administered to mice would induce regulatory cells capable of suppressing
disease severity in the gut. Furthermore, the results obtained in DCs could also be
extended to intestinal epithelial cells (IECs), which are AhR-expressing antigen
presenting cells that produce protective mediators necessary to prevent inappropriate
immune responses to food particles and commensal bacteria. Importantly, IECs also
condition DCs to have a regulatory phenotype via TGF-β and retinoic acid (Iliev et al.,
2009). Taken together, natural AhR ligands induce a regulatory phenotype in DCs
without exerting overt cytotoxicity, which is crucial to effectively dampening
inflammation, and thus may also be effective treatment options for those afflicted with
inflammatory bowel diseases.

Future directions
Collectively, the data generated in this project demonstrate that the AhR plays an
important role in mediating gut immune responsiveness. Dietary AhR ligands possess the
potential to impart regulatory and anti-inflammatory functions by acting on several cell
populations including DCs, intestinal epithelial cells, and lymphocytes. To expand this
research, several additional studies would better define the role of the AhR in intestinal
immune tissue. Since the studies in this project utilized an acute model of colitis, it is
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necessary to confirm the observed effects of AhR ligands in a chronic model of colitis,
which is in many ways more representative of human Crohn’s disease. Another important
avenue to pursue is the evaluation of the effects of AhR ligands in combination with
conventional treatment (i.e. corticosteroids) that can rapidly reduce inflammation.
Finally, one of the most fascinating topics in current research involves trying to
understand how the gut microbiome interacts with the immune system. Thus, it would be
useful to evaluate how AhR activation by various ligands in the gut mucosa specifically
alters gut bacteria populations and their functions.
In general, the most recent therapeutic approaches under development for treating
inflammatory bowel diseases are aimed at improving mucosal barrier integrity via stem
cells, restoring homeostasis of the gut bacteria via probiotics, and identifying vehicles
that deliver potent therapeutics directly to the intestines (Plevy and Targan, 2011;
Scholmerich, 2011). Selectively modulating AhR activity is a novel approach to suppress
disease severity, and our studies provide insight into natural AhR ligands that can
dampen intestinal inflammation by promoting an immunosuppressive environment.
Clearly, the AhR is a promising novel therapeutic target that warrants further
investigation for its potential to improve the function of gut mucosal immune responses.
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APPENDIX 1

Colonic gene and protein expression of aryl hydrocarbon receptor deficient mice

OVERVIEW
Since the aryl hydrocarbon receptor (AhR) knockout (KO) mice in the University
of Montana laboratory animal facility were unexpectedly less sensitive to colitis,
preliminary studies were conducted to evaluate gene and protein expression in the colons
of naïve AhR KO mice compared to naïve AhR wild-type (WT) mice. Since T cells play
a critical role in mounting inappropriate immune responses in colitis, and inflammation
causes the clinical signs of the disease, these two pathways were specifically evaluated in
the gene expression analyses. Moreover, proteomics analyses are quite extensive so
changes in proteins involved in these pathways were of particular interest.

METHODS
Laboratory animals. Six to eight week old AhR WT and AhR KO mice (both on the
C57Bl/6 background) were bred and maintained in the animal research facility at the
University of Montana. C57Bl/6 AhR WT mice were originally obtained from The
Jackson Laboratories (Bar Harbor, ME) and bred in-house. C57Bl/6 AhR KO
(B6.AhRtm1Bra) mice were obtained from Dr. Paige Lawrence (University of Rochester
Medical College, Rochester, NY) and bred as previously described (Schmidt et al.,
1996). All mice were housed under specific pathogen-free conditions and maintained on
12 h dark/light cycles.
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SuperArray. Three AhR WT samples and three AhR KO samples were pooled for gene
expression analysis. RNA and cDNA was prepared as described above. Resulting cDNA
was subjected to the RT2 Profiler PCR Array Systems for T helper Cell Differentiation
and NF-kB Signaling Pathway per the manufacturer’s instructions (SA Biosciences,
Frederick, MD). Reactions were performed with PerfeCTa SYBR Green Supermix
(Quanta Biosciences) on an Agilent Technologies Stratagene Mx3005P QPCR System
(Santa Clara, CA). Resulting data were analyzed using SA Bioscience’s Web-Based
PCR Array Data Analysis tool.

Proteomics. The colonic mucosa was collected as previously described (Calpe-Berdiel et
al., 2007). Briefly, colons were removed, washed with ice cold PBS, and opened
longitudinally such that the mucosal layer could be lightly scraped. Approximately 5 mg
of mucosal tissue was assessed for protein expression, as described by Lai and colleagues
(Lai et al., 2011). Briefly, mucosa was solubilized, trypsinized, and fractionated via
HPLC. MS was used to identify and quantify peptides. Resulting data were analyzed
using Ingenuity Systems Pathway Analysis software (Ingenuity Systems Inc., Redwood
City, CA).
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RESULTS
Genes involved with Th cell differentiation and NF-kB signaling were upregulated in
AhR KO mice.

Components of Th cell differentiation and NF-kB signaling were

investigated by commercially available array kits. Numerous genes involved in T helper
cell differentiation were upregulated including IL-4, IL-13, IFN-γ, and Tbx21 while only
Ccr6 was downregulated in AhR KO mice (Table 1A). No clear bias towards any T
helper cell subset (ie Th1, Th2, Th17 or regulatory T cells) was observed. Moreover,
many genes involved in the NF-kB signaling pathway were also upregulated while
decreases in gene expression were not observed in AhR KO mice (Table 1B). Overall,
gene expression data suggested no clear skewing of T helper cell subsets and also implied
that KO mice may have enhanced NF-kB signaling thereby making them more
susceptible to inflammation, which is still inconsistent with the results observed in the
TNBS model.

AhR KO mice have decreased expression of proteins involved in NF-kB signaling,
apoptosis, and antigen presentation. A total of 2374 proteins were identified in AhR
WT and KO mice. Interestingly, more proteins were downregulated than upregulated, as
shown in Tables 2 and 3. Of the proteins exhibiting at least a -1.5 fold change, there
were several related to immune and inflammatory responsiveness in the gut including
Card10, Mapk14 (p38-), Bax, Fadd, and Ctsb. There were also several immune and
inflammatory genes upregulated including Saa1, Fkpb5, Atrn, and Ctsl; however
increased expression of these proteins are not consistent with the decreased inflammation
observed in AhR KO mice following TNBS administration.

Networking analyses

performed with Ingenuity Systems software revealed that the top network with the
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protein expression fold changes at least +/- 1.5 is cell death, cellular movement, and gene
expression (results not shown). There were 20 focus proteins in this network including
Bax, Brp44L, Card10, Ctbp2, Ctsb, Eif2s2, Fadd, Hcfc1, and Pik3r6 among several
others.
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Table 1. Gene expression in the colon of AhR KO mice
A. T helper cell differentiation
Gene
Cacna1f
Ccl7
Ccr3
Ccr6
Csf2
Fasl
Gata3
Gata4
Havcr2
Icos

Fold Change
3.24
2.42
3.22
-2.25
4.04
27.40
4.52
4.13
2.04
3.55

Gene
Ifng
Il12b
Il12rb2
Il13
Il18r1
Il18rap
Il1r1l
Il2
Il21

Fold Change
16.40
5.26
7.39
4.04
2.31
9.49
3.13
16.52
19.51

Gene
Il2ra
Il4
Il5
Il9
Myb
Nr4a3
Stat1
Stat4
Tbx21

Fold Change
4.10
2.98
3.85
7.19
2.11
2.31
2.26
4.58
2.18

B. NF-kB signaling pathway
Gene
Atf2
Casp1
Casp8
Ccl2
Csf2
Csf3
Egr1
Fasl

Fold Change
2.55
2.75
2.60
2.45
7.62
5.58
2.17
12.47

Gene
Fos2
Htr2b
Ifng
Il10
Il1a
Il1b
Il6
Nlrp12

Fold Change
2.68
2.99
12.04
5.46
5.50
4.26
24.59
13.09

Gene
Ripk2
Stat1
Tlr6
Tlr7
Tlr8
Tnf
Tnfsf14

Fold Change
2.68
2.31
2.35
4.63
3.48
2.10
4.68

Colon tissue from AhR WT and KO mice was homogenized in Trizol and subjected to
qRT-PCR to assess changes in gene expression. Genes with fold changes +/- 2.0 relative
to WT mice are shown in the table. Data are representative of one experiment in which
tissue from three mice were pooled for each group.
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Table 2. Downregulated protein expression in AhR KO mice

Card10
Eml5
Bphl
Mptx
Plbd1
Rab5b
Hmbs
Ctbp2
Ccdc109a
Srrm1
Eif2s2
Dhrs11
Bax
Col6a3
Ttll13
Sec13
Sema6a
Hdhd2
Msh2
Clpp
Npepl1
Wwp2
Tmem43
Rbm3
Pik3r6
Cbara1
Rpl7A
S100a11
Cask
Pcdh1
Sacm1l
Mtnd4
Ndufb7
Parp3
Ttc39a
Phactr4
Hcfc1
Gm10093
Gcn1l1

Protein
Caspase recruitment domain-containing protein 10
Echinoderm microtubule-associated protein-like 5
Valacyclovir hydrolase
Mucosal pentraxin
Phospholipase B-like 1
RAB5B, member RAS oncogene family
Porphobilinogen deaminase, Isoform 2
C-terminal binding protein 2
Coiled-coil domain-containing protein 109A
Serine/arginine repetitive matrix protein 1, Isoform 2
Eukaryotic translation initiation factor 2, subunit 2 (beta)
Dehydrogenase/reductase SDR family member 11
Apoptosis regulator BAX
Collagen alpha-3(VI) chain
Tubulin polyglutamylase TTLL13
Protein SEC13 homolog
Semaphorin-6A, Isoform 2
Haloacid dehalogenase-like hydrolase domaincontaining protein 2
DNA mismatch repair protein Msh2
Putative ATP-dependent Clp protease proteolytic
subunit, mitochondrial
Aminopeptidase NPEPL1
NEDD4-like E3 ubiquitin-protein ligase WWP2
Transmembrane protein 43
Rbm3 protein
Phosphoinositide 3-kinase regulatory subunit 6, Isoform
2
Calcium uptake protein 1, mitochondrial
Ribosomal protein L7A
Protein S100-A11
Peripheral plasma membrane protein CASK
Protocadherin 1
Phosphatidylinositide phosphatase SAC1
NADH-ubiquinone oxidoreductase chain 4
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 7
NAD+ ADP-ribosyltransferase 3 PARP-3
Tetratricopeptide repeat protein 39A, Isoform 2
Phosphatase and actin regulator 4, Isoform 2
Host cell factor 1
Histone deacetylase
GCN1 general control of amino-acid synthesis 1-like 1

Fold Change

p-value

-4.5
-2.9
-2.7
-2.4
-2.3
-2.2
-2.1
-2.1
-2.1
-2.0
-2.0
-2.0
-2.0
-1.9
-1.9
-1.9
-1.9

0.1
0.2
0.05
0.2
0.08
0.3
0.09
0.2
0.1
0.01
0.04
0.04
0.01
0.3
0.01
0.08
0.05

-1.9

0.05

-1.9

0.03

-1.8

0.06

-1.8
-1.8
-1.7
-1.7

0.1
0.2
0.2
0.2

-1.7

0.09

-1.7
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6

0.09
0.4
0.3
0.5
0.1
0.4
0.2

-1.6

0.2

-1.6
-1.6
-1.6
-1.6
-1.6
-1.6

0.3
0.06
0.3
0.06
0.1
0.03
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Ndufaf1
Brp44l
Nars
Gm12597
Smpdl3a
Acss2
Tmem14c
Slc35c2
Shank1
Rab11fip1
Fadd
Pfdn5
Mtx2
Mapk14
Ppp1r12a
Picalm
Carkd
Ppip5k1
Ccdc47
Coq3
Ctsb
Rpl31

Complex I intermediate-associated protein 30,
mitochondrial
Brain protein 44-like
Asparaginyl-tRNA synthetase, cytoplasmic
Alpha-interferon
Acid sphingomyelinase-like phosphodiesterase 3a
Acetyl-coenzyme A synthetase, cytoplasmic
Transmembrane protein 14C
Slc35c2 protein
SH3 and multiple ankyrin repeat domains protein 1
Rab11 family-interacting protein 1
Protein FADD
Prefoldin subunit 5
Metaxin 2
Mitogen-activated protein kinase 14, Isoform 3
Protein phosphatase 1 regulatory subunit 12A, Isoform 2
Phosphatidylinositol-binding clathrin assembly protein,
Isoform 2
Carbohydrate kinase domain-containing protein, Isoform
2
Inositol hexakisphosphate and diphosphoinositolpentakisphosphate kinase 1
Coiled-coil domain containing 47
Coenzyme Q3 homolog methyltransferase
Cathepsin B
60S ribosomal protein L31

-1.6

0.5

-1.6
-1.6
-1.6
-1.6
-1.6
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5

0.3
0.2
0.3
0.3
0,2
0.4
0.3
0.2
0.02
0.1
0.2
0.2
0.2
0.1

-1.5

0.1

-1.5

0.3

-1.5

0.06

-1.5
-1.5
-1.5
-1.5

0.2
0.3
0.2
0.04

Colonic mucosa from naïve AhR WT and KO mice were analyzed for protein expression,
as described in Materials and Methods. Fold changes of  -1.5 compared to WT mice are
listed in the table. Results are representative of one experiment with n=3.
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Table 3. Upregulated protein expression in AhR KO mice

Gapdh
Saa1
Reep5
Rab27b
Ndufa7
Obscn
Fkbp5
Col5a3
Cc2d2a
Clns1a
Cisd1
Atrn
Rpl28
Prkaa1
Psmd9
Snrpd2
Kcnc3
Ube2d2
Rangap1
Snrpd2
Mlec
Cmas
Hdgf
Ctsl
Ist1
Nme1
Sh3bgrl3
Mt1
Pgm3
Rps11

Protein
Glyceraldehyde-3-phosphate dehydrogenase
Serum amyloid A protein
Receptor expression-enhancing protein 5
RAB27b, member RAS oncogene family
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 7
Obscurin, Isoform 3
FK506 binding protein 5
Collagen type V alpha 3 chain
Coiled-coil and C2 domain-containing protein 2A
Chloride channel, nucleotide-sensitive, 1A
CDGSH iron-sulfur domain-containing protein 1
Attractin
60S ribosomal protein L28
5'-AMP-activated protein kinase catalytic subunit alpha-1
26S proteasome non-ATPase regulatory subunit 9
Small nuclear ribonucleoprotein Sm D2
Potassium voltage-gated channel subfamily C member 3
Ubiquitin carrier protein
Ran GTPase-activating protein 1
Small nuclear ribonucleoprotein Sm D2
Malectin
N-acylneuraminate cytidylyltransferase, Isoform 2
Hepatoma-derived growth factor
Cathepsin L
IST1 homolog
Nucleoside diphosphate kinase (Fragment)
SH3 domain-binding glutamic acid-rich-like protein 3
Metallothionein-1
Phosphoacetylglucosamine mutase
40S ribosomal protein S11

Fold Change
1.5
1.5
1.5
1.5

p-value
0.3
0.4
0.3
0.2

1.5

0.3

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.6
1.6
1.6
1.6
1.6
1.6
1.7
1.8
1.8
2.1
2.5

0.3
0.3
0.3
0.3
0.3
0.5
0.04
0.2
0.1
0.3
0.1
0.2
0.3
0.2
0.1
0.2
0.2
0.1
0.006
0.2
0.2
0.04
0.2
0.06
0.1

Colonic mucosa from naïve AhR WT and KO mice were analyzed for protein expression,
as described in Materials and Methods. Fold changes of  +1.5 compared to WT mice
are listed in the table. Results are representative of one experiment with n=3.
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DISCUSSION
Since our results in both AhR WT and KO mice were quite different than the
published data, we further investigated the gut of naïve AhR KO mice for factors that
may contribute the unexpected immune response in TNBS colitis. Thus, we screened
gene expression of T helper cell differentiation and NF-kB signaling components. Gene
expression data did not indicate an increase in a specific T helper cell subset and actually
indicated heightened NF-kB signaling response. Again, these results are consistent with
the literature in that an exacerbated disease state would be expected in AhR KO mice
during colitis, which is not what we observed in TNBS-treated colitic mice.
Proteomic analyses, however, revealed decreased expression of many proteins
involved in NF-kB signaling, apoptosis, and antigen presentation. The proteins involved
in these physiologic pathways have important roles in the intestinal immune system, so
their decreased expression may at least partially account for the decreased disease
severity observed in AhR KO mice treated with TNBS. Dampening NF-kB signaling via
Card10 and Mapk14 can decrease inflammation. Since increased gene expression of NFkB signaling components was observed, this could be indicative of a compensatory
mechanism of increasing gene expression due to decreased response to stimuli.
Decreased apoptosis via Bax and Fadd has been reported to have a protective effect in
intestinal epithelial cells (IECs), as increased apoptosis in IECs affects barrier integrity
thereby exacerbating colitis. In Crohn’s disease patients, apoptotic rates of IECs are
increased from 2% to 5%, which enables luminal antigens to enter mucosal tissue
(Schulzke et al., 2006). Moreover, anti-TNF therapy decreases apoptosis and restores
epithelial barrier integrity (Zeissig et al., 2004).

Since the TNBS model of colitis
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revolves around TNBS binding colonic proteins prior to recognition by the immune
system, decreased antigen presentation would dampen the ensuing immune insult
typically caused by TNBS. However, it must be emphasized that protein expression was
evaluated in whole mucosa and not specific cell populations. Thus, the results may not
accurately reflect what is occurring in each cell population that can alter immune
responsiveness in the gut.
The data presented in Appendix 1 is preliminary so future studies could be
conducted to confirm these results. It is also expected that by extending these analyses
into TNBS-treated AhR WT and AhR KO mice we may be better able to understand how
gene and protein expression is changed in the context of this potent inflammatory
stimulus. Ultimately this data could help delineate specific pathways responsible for the
decreased inflammation observed in our AhR KO mice.
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